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The endoderm gives rise to many different cell types including those that will form the 
liver and pancreas. How cells differentiate during embryonic development is an 
important focus for the field of regenerative medicine. Understanding the normal 
development of liver and pancreatic cell types may allow us to develop strategies for 
the production of hepatocytes and pancreatic beta-cells for therapeutic purposes.  
One potential method of producing cells for therapeutic purposes is via 
transdifferentiation, or, the conversion of one cell type to another. In this thesis we 
aimed to establish a protocol for the transdifferentiation of liver ductal cells (termed 
cholangiocytes) to either hepatocyte or pancreatic lineages. We also aimed to 
investigate the signalling pathways important for normal differentiation of embryonic 
liver and pancreas. 
In order to address the potential of a cholangiocyte cell line (biliary epithelial cells or 
BECs) to transdifferentiate to other cell types, BECs were infected with a combination 
of candidate transcription factors known as ‘master switch’ genes that have previously 
been demonstrated to induce transdifferentiation to hepatic or pancreatic lineages. 
We demonstrated that overexpression of the hepatic transcription factors C/EBPα, 
C/EBPβ and HNF4 resulted in the up-regulation of the hepatocyte genes Albumin and 
Gs and de novo expression of Afp. In complementary experiments we also 
demonstrated that overexpression of the pancreatic transcription factors Pdx1, Ngn3, 
NeuroD and Pax4 resulted in de novo expression of insulin II in BECs.  While these 
results were encouraging further work is necessary to enhance the maturation status 
of the nascent cells. 
We also addressed the role of the Notch signalling pathway in the differentiation of 
embryonic hepatic and pancreatic cells using ex vivo organ culture models of liver and 
pancreas development. We treated pancreata with N-[N-(3,5-Difluorophenacetyl-L-
alanyl)]-S- phenylglycine t-Butyl Ester (DAPT) a gamma-secretase inhibitor.  Treatment 
with DAPT inhibits the Notch signalling pathway.  Following treatment with DAPT we 
observed reduced branching morphogenesis, loss of the acinar cell phenotype 
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(amylase expression) and an enhancement in endocrine differentiation (insulin and 
glucagon expression). We propose that in the absence of Notch signalling the 
proendocrine gene Ngn3 is no longer repressed by the Notch target Hes1, allowing 
endocrine differentiation to take place. Finally we observed that β-cells in pancreata 
treated with DAPT are functionally more mature in terms of responsiveness to glucose 
stimulation. Overall these results have important implications for the development of 
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Chapter 1. Introduction  
1.1. The Adult Liver 
1.1.A. Functions, Physiology and Cell Types 
The adult liver is the largest internal organ in the human body and is responsible for 
carrying out over 500 functions. These functions are diverse and range from metabolic 
functions (including gluconeogenesis, glycogenolysis and lipogenesis) to functions 
involved in detoxification, metabolite storage, immunity and ureagenesis. The liver 
also functions as both an endocrine and exocrine organ. The endocrine function of the 
liver is the production of serum albumin as well as other proteins, including 
lipoproteins. The exocrine function of the liver is the production of bile acids for the 
breakdown of lipids, however bile acids also have an endocrine function, and are able 
to regulate triglyceride, cholesterol and glucose homeostasis [1].  These examples 
typify the complex and interacting functions that the liver performs.  
Approximately 80% of liver mass is composed of a single cell type- the hepatocyte. 
Hepatocytes display remarkable functional heterogeneity which is related to their 
location within the functional unit of the liver, the acinus or lobule, (for a review see 
[2]).  
The hepatic lobule is composed of hepatocytes that surround the central vein and 
radiate out towards the portal triad (composed of a branch of the hepatic artery, 
portal vein and bile duct) in an approximately hexagonal shape (Fig 1.1). Those 
hepatocytes located closest to the central vein are termed perivenous (PV) 
hepatocytes. Hepatocytes located close to the portal triad are termed periportal (PP) 
hepatocytes.  PP hepatocytes have higher activities of enzymes involved in oxidative 
metabolism whereas PV hepatocytes exhibit a preference for xenobiotic metabolism 
[3-4]. The process of ammonia removal has been found to be highly zonated in the 
liver. Ammonia removal is facilitated by two processes, the urea cycle and the enzyme 
glutamine synthetase (GS). PP hepatocytes are responsible for ammonia removal via 
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the urea cycle and the cells have been shown to express carbamoylphosphate 
synthetase I (CPS), the rate-limiting enzyme in the urea cycle. Conversely, PV 
hepatocytes remove urea by the action of the enzyme glutamine synthetase [4]. 
Glucose metabolism is also zonated in the liver. PP hepatocytes undertake 
gluconeogenesis and therefore express the enzyme phosphoenolpyruvate 
carboxykinase (PEPCK), while PV hepatocytes perform glycolysis and express the 





Other cells that comprise the adult liver include hepatic stellate cells, sinusoidal 
endothelial cells, Kupffer cells and cells of the intrahepatic biliary system (termed 
cholangiocytes).  Hepatic stellate cells are normally quiescent cells that are activated 
upon liver injury and are involved in fibrosis and cirrhosis [5]. Sinusoidal endothelial 
Figure 1.1. Structure of the Hepatic Lobule. 
Hepatocytes located close to the portal triad (composed of a branch of the hepatic artery 
(HA), portal vein (PV) and bile duct (BD)), express carbamoylphosphate synthetase I (blue) 
and hepatocytes located close to the central vein express glutamine synthetase (red). A 
periportal to perivenous gradient of expression of metabolic enzymes leads to functional 
heterogeneity called zonation. Source: Burke and Tosh 2006 [4]. 
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cells are endothelial cells unique to the liver that filter substances that are exchanged 
between the sinusoidal lumen and hepatocytes [6]. Kupffer cells are macrophages that 
reside in the lumen of liver sinusoids and respond to infection [7]. Cholangiocytes are 
cells that line the intrahepatic duct and are responsible for collection, modification and 
transport of bile from the hepatocytes to the common hepatic duct [8]. 
1.1.B. Liver Pathologies and Treatments 
Liver disease is the name given to a wide range of pathologies that ultimately give rise 
to liver fibrosis and eventually cirrhosis, which can lead to liver failure. Causes of liver 
disease or damage include infection with hepatitis A, B and C, Wilsons disease 
(accumulation of copper in the body), excessive alcohol consumption, drug use (the 
most common form of chemical liver damage results from overdose of 
Acetaminophen-paracetamol), some metabolic diseases (e.g. alpha1-antitrypsin 
deficiency) and autoimmune destruction of hepatocytes [9]. Fibrosis is the 
accumulation of extracellular matrix that occurs when fibroblasts and hepatic 
precursors are activated, by liver injury, and adopt a myofibroblast phenotype. These 
fibroblasts are thought to include hepatic stellate cells and portal fibroblasts as well as 
potentially, fibroblasts present in the Glisson’s capsule and vascular smooth muscle 
cells [10]. Cirrhosis is described as the far end of the fibrosis spectrum but it is also 
characterised by the formation of parenchymal nodules and disorganisation of the 
lobular architecture [11]. 
 Although the liver has the capacity to regenerate, long-term damage is often 
irreversible and frequently the only option for patients is transplantation. Liver 
transplantation is often undesirable due to factors such as lack of donors, risks 
associated with organ rejection and the long-term implications of the use of 
immunosuppressant drugs. Advances have been made in the use of extracorporeal 
liver support devices (bioartifical livers) [12], however for practical reasons, such 
devices are more useful as a short-term bridge to transplantation, rather than a long-





1.1.C. Transdifferentiated Hepatocytes for Treatment of Liver Failure 
A range of tissue engineering solutions have been proposed as potential treatments 
for liver disease including stem cell treatments (For review see [13]). The gold standard 
for tissue replacement is to use a patient’s own cells to reduce the risk of rejection and 
to solve issues surrounding the ethical use of embryonic stem cells (which can be 
differentiated towards hepatocyte-like cells). One method by which a patient’s own 
cells could be used is by transdifferentiation of a non-hepatic cell type to a hepatic 
phenotype. 
Transdifferentiation is defined as the conversion of one differentiated cell type to 
another [14-15] and proposes that terminally differentiated cells are not 
developmentally “fixed” but are capable of reversal either to a stem cell-like 
progenitor intermediate or, can directly transdifferentiate to another mature cell type. 
Induced pluripotent stem cells (iPS cells) form part of the evidence that mature cells 
are capable of reversal to embryonic-like states. iPS cells are produced by viral 
introduction of four genes Oct4, Sox2, c-Myc and Klf4 [16], this was first achieved in 
mouse cells and later, iPS cells were produced from human cells, without the use of c-
Myc, reducing the risk of tumorigenicity [17]. Most recently so called, protein induced 
pluripotent stem cells (piPS cells) have been produced, using a poly-arginine protein 
transduction domains to deliver recombinant proteins of the four reprogramming 
factors directly to the cells [18-19]. Reprogramming cells in this way eliminates the 
requirement for genetic modification of donor cells, making them safer for 
transplantation. However the main limitation is the identification of robust protocols 
for the differentiation of iPS cells to mature, fully-functioning cell types. 
There is evidence to suggest that, at least some mature cell types can be converted 
directly to hepatocyte-like cells without the need for reprogramming to embryonic 
intermediates (direct transdifferentiation). Specifically, pancreatic cells are a potential 
source of donor cells for transdifferentiation to hepatocytes. It is thought that 
hepatocytes and pancreatic cells are able to undergo transdifferentiation as they have 
a close developmental relationship, both having arisen from adjacent regions of the 
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developing foregut endoderm (discussed in more detail in section 1.3). It has been 
proposed that transdifferentiation can be more easily induced between 
developmentally related tissues as there will be fewer differentially expressed genes 
than more distantly related tissues [20]. In vivo, ectopic hepatocytes have been found 
in the pancreas of rats fed on a copper-deficient diet [21] and in the islets of 
Langerhans of transgenic mice, expressing keratinocyte growth factor (KGF) under the 
control of the insulin promoter [22]. In vitro the pancreatic cell line AR42J-B13 (B13) 
has been shown to transdifferentiate to a hepatocyte-like phenotype on treatment 
with the synthetic glucocorticoid Dexamethasone (Dex [23]). The ability to remove a 
patient’s own cells, transdifferentiate them in culture, expand the transdifferentiated 
population and transplant these cells back into a patient, could represent a treatment 
for liver failure that removes the need for a donor and provides histocompatible cells 
that do not pose a risk of rejection.  
1.2. The Adult Pancreas 
1.2.A. Functions, Physiology and Cell Types 
The adult pancreas is a glandular tissue with both exocrine and endocrine functions. 
The exocrine portion of the pancreas is responsible for the production of digestive 
enzymes for the breakdown of proteins, lipids and nucleic acids, it is composed of a 
highly branched ductal epithelium that terminates in clusters of acinar cells called acini 
(Fig 1.2 B).  The endocrine pancreas is responsible for secretion of hormones that 
regulate blood glucose levels. There are five different cell types that compose the 
endocrine pancreas each secretes a specific hormone that regulates a different aspect 
of glucose homeostasis. All five cell types are located within structures called the islets 
of Langerhans (Fig 1.2C [24]). Islets are distributed through the exocrine tissue of the 
pancreas. Pancreatic α-cells produce the hormone glucagon, which raises blood 
glucose levels, β-cells produce insulin which lowers blood glucose. The levels of 
glucagon and insulin release are controlled by the hormones somatostatin and 
pancreatic polypeptide (PP), which are produced by δ- and PP-cells respectively. The β-
cell is usually the most numerous inside the islet and these tend to be found in the 
centre of the islet with α-, δ- and PP-cells surrounding them. More recently a fifth cell 
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type has been identified within the islet called the ε-cell that produces a hormone 
called ghrelin that is known to regulate insulin levels [25] and more recently has been 






1.2.B. Pancreas Pathologies and Treatments 
 The main pathology of the pancreas is Diabetes Mellitus. Diabetes is characterised by 
the inability to regulate blood glucose homeostasis and four different types of the 
disease exist, Type I, Type II, gestational diabetes and MODY (maturity diabetes of the 
young). Type II, gestational and MODY diabetes are often the result of insulin 
resistance at target cells (adipose tissue, muscle and liver), although it is increasingly 




Figure 1.2. Structure of the Adult Pancreas, Ductal System and Islet Organisation. 
A. Gross structure of the adult pancreas with elongated glandular structure and 
connection with the common bile duct and duodenum. B. The exocrine pancreas that is 
composed of a branching ductal system that terminates in bulbus acini composed of 
acinar cells. C. The endocrine cells of the pancreas arranged into islets of Langerhans. 
Islets are composed of glucagon-producing α-cells, insulin-producing β-cells, Pancreatic 
polypeptide-producing PP-cells, Somatostatin producing δ-cells and ε-cells that produce 
Ghrelin (not shown in this diagram). Source: Bardeesy and DePinho, 2002 [24]. 
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important in the pathophysiology of type II diabetes [27-28]. Type I diabetes is an 
autoimmune disease, in which patients who are genetically predisposed, produce 
autoantibodies (often islet cell cytoplasmic autoantibodies-ICAs) that target β-cells for 
destruction leading to insufficient insulin production and blood glucose dysregulation 
[29]. Although accurate blood glucose monitoring equipment and insulin 
administration have come a long way in recent years, some patients still suffer from 
insufficient glycaemic control. Long-term blood glucose dysregulation can lead to 
complications in a patient’s macrovascular system, causing vascular calcification and 
atherosclerosis, but also the microvascular system, causing retinopathy which can lead 
to blindness and nephropathy which can lead to kidney failure [30].  
Currently, most patients with type I diabetes are treated with recombinant human 
insulin injection. Significant progress has been made in producing insulin analogues 
that are absorbed more quickly and efficiently, this in combination with development 
of continuous glucose monitoring devices has improved blood glucose regulation 
outcomes for diabetic patients [31]. Despite these improvements, insulin 
administration only represents a treatment and not a cure for type I diabetes. A 
potential cure for diabetic patients is islet cell transplantation, made more feasible by 
the use of the Edmonton protocol [32] . Many patients who have received islet 
transplantation have shown improvements in glucose regulation, however very few 
remain insulin independent, especially in the long term [33]. The limitations of islet 
transplantation surround the requirement for immunosuppressants, to prevent 
rejection [33] and the potential for patients to be re-exposed to autoantigens that 
cause the disease [34]. Other potential cures for type I diabetes are gene therapy or 
cell replacement therapies aimed at restoring insulin production. Gene therapy 
treatments involve the introduction of the insulin gene, into another cell type (other 
than the β-cell). This would be achieved in vivo, most commonly through viral infection 
of a patient’s own cells and would therefore not require a donor or 
immunosuppressant regimes [35]. Given the complex way in which β-cells sense, 
produce and release insulin in response to changes in blood glucose levels, a cell type 
that simply produces insulin would not be sufficient to cure the disease, therefore cell 
replacement therapies may offer a more holistic option. Research into stem cell based 
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therapies for diabetes is ongoing (for review see [36]). However ethical and safety 
issues surround their use. As is the case for treatment of liver disease, there is 
evidence that transdifferentiated somatic cells may be a suitable cell source of β-cells 
for treatment of type I diabetes. 
1.2.C. Transdifferentiated β-Cells for the Treatment of Type I Diabetes 
The close developmental relationship between hepatic and pancreatic cells types 
indicates that liver cells may be a potential source of cells capable of 
transdifferentiation to β-cells. In fact bile-duct-derived β-cells have been observed in 
the extrahepatic bile ducts of mice, along with other endocrine pancreatic cell types, 
reinforcing the relationship between hepatic cells and β-cells [37]. Research on liver to 
pancreas transdifferentiation has focused on over-expression of the pancreatic 
transcription factor, pancreatic duodenal homeobox gene 1 (Pdx1), which is essential 
for pancreatic development and mature β-cell function (discussed in detail later in 
section 1.3.C). It has been demonstrated that Pdx1 is essential for pancreatic 
development as Pdx1 knockout mice are apanceratic [38]. 
In vivo, transgenic Xenopus embryos expressing the Pdx1 homologue Xlhbox8, in 
hepatocytes (under the control of the transthyretin (TTR) promoter), resulted in the 
formation of whole ectopic pancreas in the liver [39]. Injection of Pdx1 has also been 
used to prevent hyperglycaemia in mice treated with streptozocin (STZ), a model of 
diabetes [40]. Although the results of Pdx1 injection were only able to restore 
normoglycaemia for short periods (between 7-40 days) it is further evidence of the 
importance of Pdx1 in insulin production [41]. The crucial role of Pdx1 in β-cell 
development and function has lead to its description as a ‘master switch’ gene for 
pancreas development [42], however other genes are potential targets for diabetes 
treatments including Neurogenic differentiation (Neuro D), Neurogenin 3 (Ngn3) and 
MafA [43-44]. A combination of Pdx1, Ngn3 and MafA have been shown to produce β-
like cells from pancreatic exocrine cells, in vivo [45]. In vitro the human cell line HepG2 
has been infected with the same Xlhbox8 construct as in Xenopus embryos, resulting in 
the formation of both pancreatic endocrine and exocrine cells [39]. Cultured 
hepatocytes have also been induced to transdifferentiate to insulin producing cells and 
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when transplanted into STZ treated mice can reduce blood glucose levels [46]. In terms 
of clinical applications cultured cells may be preferable to in vivo treatments as they 
reduce the risk of vector toxicity and cells can be screened prior to implantation to 
improve quality and safety. 
Aside from the use of genetic modification to produce β-like cells, extracellular factors 
that are linked to β-cell differentiation have been proposed as potential methods of 
inducing and/or enhancing transdifferentiation. Laminin 1 is known to be important for 
the differentiation of foetal pancreatic cells to β-cell fates [47]. Betacellulin can 
promote β-cell differentiation in embryonic pancreas [48] and has been shown to 
induce islet formation in the liver (in combination with Neuro D) [49]. Activin A in 
combination with betacellulin has been shown to induce rat pancreatic duct cells to 
assume a β-cell-like phenotype and these cells have been used to rescue blood glucose 
regulation in STZ treated mice [50]. These extracellular factors may indicate that vector 
free transdifferentiation may be possible, which would pose fewer risks to patients, 
but also these factors may be used to improve the β-cell phenotype of cells 
transdifferentiated by genetic modification.       
 
1.3. Embryonic Development of Liver and Pancreas    
1.3.A. Gut Tube Formation 
Gastrulation is a process of cell movements that results in the appearance of the three 
primary germ layers, the ectoderm, mesoderm and endoderm.  Cells of the ectoderm 
eventually differentiate to give rise to epidermal and neural cells [51]. Mesoderm cells 
become muscle cells including cardiac, skeletal and smooth muscle as well as blood 
cells and cells of the urinogenital system. Endodermal progenitors will eventually give 
rise to cells that will form the organs of the respiratory tract (including the lungs), and 
the gastrointestinal tract (including the stomach, intestine and colon) as well as 
associated organs (including liver and pancreas) [52]. Endodermal cells also give rise to 
cells of glands such as the thyroid and thymus [52]. 
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Definitive endoderm is specified by a gradient of Nodal signalling, indeed high levels of 
Nodal signalling give rise to endoderm formation, lower levels favours mesoderm 
formation [53]. Transcription factors, downstream of Nodal signalling that are 
important in endoderm development include Mxl1, Sox17, Foxa2 and Tcf2 [53]. After 
gastrulation (approximately E7.5 in mouse embryos) the endoderm is present as a cup-
like structure, consisting of around 500 cells in a single layer, covering the mesoderm 
(Fig 1.3). Although immature the endoderm already shows some anterior-posterior 
patterning. The transcription factors Hhex, Sox2 and Foxa2 are expressed anteriorally 
in the embryo and Cdx1, 2 and 4 posteriorally, these transcription factors are essential 
for establishment of A-P positioning in the early gut tube. Hhex, Sox2 and Foxa2 are 
required for foregut development and Cdx genes are required for hindgut 
development [52]. By embryonic day 8.5 the cup-like endoderm is transformed into a 
primitive gut tube with four distinct regions (Fig 1.3). Region I is the ventral foregut 
that will develop into liver and ventral pancreas. Region II is dorsal foregut endoderm 
which will give rise to stomach, dorsal pancreas and duodenum, while region III, 
midgut endoderm, will contribute to the intestine. Region IV is hindgut endoderm, 










Figure 1.3. Early Gut Tube Formation 
A. At E7.5 the endoderm is a one cell think cup-like structure that covers the mesoderm and 
ectoderm. Even this early in development the endoderm displays some anterior-posterior 
identity. B. By E8.5 the endoderm has transformed into an open tube structure with four 
distinct regions. The AIP (anterior intestinal portal) and CIP (caudal intestinal portal) extend 




The process of primitive gut formation is complete when the region at the anterior end 
of the endoderm, called the anterior intestinal portal (AIP) and the region at the 
posterior end of the endoderm, called the caudal intestinal portal (CIP) have extended 
towards the centre of the embryo and closed to form the primitive gut tube, this is 
complete by E9.  
 By E9.5 the process of organ budding begins, during this process epithelium of the 
endoderm invades the surrounding mesenchyme to form buds that will eventually, 
differentiate into the different cells lineages required for organ specification. It is 
thought that an overlapping network of cross-acting transcription factors are required 
to specify particular lineages from the four regions of the primitive gut tube (Fig 1.4) 
[52]. For the purposes of this thesis we shall focus on the development of the liver and 






Figure 1.4. Specification of the Early Gut Tube and Anterior-Posterior Transcription Factor 
Expression. 
Schematic of E10.5 gut tube showing regions specified for different organ development. Liver 
region (orange) pancreatic region (green). Below is a representation of the overlapping 
domains of transcription factor expression that is important for specification of the different 
domains. Not all factors are expressed at the same time and not all are expressed as 
development continues. Source: Zorn and Wells, 2009 [52].   
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1.3.B. Embryonic Liver Development 
1.3.B.1. Liver Specification 
As the gut tube begins to close, two populations of endodermal progenitor cells 
become primed for hepatic differentiation through the action of Foxa [55] and Gata4 
[56] transcription factors. It is thought that these progenitors arise from three different 
regions of the developing foregut endoderm [57], which converge to reside alongside 
the developing heart tissue [58]. Developing heart tissues of the propericardium and 
septum transversum produce signals of the Fibroblast Growth Factor (FGF) family (Fig 
1.5). FGF1 and 2 are essential for mouse liver development and treatment with 
exogenous FGF1 and 2 has been shown to be sufficient to replace cardiac mesoderm in 














Figure 1.5. A Schematic of Signalling Pathways Convergent on the Developing Liver. 
Schematic of the signals expressed in tissues surrounding the developing endoderm 
(purple). FGF signals from the cardiac mesenchyme (CM,red) and BMP signals from the 
septum transversum (ST, blue) are important for establishing liver specification. WNT 
signalling may also be required for liver specification, either directly or through activation 
of BMPs. Source: Burke et al, 2006 [58].  
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The septum transversum also produces bone morphogenic proteins (BMPs) that act in 
parallel with FGFs to control hepatic specification, specifically BMP4 is necessary for 
the induction of liver genes and repression of the pancreatic fate [60]. It is thought 
that BMP4 acts by up-regulation of Gata4 [60] which is responsible for priming 
endoderm cells to assume hepatic fates.  
More recently a role for Wnt signalling in hepatic development has been identified; 
however evidence for the action of Wnts is contradictory. In early development Wnts 
are thought to repress Hhex expression in the posterior endoderm (Hhex is the earliest 
marker of liver development and is an essential regulator of hepatic differentiation). 
Furthermore expression of the frizzled-related protein 5 gene, that encodes a secreted 
Wnt antagonist [61] in the foregut endoderm, indicates inhibition of Wnt signalling 
may be required for hepatic specification. In contrast the zebrafish mutant 
Prometheus (prt) shows abnormal liver specification and reduced liver development 
[62]. The prt gene encodes a novel Wnt2b homologue called Wnt2bb that is expressed 
in the lateral plate mesoderm, adjacent to the developing liver region in zebrafish [62]. 
It has been proposed that a combination of Wnt2bb and Wnt2b signalling is needed 
for liver specification in zebrafish, with loss of function leading to liver agenesis and 
excess expression leading to ectopic liver production at the expense of pancreatic 
tissue [63]. This is the first evidence for a positive role for canonical Wnt signalling in 
liver specification; however prt mutants that lack evidence of early liver specification, 
often recover liver development and survive into adulthood [62]. This may indicate a 
compensatory mechanism for Wnt signalling in liver specification.  
The Wnt2bb orthologue Wnt13 is expressed in mice under the heart (Fig1.5), making 
its expression pattern similar to that of Wnt2bb in zebrafish [64] perhaps indicating a 
role for Wnts in mammalian liver specification.  
1.3.B.2. Liver Bud Formation 
By E8.5 in mouse embryos the combination of FGFs, BMPs and potentially Wnt 
signalling from the septum transversum, results in the appearance of hepatic 
progenitors called hepatoblasts. Hepatoblasts are bipotential precursors that will give 
rise to both hepatocytes and cholangiocytes of the intrahepatic ductal system. 
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Hepatoblast specification is thought to be induced by FGF, BMP and Wnt activation of 
Foxa1,2,3 transcription factors and HNF1β [65-66]. Hepatoblasts are characterised by 
the expression of Hhex [67], albumin (Alb), alpha fetoprotein and (Afp) and 
Transthyretin [68].  
The change in morphology from endodermal progenitor to hepatoblast results in the 
formation of a bulging columnar epithelium, which impinges on the surrounding 
septum transversum mesenchyme. At E9.5 the basement membrane surrounding the 
developing liver is degraded, the hepatoblasts delaminate and invade the surrounding 
septum transversum. Hepatocytes migrate by forming a pseudostratified epithelium 
and undergo interkinetic nuclear migration [69]. Migration is controlled by Hhex 
expression, which allows formation of the pseudostratified epithelium [69] but also 
requires the action of matrix metalloproteinases [70] and the transcription factors 
Prox1 [71], Gata6 [72], Hnf6 and Onecut2 [73].  
After invasion into the septum transversum mesenchyme the hepatic tissue grows in 
volume under the combined action of HGF [74], TGFβ [75] and FGF8 [59] signals, and 
thereafter hepatoblast differentiation to hepatocytes and cholangiocytes begins. 
1.3.B.3. Bile Duct Morphogenesis 
Before discussing cell fate decisions in hepatoblasts it is important to discuss the 
formation of tissue architecture, which coincides with cellular differentiation. During 
the mid-gestational stages of development, differentiating hepatocytes are arranged 
into cords and become associated into sinusoids. The transcription factor HNF4α is 
necessary for hepatic morphogenesis and establishment and maintenance of 
sinusoidal architecture [76]. Also important is the development of the sinusoidal 
capillary network and development of the intrahepatic and extrahepatic biliary trees 
(for review see[77]), however for the purposes of this thesis only intrahepatic biliary 
development will be discussed in detail. 
Bile duct morphogenesis is first observed by the formation of the ductal plate, a 
monolayer of biliary progenitor cells that surrounds the PP mesenchyme at E14.5-15.5 
in mouse embryos [78](Fig. 1.6A). Ductal plate formation is activated by Jag1 
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expression in endothelial cells; this activates Notch signalling which triggers the onset 
of biliary differentiation in PP hepatoblasts [79]. Cells of the ductal plate express biliary 
markers including Ck19, Sox9 and Hnf1β and also express the Notch ligand Jag1 [79]. 
The ductal plate then undergoes a process of remodelling, between E16.5-17.5, which 
results in the formation of branching ductal structures. At specific locations within the 
ductal plate Jag1 expression in existing ductal plate cells activates the Notch signalling 
pathway which causes the formation of a second layer of hepatoblasts surrounding the 
ductal plate [79]. This second layer of hepatoblasts does not immediately differentiate 
to a duct progenitor phenotype, but becomes separated from the Sox9-positive ductal 
plate by a luminal space; this produces an asymmetric duct structure [78] (Fig 1.6 B-C). 
Between E17.5 and postnatal day two of mouse development, the hepatoblasts of the 
asymmetric duct differentiate to a ductal phenotype [78]. Proliferation of the 
surrounding mesenchyme, development of periluminal glandular structures and 
apoptosis of redundant ductal plate cells [80] leads to a mature duct system by post 
natal day 15 (Fig 1.6D).   
Notch signalling is thought to promote tubulogenesis via regulation of Hes1 
expression, which is not required for duct cell differentiation but is essential for duct 
morphogenesis [81]. TGFβ signalling is also important for duct morphogenesis in the 
liver and is thought to act via activation of Sox9 expression, however Sox9 deficient 
embryos only show a delay in biliary morphogenesis and eventually give rise to 
functional ducts [78]. Other transcription factors involved in biliary cell differentiation 
are also involved in morphogenesis including Hnf1β [82]. However changes in duct 
structure caused by down-regulation of these genes may be the result of failure to 







1.3.B.4. Hepatoblast Cell Fate Decisions 
As described above both hepatocytes and bile duct cells (or cholangiocytes) are 
derived from a bipotential population of hepatoblasts. The developmental fate of 
hepatoblasts is dictated by their location within the developing liver. Hepatoblasts 
located close to the portal vein will differentiate to cholangiocytes (initially forming the 
ductal plate) and hepatoblasts located within the parenchyma will become 
hepatocytes. The signal thought to specify hepatocyte or cholangiocyte fate is an 
Activin/TGFβ signalling gradient that is established between the portal vein and the 
parenchyma (Fig 1.7). Activin/TGFβ signalling is high around the portal vein and this 
allows for differentiation to a cholangiocyte phenotype, conversely Activin/TGFβ 
signalling is low within the parenchyma where hepatocytes develop [83]. The precise 
mechanism of establishment of the Activin/TGFβ signalling gradient is unclear, 
however recent evidence suggests that the Onecut transcription factors HNF6 and OC2 
may inhibit Activin/TGFβ signalling in the parenchyma, allowing hepatocyte 
differentiation [84]. Inhibition of Activin/TGFβ signalling within the parenchyma is 
potentially insufficient to independently establish the required gradient and the 
interaction of other signalling pathways including HGF, EGF and Wnt signalling have 
been proposed (Fig 1.7). Notch signalling is also involved in cholangiocyte 
development, although this is thought to act downstream of Activin/TGFβ signalling 
[83].  
Figure 1.6. A Model of Hepatic Duct formation by Asymmetric Tubulogenesis. 
A. Appearance of the single layer ductal plate. B. Formation of a second layer of hepatoblasts 
over the ductal plate. C. Emergence of luminal space between ductal plate and hepatoblasts, 
forming a temporary asymmetric duct. D. Differentiation of hepatoblasts to ductal fate 







Notch is thought to act by alteration of liver enriched transcription factors, specifically 
causing the up-regulation of Hnf1β, which is required for cholangiocyte differentiation, 
and down-regulation of Hnf1α, Hnf4 and C/EBPα, which are required for hepatocyte 
differentiation [85].  
Hepaotcyte differentiation is controlled and maintained by a complex network of 
cross-regulatory cascades of transcription factors [86] from six different families of 
liver enriched transcription factors (Table 1.1). These transcription factors are 
responsible for activation of liver genes such as Albumin, alpha1 antitrypsin (α1-AT), 
alpha fetoprotein (AFP), phosphoenolpyruvate carboxykinase (PEPCK), transthyretin 
(TTR) and tyrosine aminotransferase (TAT). Liver enriched transcription factors are also 
responsible for transactivation of other transcription factors that form the hepatocyte 
network as well as direct activation of hepatic genes [87].     
Figure 1.7. Cell Fate Decisions in Hepatoblasts. 
HNF6 and OC-2 are expressed at low levels in hepatoblasts and hepatocytes but at high levels 
in duct cells. HNF6/OC-2 activates a cascade of factors that results in establishment of an 
activin/TGFβ gradient that, when high promotes biliary differentiation over hepatocyte 
differentiation. The downstream factors activated by Activin/TGFβ are not shown. Source: 
Clotman and Lamaigre, 2006 [83].   
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Table 1.1. Transcription factors important for differentiation and maintenance of gene 
expression in hepatocytes. Compiled from Schrem et al, 2004 [88] and Costa et al, 2003 [89].  
 
1.3.C. Embryonic Pancreas Development 
Development of the pancreas in mouse can be broadly divided into two phases, 
primary and secondary transition [90]. Primary transition occurs between E8.5-10.5 
and involves specification of pancreas from the endoderm, bud formation, pancreatic 
progenitor appearance and appearance of the first wave of endocrine cells. A period of 
bud outgrowth and dorsal and ventral bud fusion occurs between E10.5-13.5 prior to 
the onset of secondary transition. Secondary transition begins at E13.5 and is complete 
by E15.5 and is characterised by further growth and branching morphogenesis as well 
as the appearance of fully differentiated α-,β-,δ-, PP-,ε- and acinar cells. Between 
E15.5 and 18.5 further growth and formation of islet structures occurs and maturation 
of the islets continues into early postnatal life.  
1.3.C.1. Pancreas Specification 
In contrast to liver organogenesis the pancreas arises from two distinct regions of the 
developing foregut endoderm. These regions give rise to two embryonic buds; the 
dorsal and ventral pancreatic buds. As development progresses these two buds fuse to 
give rise to the mature pancreas. 
Transcription Factor Family 
Transcription factors important for 
regulation of gene expression in hepatocytes 
Forkhead Box (Fox) family Hnf3α, Hnf3β 
Onecut (OC) family Hnf6 
Basic Region leucine zipper (bZIP) family C/ebpα, C/ebpβ 
Pou-Homeodomain family Hnf1α 
Nuclear hormone receptor family Hnf4α 
Proline and acidic amino acid-rich basic 
leucine zipper (PAR bZIP) family 
D-site binding protein 
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Specification of the pancreatic buds from early endoderm is dependent, first on 
anterior-posterior patterning of the early gut tube endoderm. Signals from the lateral 
plate mesoderm, such as activin, BMP and retinoic acid, pattern the developing 
endoderm in a posterior-dominant fashion. Stimulation of these signalling pathways 
during development leads to formation of early pancreatic progenitors in more 
anterior regions of the gut tube than those that normally specify pancreas [91]. 
Retinoic acid is required for specification of the dorsal pancreatic endoderm, and 
ventral pancreas can still develop in the absence of retinoic acid signalling [92]. 
Although these signals do not directly induce differentiation to pancreatic lineages, 
they act with transcription factors expressed within the epithelium to produce cells 
that are primed for pancreatic differentiation. Genes expressed within the pre-
pancreatic endoderm include Hhex, Hnf6, Hnf1β and Foxa2 [93]. However these are 
expressed in other regions of the developing endoderm. The earliest specific marker of 
pancreatic specification is Pdx1, which is first observed in the ventral pancreatic 
domain at E8.5 then in the dorsal domain at E8.75 [94]. 
1.3.C.2. Dorsal and Ventral Bud Formation    
The dorsal and ventral pancreatic buds are initiated by exposure to different stimuli 
that are dependent on the proximity of the buds to different tissues within the 
developing embryo. At E8.5 the dorsal pre-pancreatic endoderm lies adjacent to the 
notochord, which is required to produce signals for dorsal pancreatic bud formation 
[95]. Notochord signalling to the dorsal pancreatic region is thought to function 
through activin/TGFβ signals that act by repressing Sonic Hedgehog (Shh) in the pre-
pancreatic endoderm [96]. Sonic Hedgehog repression is required for pancreatic bud 
formation and Apelqvist et al have demonstrated that expression of Shh under the 
Pdx1 promoter in embryos leads to intestinal differentiation in pre-pancreatic 
endoderm [97]. FGF2 has also been implicated as a notochord derived signal for Shh 
repression in the dorsal pancreas [98]. 
 At around E8.75-E9 the notochord is displaced from the endoderm by dorsolateral 
splanchnic mesenchyme which becomes the dorsal aorta. Signals from the dorsal aorta 
are required for further dorsal pancreatic bud formation [99]. 
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The ventral pancreatic bud is initially in contact with the lateral plate mesoderm (LMP) 
that provides instructive signals for ventral pancreatic bud formation. Lateral plate 
mesoderm induction of ventral pancreas can be mimicked by BMP and activin 
signalling [100], indicating that these are the signals that control ventral budding. Later 
the ventral bud is exposed to the septum transversum mesenchyme where FGF and 
BMP signals specify liver development (See 1.3.B) and restrict the pancreatic fate to 
the ventral bud [100].  
1.3.C.3. Early Pancreatic Progenitors 
Formation of the pancreatic buds between E8.5-E10.5 results in the appearance of 
pancreatic progenitors that are specified to become pancreas. These progenitors are 
identified by co-expression of Hlxb9, Pdx1, the homeodomain transcription factors 
Nkx2.2 and Nkx6.1 and pancreas-specific transcription factor 1α (Ptf1α) [93]. These 
transcription factors are important for both formation of the pancreatic buds and later 
for differentiation to pancreatic cell types. 
 
 
Figure 1.8. Correlations Between Early 
Morphogenetic Events and Pancreatic 
Gene Expression in the Dorsal 
Pancreatic Bud. 
The earliest pancreatic gene 
expression is observed in the pre-
pancreatic endoderm around E8.25 
(Hlxb9, red), followed by Pdx1 
expression at E8.5 (green) which is 
the earliest specific marker of 
pancreatic development. Later at 
E9.25 Ptf1α is co-expressed in the 
pancreatic bud (blue) however by 
E11.5 its expression is restricted to 
the tips of developing branches which 
will become exocrine acinar cells. 




Hlxb9 is expressed as early as E8.25 in the pre-pancreatic endoderm (Fig 1.8). In the 
absence of Hlxb9 the dorsal bud fails to form, ventral pancreas specification is still 
initiated but β-cell differentiation is perturbed [101]. Hlxb9 is expressed in pancreatic 
progenitors of both the dorsal and ventral pancreatic buds by E9.5 but becomes 
restricted to β-cells in later development.  
Pdx1 is not required for specification of the pre-pancreatic endoderm, as Pdx1 
knockout embryos show normal bud formation [102]. Pdx1 is necessary for 
differentiation to early pancreatic progenitors and post-bud stages of development 
[103] as a result Pdx1 knockout mice are apancreatic [38]. Pdx1 is expressed as early as 
E8.5 prior to gut tube closure but after E14.5 is restricted to selected cells of the 
central pancreatic epithelium that will become β-cells. 
The homeodomain transcription factors Nkx2.2 and Nkx6.1 have no known function in 
bud formation and double mutant embryos have no early phenotype, but at later 
stages β-cells fail to develop [104]. Nkx2.2 is expressed around E8.75 and Nkx6.1 later 
at around E9.5. During development, Nkx2.2 is restricted to α-, β-, and PP-cells and 
Nkx6.1 is restricted to β-cells only.  
Ptf1α is essential for the acquisition of the pancreatic progenitor phenotype and later 
acquisition of pancreatic fates [105]. Ptf1α is thought to induce dorsal pancreas 
development after induction in pancreatic endoderm by adjacent endothelial cells 
[106]. During differentiation Ptf1α is restricted to the growing tips of the branching 
epithelium that will give rise to acinar cells.    
The pancreatic precursor population is also dependent on the transcription factor Sox9 
for proliferation, survival and maintenance of the progenitor cell type. Sox9 is only 
expressed in a subset of pancreatic progenitors and is thought to act via a Notch-
dependent mechanism [107]. 
1.3.C.4. Appearance of Early Endocrine Cell Types 
The appearance of expression of endocrine peptide hormones has been reported as 
early as E9.5 with the appearance of both insulin and glucagon detected by 
immunoreactivity [108]. Cells at this stage appear to co-express insulin and glucagon 
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and it has been proposed that this co-expression is transient and extinguished as 
development proceeds, leading to a restriction in expression to produce differentiated 
islet cell types [108].  Later at E10.5 cells expressing different combinations of insulin, 
glucagon and somatostatin have been observed by single cell RT-PCR of dorsal 
pancreatic bud cells [109]. The fate of early endocrine cells is still debated and recent 
cell lineage tracing of mature α- and β-cells has demonstrated that they are derived 
from cells that have never previously transcribed insulin or glucagon [110]. This 
indicates that early, primary transition cells that express endocrine genes may not 
contribute to the adult islet.   
1.3.C.5. Bud Outgrowth  
Prior to the onset of secondary transition, progenitor cells of the dorsal and ventral 
pancreatic buds expand rapidly between E10.5-13.5. At this stage the pancreatic 
epithelium is closely associated with the mesenchyme and mesenchymal-epithelial 
signalling is essential for proliferation of pancreatic progenitors [111]. Factors thought 
to mediate the mesenchyme stimulation of epithelial outgrowth include Fgf10. Fgf10 
knockout mice have hypoplastic pancreata due to reduced growth of epithelial 
progenitors [112]. Wnt signals have also been shown to be required for epithelial 
outgrowth as overexpression of a dominant-negative form of the Frizzled receptor Frz3 
in pancreatic progenitors results in perturbed growth of the epithelium [113]. Growth 
of the epithelium at this stage is very important as adult pancreas size is thought to be 
limited by the size of the progenitor pool established at this stage and is not 
dependent on the later effects of growth-factor-regulated proliferation or apoptosis 
[114]. 
During this phase the gut tube rotates to causing the dorsal and ventral pancreas to 
fuse to become one organ around E12.5 (Fig 1.9[115]). Although the mechanism of 
bud fusion is not well understood the embryonic buds are thought to fuse at the 
junction between the main pancreatic duct and the accessory duct and at a second 
















1.3.C.6. Secondary Transition - Branching Morphogenesis 
The earliest onset of branching morphogenesis is observed at E12.5 and is thought to 
occur by asymmetric division of multipotent progenitors, this causes new cells to push 
away from the centre of the pancreatic epithelium to produce branches [117]. These 
multipotent progenitors express carboxypeptidase 1 (Cpa1) and are thought to give 
rise to endocrine, exocrine and duct cells [117]. By E13.5 the branches appear as 
protrusions form the epithelium with bulbus tips (Fig1.10). Initiation and regulation of 
branching morphogenesis is poorly understood however recently, Eph-related 
receptor tyrosine kinase signalling (EPH) has been shown to be required for branching 
to take place [118].  
Figure 1.9. Gut Tube Rotation and Fusion of Pancreatic Buds. 
At E12.5 the gut tube rotates bringing the ventral bud in line with the dorsal bud. The 
dorsal and ventral buds fuse at two points to become a single organ. Note the ventral bud 
is posterior and inferior to the dorsal bud and forms the head and uncinate process of the 
mature organ. Source: Savides et al, 1996 [115]. 
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Proliferating pancreatic progenitors within the tips of the growing branches leave 
behind progeny that lose their potential to differentiate to exocrine fates and form the 
stalks of developing branches (Fig 1.10). Stalk cells are specified to become either duct 
cells or endocrine precursors. Later in development endocrine precursors will migrate 
out of the stalks, leaving trunks composed only of duct cells [117]. Bona fide secondary 
transition is said to occur around E14 when tip progenitors differentiated to become 
exocrine cells [119]. Branching morphogenesis continues past secondary transition and 











1.3.C.7. Differentiation of Endocrine cell types 
All endocrine cells are derived from Neurogenin3 (Ngn3)-positive precursors and Ngn3 
is both necessary and sufficient to drive endocrine differentiation [120-121]. A few 
Ngn3-positive cells are observed in the pancreatic progenitor pool at E8.5 and Ngn3 
expression peaks around E11.5-15.5, after which it decreases until postnatal life when 
it is not expressed in pancreatic tissues [122]. Neurogenein3 is usually expressed in 
endocrine precursors that are derived from Pdx1-positive progenitors [122], however 
Figure 1.10. Distribution and Differentiation of Pancreatic Progenitors during Branching 
Morphogenesis 
Multipotent pancreatic progenitors multiply and form tips of developing branches (yellow). 
As tip cells proliferate they leave behind endocrine/duct specific progeny (red) that form 
the developing stalk. Endocrine progenitors emerge in the stalk (green) these will 
eventually delaminate leaving a stalk composed of duct cells (orange). During secondary 




some are found outside the Pdx1 domain suggesting a possible endocrine 
differentiation pathway that is independent of Pdx1 expression [93]. 
 Mice deficient for Ngn3 fail to produce mature endocrine cells or endocrine 
precursors [122]. Neurogenin3 overexpression in embryonic pancreas results in 
excessive differentiation of endocrine precursors [122] and can be used to direct 
endocrine differentiation of embryonic stem cells in vitro [123]. Expression of Ngn3 is 
regulated by Notch signalling (reviewed in detail in Chapter 4 section 4.1.1A ) via 
activation of the Notch target Hairy Enhancer of Split 1 (Hes1), which is a 
transcriptional repressor of Ngn3 [124]. Inhibition of Notch signalling allows 
transcription of Ngn3 and endocrine differentiation [120]. Neurogenin3 expression is 
also controlled by positive regulation, most noticeably by Hnf6 which binds to and 
stimulated the Ngn3 promoter [125]. Hnf6 deficient mice have a marked reduction in 
endocrine differentiation and almost no Ngn3 expression [125]. Other transcription 
factors with binding sites in the Ngn3 promoter include Hnf1α and Hnf3β [124].        
Neurogenin 3 is also sufficient to direct endocrine precursor delamination from the 
epithelium into the mesenchyme where they begin to cluster into islets of Langerhans 
(Fig 1.11[126]).  Neurogenin 3 acts by activation of Snail2 which post-transcriptionally 
represses E-cadherin. E-cadherin repression in combination with breakdown of the 
basal lamina is sufficient to allow endocrine precursors to migrate into the 
mesenchyme [127]. 
 
Figure 1.11. Schematic of Differentiation 
and Delamination of Endocrine 
Precursors from the Developing 
Branches of the Pancreatic Duct 
Ngn3-positive endocrine precursors 
present in the trunk of developing 
branches, repress E-cadherin expression 
and basal lamina breaks down. 
Progenitors migrate into the 
surrounding mesenchyme where they 
differentiate into endocrine cells and 
coalesce into islets. Source: Mastracci 
and Sussel, 2012 [126]. 
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Finally Ngn3 induces differentiation to endocrine lineages by initiating a ‘core program’ 
of transcription factors that are expressed in all endocrine precursors and are required 
for development to all endocrine cell types [128]. This core program includes Isl1, 
neurogenic differentiation factor 1 (NeuroD) and insulinoma-associated 1 
(Insm1)[128]. The LIM homeodomain transcription factor Isl1 is required for 
development of the dorsal pancreatic mesenchyme as well as differentiation to 
endocrine fates. Isl1 knockouts have a total loss of differentiated islet cells [129]. Isl1 is 
expressed in all mature endocrine cells but only at low levels in β-cells [121]. NeuroD 
knockout mice display reduction in all endocrine cells, but particularly in β-cells and  
endocrine cells fail to aggregate into mature islets [130]. In mature islets, NeuroD is 
important for insulin gene transcription, however knockouts do show some insulin 
production, indicating a compensatory mechanism [131]. The Zinc-finger factor 
Insulinoma-associated 1,IA-1 (Insm1) gene has also been indicated in endocrine cell 
differentiation as Insm1 deficient mice show reduction in α-,β-, and δ-cell types [132]. 
Insm1 binding sites are present in the insulin promoter that negatively regulate insulin 
transcription, however Insm1 function is restricted to development and is not 
expressed in mature endocrine cells [133].  
Once this core program of endocrine transcription factors has been activated Ngn3-
positive cells, exit the cell cycle, down-regulate Ngn3 expression and begin 
differentiation to specific endocrine cell types within the developing islet.   
1.3.C.8. Islet Cell Differentiation 
After Ngn3-dependent specification on endocrine precursors and their delamination 
from the pancreatic epithelium, endocrine precursors begin to differentiate towards 
the five different cell types of the islet; α-,β-,δ-, PP-, and ε-cells. Figure 1.12 gives an 
overview of the transcription factors that are required for differentiation to the five 
islet cell types [134].  
There are several important cell fate junctions in islet cell differentiation; firstly 
differentiation of endocrine progenitors to ε-cell fate. The exact mechanism of ε-cell 
specification from endocrine progenitors is unclear, however mature ε-cells express 
both Nkx2.2 and Isl1 but not Nkx6.1 or Pax6 [135]. It has been proposed that the 
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reduction in Pax6 may direct ε-cell differentiation. Pax6 mutants show an increase in ε-
cells that is not the result of increased proliferation [136].  
The next important cell fate decision in the islet is the differentiation of α/PP 
progenitors vs. β/δ progenitors, this is thought to be dependent on Arx/Pax4 
interactions. Pax4 is expressed early in pancreatic development (E9.5) but by birth is 
restricted to β-cells [121]. Pax4 null mice show a total absence of β- and δ-cells and a 
reciprocal increase in α-cells [137]. In contrast Arx mutants show an absence of α-cells 
and an increase in β- and δ-cells [138]. Both Arx and Pax4 are transcriptional 
repressors that interact to control each other’s expression [139]. These data suggest 
that endocrine progenitors that express both Pax4 and Arx may be stimulated by an 
unknown factor to induce preferential expression of either Pax4 or Arx. If Pax4 
expression predominates β/δ precursors form, continued expression of Pax4 results in 
β-cell differentiation, however loss of Pax4 results in δ-cell fate [139]. If Arx expression 
predominates α/PP precursors are produced, this mechanism is supported by the 
observation that Arx expression is sufficient to induce α- and PP-cell phenotypes in 
mature β-cells [140]. Sustained Arx expression in α/PP progenitors results in 
acquisition of α-cell fate, however the mechanism of PP-cell differentiation is not 





















1.3.C.9. Exocrine Differentiation 
As previously mentioned exocrine differentiation occurs during secondary transition 
when tip cells of developing branches become acinar cells. Two transcription factors 
are important for acinar cell differentiation; Ptf1α and Mist1. Ptf1α mutants show 
complete absence of exocrine tissue [141] and Mist1 knockouts have extensive 
Figure 1.12. Schematic of Transcription Factor Expression during Differentiation of Endocrine 
Cells 
Proposed transcription factors important in cell fate specification of endocrine precursors. β-
cell progenitors (pink), δ-cell progenitors (yellow), α-cell progenitors (blue), ε- and PP-cell 
progenitors (white). The mechanism of differentiation of ε- and PP cells is not well 
understood and is not represented here. Source: Collombat et al, 2006 [134]. 
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disorganisation of exocrine tissue and dysregulation of acinar cell function, stability 
and identity [142]. The factors controlling acinar cell differentiation are not well 
understood but Notch signalling has been implicated in preventing endocrine fate by 
expression of Hes1 which represses Ngn3 (Figure 1.13). Notch is also thought to inhibit 
Ptf1α function until E14.5 when notch silencing allows Ptf1α-directed acinar 







Little is known about the factors required for exocrine duct cell differentiation 
however candidate transcription factors include Hnf6 and Sox9. Hnf6 is expressed in 
duct cells through development and Hnf6 null mice demonstrate abnormal duct 
Figure 1.13. Schematic of the Repression of Endocrine and Exocrine Cell Fates by Notch 
Signalling. 
At E10.5 active Notch signalling results in activation of the Notch target Hes1, Hes1 represses 
the pro-endocrine gene Ngn3 maintaining pancreatic progenitors (A). Escape from active 
Notch at E11.5-12.5 results in de-repression of Ngn3 by Hes1 and differentiation of exocrine 
precursors (B). Progenitors that remain exposed to active Notch by E13.5 become endocrine 
precursors and Ptf1α remains inactive due to active Notch (C). Escape from Notch at E14.5 
results in activation of Ptf1α and differentiation to acinar cell fates (D).  
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morphogenesis and develop cysts similar to those found in pancreatic cystic disease 
[144]. Adult duct cells express Sox9 and during development it is thought to function 
upstream of Ngn3 to regulate multipotent progenitors [145]. Recently Sox9 in 
combination with Hnf6 has been shown to induce ductal genes in metaplastic acinar 
cells [146], indicating a potential role for Sox9 in directing ductal differentiation.   
1.4. Thesis Aims 
The overall aim of this thesis was to (1) determine the potential to induce the 
transdifferentiation of cholangiocytes to hepatic and pancreatic lineages (2) identify 
signalling pathways that are important in pancreas and liver development and that can 
be used to promote transdifferentiation of endodermally derived cells.  
The aim of the research described in Chapter 3 was to establish a model of normal 
cholangiocytes that can be efficiently infected with adenoviral vectors and use this to 
overexpress key hepatic and pancreatic transcription factors. To achieve this, a 
cholangiocyte cell line called BECs was used and optimised for adenoviral infection. 
Overexpression of transcription factors was used to test whether direct 
transdifferentiation of cholangiocytes to hepatocyte or pancreatic β-cell lineages could 
be achieved. The research in this chapter also aimed to investigate the effects of 
extracellular factors such as dexamethasone, insulin/transferrin/selenium, oncostatin 
M, sodium butyrate and nicotinamide on the transdifferentiation of cholangiocytes to 
hepatocyte-like cells. 
The aim of Chapter 4 was to investigate the role of different signalling pathways in 
liver and pancreas development. Using an ex vivo embryonic bud culture system, the 
role of Notch, TGFβ, WNT and phosphatidylinositol signalling, on hepatic and 
pancreatic differentiation were investigated. Activation and/or inhibition of different 
signalling pathways were used to provide insight into organ development.  
Following on from Chapter 4, the aim of Chapter 5 was to further investigate in more 
detail the effects of inhibiting Notch signalling in pancreas development in terms of (1) 
branching moprhogenesis (2) Endocrine vs. Exocrine cell fate decisions and (3) β-cell 
maturation and function.    
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Chapter 2. Materials and Methods 
2.1. Materials 
2.1.A. Cell Lines, Tissue Culture Reagents and Media Composition 
Biliary Epithelial Cells (BECs) were obtained as a gift from Dr Yoshiyuki Ueno [147], 
Tohoku University, Japan. The Murine Insulinoma Cell line (MIN6) and the Human 
Embryonic Kidney cell line 293 (HEK293) were both obtained from the European 
Collection of Cell Cultures, Porter Down, UK.  
Phosphate buffered saline (PBS; Autogen Bioclear) was used to wash cell lines prior to 
passaging using Trypsin-Ethylenediaminetetraacetic acid (EDTA) (Gibco). Gamma 
irradiated Foetal bovine serum (FBS; Gibco) was routinely used for tissue culture 
purposes; except for virus production when Heat inactivated FBS (Sigma) was used. 
Stock solutions of penicillin/streptomycin, L-glutamine (Sigma) and gentamycin (Gibco) 
were stored at -20˚C prior to use. Dexamethasone (Dex) was prepared in 100% ethanol 
and stored at -20˚C. DMSO (Sigma) for cryopreservation was diluted to 5% (v/v) in FBS 













Table 2.1. Composition of Media used in the Culture of Cell Lines 
Media Composition 
BEC culture media Dulbecco’s modified Eagles Medium (DMEM; Sigma) with 10% 
(v/v) FBS, 2mM L-glutamine, 100U/ml penicillin and 100µg/ml 
streptomycin. 
MIN6 culture media High glucose (25mM) DMEM (Sigma) with 10% (v/v) FBS, 2mM 
L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin. 
HEK293 culture media DMEM (Gibco) with 10% (v/v) heat inactivated FBS, 100U/ml 
penicillin and 100µg/ml streptomycin. 
Hepatocyte differentiation 
media (KS) 
Keratinocyte serum free media (KSFM; Gibco) with 10% (v/v) 
FBS, 2mM L-glutamine, 100U/ml penicillin, 100µg/ml 
streptomycin, 100µg/ml amphotericin B, 50µg/ml gentamycin, 
50µg/ml bovine pituitary gland extract (bPGE) and 5ng/ml 
human recombinant EGF (hrEGF). 
Hepatocyte differentiation 
media (KdS) 
KS media supplemented with 10nM Dexamethasone 
Hepatocyte De-
differentiation media (DS) 
Dulbeccos modified Eagles Medium (DMEM; Sigma) with 10% 
(v/v) FBS, 2mM L-glutamine, 100U/ml penicillin, 100µg/ml 
streptomycin, 100µg/ml amphotericin B, 50µg/ml gentamycin, 
50µg/ml bovine pituitary gland extract (bPGE) and 5ng/ml 
human recombinant EGF (hrEGF). 
RPMI media RPMI 1640 Media (Sigma) with 10% (v/v) FBS, 2mM L-
glutamine, 100U/ml penicillin and 100µg/ml streptomycin. 
         
2.1.B. Isolation and Ex vivo  Culture of Embryonic Hepatic and Pancreatic 
buds 
PBS, FBS and stock solutions of L-glutamine, penicillin / streptomycin and gentamycin 
were prepared and stored as for cell culture. Stocks of bovine plasma fibronectin 
(Sigma) were reconstituted in 8M Urea and made to a final concentration of 50mg/ml 
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in MilliQ water and stored at -20˚C. Subbed coverslips were prepared with a fresh 
coating of 50µg/ml bovine plasma fibronectin (made up in 1.8ml sterile MilliQ water 
and 0.2ml 8M Urea prior to use. To sub; coverslips were first washed with hot soapy 
water, rinsed in MilliQ water, rinsed in 95% ethanol with 0.1% acetic acid and allowed 
to air dry. In a fume hood the dried coverslips were placed in 2% 3-
triethoxysilylpropylamin (APTS; Sigma) in acetone for 10 mins, rinsed twice in acetone 
for 10 secs and finally rinsed in MilliQ water, before drying and 37˚C. Subbed coverslips 
were wrapped in foil and baked at 180˚C for 3 hours and left to cool overnight. 
Table 2.2. Composition of Media used for Isolation and Culture of Ex vivo Buds 
Media Composition 
Dissection media Minimum essential media Eagles (MEME; 
Sigma) containing Hanks salts with 10% (v/v) 
FBS, 2mM L-glutamine. 
Culture media Basal medium Eagles (BME; Sigma) containing 
Earles salts with 10% (v/v) FBS, 2mM L-
glutamine, 100U/ml penicillin, 100µg/ml 
streptomycin and 50µg/ml gentamycin.  
 
2.1.C. Immunostaining of Monolayer Cultures and Buds 
Cells were fixed in either 1:1 acetone: methanol or 4% (w/v) Paraformaldehyde (PFA; 
Fisher scientific). Buds were fixed with either ice cold 1:1 acetone: methanol for 5 mins 
or MEMFA for 30 mins (3.8% Formaldehyde, 0.15M MOPS, 2mM EGTA, 1mM MgSO4 
(Sigma)).  Cells fixed with PFA and buds fixed with MEMFA were permeabilised with 
0.1% (v/v) TritonX-100 (Sigma) in PBS. All cells and buds were blocked with 2% (w/v) 






Table 2.3. Primary Antibodies used for Immunostaining 




Albumin Rabbit DAKO 1:100 F0117 
Alpha fetoprotein (AFP) Rabbit Sigma 1:200 A8452 
Amylase Rabbit Sigma 1:200 A8273 
CCAAT-Enhancer binding protein 
α (C/EBPα) 
Rabbit Santa Cruz 1:100 SC-61 
CCAAT-Enhancer binding protein 
β (C/EBPβ) 
Mouse Santa Cruz 1:150 SC-7962 
Connexin 43 (Cx 43) Mouse Santa Cruz 1:100 SC-13558 
Cytokeratin 7 (Ck 7) Mouse AbCam 1:50 Ab82253 
Cytokeratin 19 (Ck 19) Rabbit AbCam 1:50 Ab52625 
Cytokeratin- wide spectrum (Pan-
Ck) 
Rabbit DAKO 1:200 Z0622 
Dolichos Biflorus Agglutinin (DBA) Lectin Vector  1:100 FL-1031 
Epithelial Cadherin (E-Cad) Mouse DB 
biosciences 
1:100 610181 
Glucagon Mouse Sigma 1:100 G2654 
Hepatocyte nuclear Factor 4 
(HNF4) 
Rabbit Santa Cruz 1:100 SC-8987 
Insulin Guinea Pig Sigma 1:100 I8510 
Pancreatic and duodenal 
homeobox gene 1 (Pdx1) 




Peanut Agglutinin (PNA) Lectin Vector  1:100 FL-1071 
Phosphohistone H3 (PH3) Rabbit Upstate 1:200 09-797 
Somatostatin (SS) Rabbit DAKO 1:100 A0566 





Table 2.4. Flurophore Conjugated Secondary Antibodies for Immunostaining 
Antibody Species Conjugated 
flurophore 
Supplier 
Anti-Guinea Pig IgG Rabbit TRITC Sigma 
Anti-Mouse IgG Horse FITC Vector Labs 
TRITC 
AMCA 
Anti-Rabbit Goat FITC Vector Labs 
TRITC 
 
Samples not stained with the AMCA flurophore were counterstained with the nuclear 
marker  4',6-diamidino-2-phenylindole (DAPI; Sigma) diluted to  1:1000 in PBS. 
2.1.D. RT-PCR Reagents and Primers 
RNA was isolated using Tri-reagent (Sigma) and pellets were treated with RNAse-free 
DNAse (Ambion). Reverse transcription was performed using SuperScriptII™ reverse 
transcriptase (Invitrogen) and PCR used 2x ReddyMix ™PCR Master mix (Abgene). PCR 










Table 2.5. Sequence and Melting Temperature of Primers used for RT-PCR all primers were 
designed to target murine genes but also amplified human transcript where indicated. 
Primer Sequence (Forward/ Reverse) Tm (˚C) 
Β-actin AAG AGC TAT GAG CTG CCT GA / 
 TAC GGA TGT CAA CGT CAC AC 
56 
Alpha fetoprotein (AFP) GGA GGC TAT GCA TCA CCA GT / 
 CCG AGA AAT CTG CAG TGA CA 
56 
Albumin GCA GAG GCT GAC AAG GAA AG / 
 TTC TGC AAA GTC AGC ATT GG 
58 
Amylase GGG AGG ACT GCT ATT GTC CA/  
CAT TGT TGC ACC TTG TCA CC 
56 
Carbamoyl Phosphate Synthetase (CPS) TGA GTG GGT CTG CCA TGA AC / 
 TGG ACA TTG AAT GGC CCA GA 
56 
CCAAT-Enhancer binding protein α 
(C/EBPα) 
ACA AGC TGA GCG ACG AGT AC/ 
ACA GCT GCT CCA CCT TCT TC 
60 
CCAAT-Enhancer binding protein β 
(C/EBPβ) 
CTA ACC CAT GCG AGA ACG AT/ 
GCT TGC ACA GAC ACT CGA AG 
56 
Cytokeratin 7 (Ck 7) GCA GGA TGT GGT GGA AGA TT/  
CGT GAA GGG TCT TGA GGA AG 
56 
Cytokeratin 19 (Ck 19) ACC CTC CCG AGA TTA CAA CC/  
AGA GTC AGC TCA TCC AGC AC    
56 
Epithelial Cadherin (E-cad) TCG TTC TCC ACT CTC ACA/ 
GCTGGACCGAGA GAG TTA 
58 
Gamma Glutamyl Transpeptidase (GGT)  GCT CAT GAA TGC CCA CAG TA/ 
 CCA GCT CAT AAC CAC GGA TT 
56 
Glucagon GCA CAT TCA CCA GCG ACT AC/ 
CTG GTG GCA AGA TTG TCC AG 
56 
Glucokinase TAC ACC TGT TCG CAG CTC A/  
 TGG TGA ATG TGC CCT GTG A 
 
Glutamine Synthetase (GS) TTT ATC TTG CAT CGG GTG TG / 
 TTG ATG TTG GAG GTT TCG TG 
56 
Hairy Enhancer of split 1 (Hes 1) GCT GGA GAA GGC AGA CAT TC/ 
TGA TCT GGG TCA TGC AGT TG 
58 
Hepatocyte Nuclear Factor 1 α ( HNF 
1α) 
ACG TCC GCA AGC AGC GAG/ 
TAC ACT CTT CCA CCA AGG TC 
58 
Hepatocyte Nuclear Factor 1 β (HNF 1β) CTT TAA TGG GAG GCT TCC TGA GAT G/ 
GTT GAA ATT CCA AGA GTG ACT TGC TC 
56 
Hepatocyte Nuclear Factor 4 (HNF 4) CTC TTC TGA TTA TAA GCT GAG GAT G/ 
CCA CAG GAA GGT GCA GAT TGA TCT G 
56 
Hepatocyte Nuclear Factor 6 (HNF 6) GCA ATG GAA GTA ATT CAG GGC AG/ 
CAT GAA GAA GTT GCT GAC AGT GC 
56 
Insulin I TAG TGA CCA GCT ATA ATC AGA G/ 
ACG CCA AGG TCT GAA GGT CC 
56 
Insulin II  CCC TGC TGG CCC TGC TCT T/ 
AGG TCT GAA GGT CAC CTG CT 
56 
Neuro D (mouse and human) GGA TCC ACA TGA CCA AAT CAT ACA G/ 
GGA TCC TCT AAT CGT GAA AGA TGG CA 
58 
Neurogenin 3 (Ngn 3) (mouse and GTC GGG AGA ACT AGG ATG/  58 
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human) GGA GCA GTC CCT AGG TAT G 
Pancreatic and duodenal homeobox 
gene 1 (Pdx 1) (mouse and human) 
TGT AGG CAG TAC GGG TCC TC/ 
CCA CCC CAG TTT ACA AGC TC 
56 
Pancreatic Polypeptide (PP) TAC TGC TGC CTC TCC CTG TT/ 
CCA GGA AGT CCA CCT GTG TT 
56 
Pax 4 (mouse and human) ACC CTG TGA CAT TTC ACG GAG/ 




CAC AGA CCA GCG AAT AAC AA/  
AGC AAA GAT ACC AGC AGC CA 
 
Smooth Muscle Actin (SMA) CTG ACA GAG GCA CCA CTG AA / 
CAT CTC CAG AGT CCA GCA CA 
 
Somatostatin (SS) CCG TCA GTT TCT GCA GAA GT/  
CAG GGG CAA GTT GAG CAT CG 
56 
SYR-box 9 (Sox9) GGG GCT TGT CTC CTT CAG AG/  
TGG TAA TGA GTC ATA CAC AGT AC 
56 
 
2.1.E. Western Blotting Buffers for Pdx1 and Insulin 
Table 2.6. Buffers used for Pdx1 and Insulin Western Blots 
 Pdx1 Western Insulin western 
Lysis buffer 50mM Tris-HCl (pH 8), 150mM NaCl, 
1% (v/v) Triton-X 100, 1mM EDTA 
and 1:100 Protease inhibitor 
cocktail (sigma) 
0.18M HCl in 35% (v/v) ethanol and 
1:100 protease inhibitor cocktail for 
mammalian tissues (sigma) 
Sample 
loading buffer 
4% SDS (w/v), 20% glycerol (v/v), 
0.004% Bromophenol Blue, 0.125M 
Tris-HCl (pH 6.8) and 5% (v/v) Beta-
mecaptoethanol 
200mMTris-HCl (pH6.8), 40% (v/v) 
glycerol, 1% (w/v) SDS, 0.01% (w/v) 
coomassie brilliant blue R250 
SDS-PAGE 
running buffer 
25mM Tris-HCl, 192mM glycine and 
0.1% (w/v) SDS 
0.1M Tris-HCl, 0.1M tricene, 
0.1%(w/v) SDS 







2.1.F. Adenoviral Vectors 
Table 2.7 Adenoviral Vector Constructs and their Source 
Adenoviral construct Source 
Ad-RSV- GFP Emma Regardsoe, University of Oxford, UK. 
Ad-C/EBP α Vector Biolabs, Philadelphia, USA. 
Ad-CMV-LAP (C/EBPβ) Hiroshi Sakaue, Kobe University, Japan. 
Ad- CMV- HNF4 Ramiro Jover, University of Valencia, Spain 
Ad-CMV- NeuroD-eGFP Harry Heimberg, Vrije Universiteit, Belgium. 




2.1.G. Extracellular Factors and Other Compounds 
Table 2.8. Extracellular Factors and Compounds used to Culture Cells and Buds 
Compound [Stock] [Working] Supplier 
Dexamethasone (Dex) 1mM 1µM Sigma 
Insulin/Transferrin/Selenium (ITS) 100X 1X 
Na C4H5O2 (Na Butyrate) 100mM 0.5mM 
Nicotinamide (Nic) 2M 20mM 
Oncostatin M (OSM) 10µg/ml 10ng/ml 
N-[N-(3,5-Difluorophenacetyl-L-
alanyl)]-S- phenylglycine t-Butyl 
Ester (DAPT) 
25mM 50µM Calbiochem 
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Jagged 1 100µg/ml 100ng/ml R and D 
Systems 
Hepatocyte Growth Factor (HGF) 100µg/ml 100ng/ml 
Glycogen Synthase Kinase (GSK) 
Inhibitor 
5mM 1µM Gift 
Dr Paul Whitley 
PIKfyve inhibitor YM201636 100µM 400nM 
 
2.2 Methods 
2.2.A Culture of Cell Lines; Maintenance, Storage and Revival 
BECs were typically maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% Foetal Bovine Serum (FBS), 2mM L-Glutamine (L-Glut), 
100U/ml Penicillin and 100µg/ml Streptomycin. BECs were cultured in 75cm2 NUNC 
tissue culture flasks at 37˚C and 95% air / 5% CO2. Cells were passaged when 80-90% 
confluent. Min 6 cells were maintained in High glucose (25mM) DMEM with 10% FBS, 
2mM L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin. Min 6 cells were 
cultured and passaged in the same way as the BEC cells. Media was changed on all 
cells every other day.  
To passage the cells, flasks were briefly washed with pre-warmed PBS prior to addition 
of 3ml Trypsin/EDTA (GIBCO), this was incubated at 37˚C for 3-5 minutes until cells 
could be removed by gentle tapping. Trypsin was neutralised by addition of 7ml of pre-
warmed culture media and cells were centrifuged at 180 g for 4 minutes. After 
centrifugation, the supernatant was discarded and the pellet re-suspended in 10 ml of 
complete media. BECs were subcultured 1:10 and Min 6 cells 1:3. For immunostaining 
cells were subcultured onto glass coverslips in 35mm dishes.  
Cells for cryopreservation were trypsinised and centrifuged as described above and the 
pellet re-suspended in 1ml FBS with 5% DMSO. Cells were stored at -20˚C for one hour, 
and then placed at -80˚C overnight in an isopropanol bath, prior to long term storage 
in liquid nitrogen. 
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Cells were revived by rapidly thawing in a 37˚C water bath; the cells in freezing media 
were diluted into 10ml of pre-warmed culture media and incubated at 37˚C overnight. 
Once cells had attached the media was changed the next day to remove any remaining 
DMSO and then subsequently every other day.  
2.2.B. Embryonic Liver and Pancreas Dissection and Ex vivo  Culture 
All tissue buds were grown on pre-subbed, fibronectin-coated, glass coverslips. Subbed 
coverslips were freshly coated with bovine plasma fibronectin prior to each isolation 
by diluting stock fibronectin ([50mg/ml] in urea) to a final concentration of 50µg/ml in 
MilliQ water, 30µl of diluted fibronectin was spotted onto the centre of each coverslip 
and allowed to dry at room temperature.  
Embryos were harvested from pregnant, female CD1 mice at 11.5 days postcoitum, the 
appearance of the vaginal plug was considered as 0.5 days post-coitum (dpc). Mice 
were killed by cervical dislocation and the uterus, containing the embryos was 
removed by cutting the base of the uterus and the end of the uterine horn, where it 
meets the ovary. Individual embryos were contained within bulges of extra embryonic 
tissue (decidua), these were cut from the uterus (Fig 2.1A[148]) and embryo gently 
pressed out (Fig 2.1B) and transferred to dissection media (see table 2.2). 







Embryonic liver buds were dissected using a dissecting microscope and tungsten 
needle to cut open the embryo, exposing the internal organs (Fig 2.2 A and B). The 
liver lobes were then removed to fresh media prior to plating out. Embryonic pancreas 
A B 
Figure 2.1. Photographs of Dissection of E11.5 Mouse Embryo 
 An individual embryo surrounded by extra embryonic decidus membrane (A) and an individual 
embryo removed from deciduas membrane (B). Images modified from Burke et al, 2010 [148].  
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was dissected by stripping the heart and liver from the remaining organs to expose the 
stomach. Pressing down on the stomach exposed a clear line separating the stomach 
form the dorsal pancreatic bud, this was carefully removed ensuring not to 
contaminate the pancreatic tissue with closely associated intestine (Fig 2.2 C). The 
isolated pancreatic buds were removed to fresh dissection media prior to plating out.  
Liver lobes were further dissected into small pieces, suitable for culture. A plastic 
cloning ring with an internal diameter of approximately 3mm was placed onto the 
fibronectin-coated coverslip inside a 35mm dish and filled with culture media (see 
Table 2.2). A 200l Gilson pipette with a large bore tip was used to transfer each liver 
piece or whole pancreatic bud into the cloning ring. Care was taken to orientate the 
tissue so that the cut side was facing down onto the fibronectin, to aid attachment.  
The culture dish was then removed to an incubator at 37˚C and 5% CO2 overnight. 
After 12 hours the buds were checked for attachment to the fibronectin, the media 
was changed (extracellular factors added if required) and buds were maintained for up 































2.2.C. Adenovirus Preparation, Titration and Infection of Cell L ines 
HEK293 cells were used for adenovirus amplification. HEK cells were cultured in DMEM 
with 10% (v/v) heat inactivated FBS, 100U/ml penicillin and 100µg/ml streptomycin at 
37˚C in 95% air/5% CO2 . Four T175 flasks were seeded with HEK293 cells and allowed 
to reach 70% confluence. Each flask was then infected with either 10µl, 1µl, 0.1µl or 
0.01µl of the desired virus and returned to the incubator. The ‘pre-stock’ was collected 
from the flask that demonstrated approximately 50% cytopathic effects (CPE) of the 
A B 
C 
Figure 2.2. Photograph of Dissection of Internal Organs of E11.5 Mouse Embryo 
 The internal organs after removal of the epidermis and backbone of the embryo (A and B) showing 
the developing liver. The internal organs after removal of the heart and liver exposing the stomach 
and dorsal pancreatic bud, circled in white (C). H=Heart, l=Liver, i= Intestine, lb= Lung buds, o= 
oesophagus, s= Stomach.   Images modified from Burke et al, 2010 [148].  
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virus after 2-3 days (ie. 50% of cells were detached after 2-3 days). The pre-stock was 
collected by tapping the remaining cells from the bottom of the flask, collecting cells 
and media and centrifuging at 1000 rpm for 4 mins. The pellet was then resuspended 
in 1 ml of fresh media and subjected to four freeze/thaw cycles on dry ice/ethanol and 
37˚C water bath, to lyse the cells. The pre-stock was then stored at -80˚C until required 
for further amplification.  
To test the pre-stock three 70% confluent, T175 flasks were inoculated with 125µl, 
12.5µl, or 2µl of the pre-stock. The appropriate volume was taken as the flask that 
showed 50% CPE between 2-3 days of incubation. To further amplify the virus the 
appropriate volume of pre-stock was used to inoculate 12 x 70% confluent T175 flasks 
and incubated for 2-3 days to allow infection to proceed. The virus was collected by 
tapping the remaining cells from the flasks, pooling the cells and media from all 12 
flasks, and centrifuging at 2000rpm for 10 mins. The supernatant was discarded and 
the pellet resuspended in 5ml of 100mM Tris-HCl (pH 8.0). The pellet was then 
subjected to four rapid freeze/thaw cycles prior to centrifugation at 2000rpm for 5 
mins. The virus was then purified by collecting the supernatant in approximately 0.6x 
volumes of 100mM Tris-HCl supersaturated with CsCl (pH 8.0) and mixed gently. The 
virus was then transferred to an ultracentrifuge tube (Beckman), sealed and 
centrifuged at 65000rpm for four hours at 22˚C. After centrifugation a white band of 
virus was produced, this was extracted using a 25G needle and returned to a new 
centrifuge tube. The volume was made up using balance solution (1:0.6, 100mM Tris-
HCl: 100mM Tris-HCl saturated with CsCl) and the fresh tube further centrifuged at 
65000rpm at 22˚C, overnight.  
To remove the CsCl and to concentrate the virus, the band was extracted from the 
centrifuge tube and injected into a gamma irradiated Slide-A-Lyzer™ dialysis cassette 
(0.5-3ml; Pierce). This was suspended in 1L of dialysis buffer (10mM Tris-HCl pH 7.4, 
1mM MgCl2, 135mM NaCl) at 4˚C, with constant stirring for 4h. After 4h the dialysis 
buffer was replaced and left to dialyse overnight. The concentrated virus was then 
extracted from the cassette, passed through a 0.22µM filter and aliquoted prior to 
storage at -80˚C.  
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The concentration of the virus (infectious units/ml; IFU/ml) was estimated using the 
Adeno-X™ rapid titre kit (BD Biosciences) according to the manufacturer’s instructions. 
Cells were stained using mouse anti-hexon primary antibody (1:1000) for 1h and rat 
anti-mouse, HRP conjugated secondary (1:5000; BD Biosciences) for 1h. DAB substrate 
kit for peroxidise (Vector) was used to visualise the staining and the concentration 
estimated by counting the positive cells in each field of view under 20X magnification 
(the optimum dilution counted contained 10% or fewer, positive cells), an average of 6 
fields of view were counted. The titre was calculated using the following equation: 
   
                
                                               
                   
   
Routine infection of BECs involved infection of 30-40% confluent cells at a multiplicity 
of infection (MOI) of 500 IFU/cell. The volume of virus was calculated according to the 
concentration of each virus used and added to the standard BEC culture media with 
10µg/ml dextran (Sigma) to aid infection efficiency. The virus was incubated with the 
cells overnight at 37˚C, the following day the media was changed to 1% FBS media to 
allow slower culture of cells and expression of the transgene for at least 5 days. Media 
was changed every 2 days until cells were collected for analysis.  
 
2.2.D. Immunostaining of Cells and Cultured Buds 
Cell lines for immunostaining were grown on glass coverslips in 35mm dishes.  Prior to 
fixation, the dishes were washed with PBS then fixed with either ice cold 
Acetone:Methanol for 5 mins or  4% PFA for 20 mins at room temperature. The cells 
were then washed twice with PBS to remove fixative and stored in PBS at 4˚C. Cells 
fixed in PFA required permeabilising in 0.1% triton-X for 30 mins prior to beginning the 
rest of the immunostaining protocol. Buds for immunostaining were fixed in 
Acetone:Methanol or MEMFA (See 2.1.3) for 30 mins at room temperature, if MEMFA 
fixed buds were permebalised in 1% triton-X100 for 30 mins as for cells.  
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The antibodies that required antigen retrieval were treated with 1x antigen retrieval 
buffer (Lab Vision), either citrate or EDTA antigen retrieval depending on the specific 
antibody used, the buffer was added for 1 hour at 37˚C then removed by washing 
three times with PBS. 
Cells and buds were blocked with 2% blocking buffer (Roche) for 30 mins at room 
temperature prior to addition of the primary antibody made up in 2% blocking buffer 
to the required dilution (See table 2.3), primary antibodies were incubated overnight 
at 4˚C. Excess primary antibody was removed by washing with PBS three times for 15 
mins then the secondary antibody was applied at the required dilution in 2% blocking 
buffer and incubated at room temperature for 2-3 hours in the dark. The excess 
secondary antibody was then removed by applying three 15 min washes with PBS. 
Nuclear counter-staining was conducted using 4’,6-diamidino-2-phenylindole (DAPI; 
Sigma) at 1:1000 in PBS for 20 mins at room temperature and was removed with three 
washes with PBS prior to mounting the coverslips on glass slides using aqueous 
mounting media (GelMount, Sigma). 
 
2.2.E. RT-PCR 
RNA from BECs was harvested from 2x 35mm dishes in 1ml Tri-reagent (Sigma) and 
removed from the dish with a cell scraper. RNA from buds required the pooling of 10 
buds into 1ml of Tri-reagent.   RNA was isolated according to the manufactures 
instructions.  Briefly, 200μl of chloroform was added to the Tri-reagent and mixed for 
2-3 minutes the samples were centrifuged at 12 000x g for 15 mins at 4˚C. The 
colourless top phase of the separation was removed to a new tube and 500μl of 
isopropanol was added for 10 minutes prior to centrifugation of the sample at 12 000x 
g for 10 minutes. The supernatant was removed and pellet washed with 1ml 75% 
ethanol prior to centrifugation at 7500x g for 5 minutes. The pellet was briefly air dried 
and re-dissolved in RNase-free water. 
The concentration of all RNA was measured using the 260nm and 280nm absorbance 
ratio. The samples were DNase treated using RNase-free DNase (Ambion) according to 
the manufacturer’s instructions. The 260-280nm ratio was re-checked after DNase 
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treatment and samples tested for genomic DNA contamination by running a β-actin 
control PCR prior to RT. 
Reverse transcription was carried out using SuperScriptII™ reverse transcriptase 
(Invitrogen), 1μg of DNase treated RNA was mixed with 1μl 10mM dNTP and 1μl Oligo 
(dT) 12-18, this was made up to a total volume of 10μl with water and incubated at 65˚C 
for 5 mins. The samples were placed on ice for one min and 4μl of 5x RT buffer added 
along with 2μl 0.1M DTT, 1μl of RNase Out and 1μl SS II RTase (Invitrogen), this was 
incubated at 42˚C for 52 mins prior  to inactivation of the enzymes at 70˚C for 15 mins. 
PCR was carried out using 2μg of cDNA, 1μl of forward and reverse primers of interest 
and 14μl of ReddyMix (Abgene) PCR master mix. The PCR cycle was selected according 
to the specific annealing temperature of the primers used (see table 2.5). The PCR 
products were then run on a 2% agrose gel containing 2% ethidium bromide and were 
visualised using the alpha imaging system gel reader 3400 (Alpha Innotech).  
 
2.2.F. Western Blotting for Pdx1 and Insulin 
Western blotting of protein extracted from BEC cells was performed in order to detect 
Pdx1 and insulin.  For Pdx1 detection in BECs, protein was collected from 70-80% 
confluent T75 tissue culture flasks by trypsinising at 37˚C for 3-5 mins until cells could 
be removed by gentle tapping and centrifuged for 4 mins at 180 g.. The resulting pellet 
was washed twice with PBS and finally re-suspended in 100μl of Pdx1 lysis buffer 
(50mM Tris-HCl (pH 8), 150mM NaCl, 1% (v/v) Triton-X 100, 1mM EDTA and 1:100 
Protease inhibitor cocktail). After addition of the lysis buffer the samples were mixed 
gently at 4˚C for 15 mins and centrifuged at 14000 x g for 20 minutes, the supernatant 
was removed to a new tube and stored at -80˚C until required. The concentration of 
protein in each sample was quantified using the BioRad protein quantification assay 
and absorbance at 595 nm and compared to known standards according to the 
manufacturer’s instructions. 
A total of 25μg of protein was used for Pdx1 western blotting and made up to a total 
volume of 10μl in lysis buffer, to this 10μl of Pdx1 sample loading buffer (4% SDS (w/v), 
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20% glycerol (v/v), 0.004% Bromophenol Blue, 0.125M Tris-HCl (pH 6.8) and 5% (v/v) 
Beta-mecaptoethanol) was added , the sample was then heated to 100˚C for five mins. 
Once prepared samples were loaded into a 10% Tris-HCl gel (Criterion), and the SDS-
PAGE run at 120v for 90 mins in Pdx1 running buffer (25mM Tris-HCl, 192mM glycine 
and 0.1% (w/v) SDS).  
On completion of the SDS-PAGE the gel was removed and equilibrated in transfer 
buffer.  Immun-Blot PVDF (polyvinylidene fluoride) membrane (BioRad) was pre-
soaked in Methanol for 10 minutes then equilibrated along with the gel in transfer 
buffer (25mM Tris-HCl, 192mM glycine and 20%(v/v) Methanol ). The transfer was run 
at 100v for 40 minutes in a Trans-Blot™ electrophoretic transfer cell (BioRad).  
The membrane was blocked with 4% non-fat milk solids (Marvel) in PBS-T (PBS with 
0.1% v/v Tween-20; Sigma) for 1 hour and then primary rabbit anti-Pdx1 antibody 
(rabbit polyclonal anti- PDX antibody was made by Professor Jonathan Slack against an 
18-amino-acid C-terminal peptide conjugated to keyhole limpet haemocyanin) added 
overnight at 1:100. The excess primary antibody was removed with three washes of 
PBS-T prior to the addition of the HRP-conjugated secondary antibody at 1:5000 for 1 
hour. The excess secondary antibody was washed three times with PBS-T and 
visualized using ECL plus western blotting analysis system (Amersham), according to 
the manufacturer’s instructions.  
Protein for western blotting was extracted from 20 pooled buds by scraping and 
homogenising in Insulin lysis buffer (0.18M HCl in 35% (v/v) ethanol and 1:100 
protease inhibitor cocktail). A total volume of 100µl of lysis buffer was used to collect 
all 20 buds which were sequentially homogenised through 25 and 30G needles. 
The lysis buffer and protein was then rotated overnight at 4˚C prior to centrifugation at 
13000rpm for 10 mins and neutralisation of the HCl with equimolar amounts of NaOH. 
Protein content was measured using BioRad protein quantification assay as for cells. 
A total of 5µg protein was mixed with equal volumes of 2x insulin sample loading 
buffer (200mMTris-HCl (pH6.8), 40% (v/v) glycerol, 1% (w/v) SDS, 0.01% (w/v) 
coomassie brilliant blue R250) and heated to 100˚C for 5 mins. Once prepared, samples 
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were loaded onto a pre-cast Criterion 16.5% Tris-Tricene gel (BioRad) in insulin running 
buffer with ultra-low range molecular marker (1.06-26.6KDa; Sigma) and subjected to 
SDS-PAGE at 50v for 10 mins, followed by 120v for 90 mins in insulin running buffer 
(0.1M Tris-HCl, 0.1M tricene, 0.1%(w/v) SDS) . 
On completion of the SDS-PAGE the gel and PVDF membrane were equilibrated in 
transfer buffer as for Pdx1 western and the transfer conducted 25v for 10 mins on a 
Trans-Blot SD semi-dry electrophoretic transfer cell (BioRad). 
The membrane was blocked with 4% non-fat milk solids (Marvel) in PBS-T (PBS with 
0.1% v/v Tween-20; Sigma) for 1 hour  and incubated with rabbit polyclonal anti-insulin 
antibody (Sigma) at 1:100 overnight at 4˚C on a rocker. The primary antibody was 
removed with stringent PBD-T washes and incubated with the secondary anti-rabbit, 
HRP conjugated antibody (Vector) at 1:1000 at room temperature.  The secondary 
antibody was washed three times with PBS-T and visualized using ECL plus western 
blotting analysis system (Amersham), according to the manufacturer’s instructions.  
 
2.2.G. Glucose and Amino Acid Stimulated Insulin Secretion A ssay and 
ELISA 
The function of pancreatic beta-cells was tested by challenging with either glucose or 
amino acids.  Twenty buds were required and pooled for each glucose or amino acid 
challenge assay. Buds were first washed with PBS then incubated with phenol red-free 
DMEM (Sigma) with either 5.5mM glucose (control glucose) or 25mM glucose (high 
glucose), for 1 h at 37˚C. For the amino acid challenge assay, buds were incubated in 
phenol red-free DMEM with either 0.1mM non-essential amino acids (NEAAs; Gibco) 
for control or 0.2mM NEAAs for high amino acid treated buds, also for 1h at 37˚C.  
After incubation for 1h media was collected and concentrated using a centricon YM-3 
centrifugal device with a normal molecular weight cut-off limit of 3KDa (Millipore) and 
centrifuged at 4000x g for 40 mins at 4˚C in a swinging bucket centrifuge. 
Approximately 200µl of concentrated media was retrieved and mixed 1:100 with 
protease inhibitor cocktail (containing 104mM 4-(2-aminoethyl)benzenesulfonyl 
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fluoride (AEBSF), 1.5mM pepstatinA, 1.4mM E-64, 4mM bestatin, 2mM leupeptin, and 
80µM aprotinin Sigma) prior to short term storage at -80˚C. Protein was also isolated 
from the buds by acid/ethanol extraction as for insulin western blots.  
Total protein in the media was measured using Roti®-Nanoquant (Carl Roth GmbH) 
protein quantification system according to the manufacturer’s instructions and total 
protein in the pellets was quantified using BioRad protein quantification assay as for 
insulin westerns.  
The ELISA was performed using an ultrasensitive mouse insulin ELISA kit (Mercodia), 
using the test procedure for the 5µl sample volume as per the manufacturer’s 
instructions.  Briefly 25µl of calibrator 0 was added to all wells of a 96 well plate, 5µl of 
either calibrator 3-7 or 5µl our samples were added to sample wells in triplicate. 50µl 
of enzyme conjugate solution was added to each of the wells and incubated on a plate 
shaker at 700-900 rpm for two hours at room temperature. After incubation each well 
was washed six times with wash buffer and samples were incubated with 200µl of 
3,3′,5,5′-Tetramethylbenzidine substrate (TMB) for 30 mins at room temperature. 50µl 
of stop solution was added to each well after incubation and absorbance measured at 
450nm using an automated plate reader.  
2.2.H. Measurements and Statistics 
Fluorescent images were collected using a Leica DMRB compound microscope. All 
experiments were conducted at least three times. Numerical data is recorded as the 
mean of three experiments ±SE and analysed for statistical significance using a 






Chapter .3. Transdifferentiation of 
BECs to Hepatocyte and Pancreatic 
Lineages 
3.1. Introduction 
3.1.A. Cholangiocytes  
Cholangiocytes are intrahepatic bile duct cells that form the ducts of the liver; they are 
responsible for the collection, modification and transportation of bile from 
hepatocytes into the common hepatic duct [8]. Cholangiocytes develop from the 
ductal plate at approximately eight weeks of gestation in humans from a bipotential 
precursor population of hepatoblasts which also give rise to hepatocytes [149]. The 
differentiation of cholangiocytes from periportal hepatoblasts is distinguished by 
strong expression of cytokeratin 7 (CK7) and binding sites for the lectin dolichos 
biflorus agglutinin (DBA) in the basal lamina, followed by expression of cytokeratin 19 
(CK19) and binding sites for the lectin peanut agglutinin (PNA) as development 
progresses [150]. In adult life the cholangiocytes of the intrahepatic duct are thought 
to be heterogeneous both in terms of morphology and functional activity. 
Morphologically, cholangiocytes increase in size as they extend from the canals of 
Hering to the hepatic duct and can be broadly divided into small cholangiocytes 
(<15μm diameter) and large cholangiocytes (>15μm) in rat bile ducts. In humans, small 
ducts include the cholangiocytes of the bile ductules (<15μm), which are sometimes 
referred to as cholangioles, interlobular bile ducts (156-100μm) and septal bile ducts 
(100-300μm), while large ducts include the cholangiocytes of the area ducts (300-
400μm), segmental ducts (400-800μm) and hepatic duct (>800μm) [151].  It has long 
been thought that the main function of cholangiocytes is the modification of bile by 
secretion and re-absorption of water and electrolytes. However, recent work has 
shown significant heterogeneity in the function of small and large cholangiocytes. 
Microarray analysis of gene expression in large and small cholangiocytes has revealed 
that small cholangiocytes more strongly express proteins related to cell proliferation, 
such as Histone H3 and express fewer proteins related to differentiation such as 
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Aquaporin 8 [147]. These observations have lead to the hypothesis that small 
cholangiocytes are more immature and undifferentiated compared to the larger ducts 
[147]. The hypothesis that small cholangiocytes are more undifferentiated than large 
cholangiocytes is also supported by the observation that small bile ducts proliferate in 
response to Carbon tetrachloride (CCl4) damage and begin to express proteins related 
to differentiation, while large cholangiocytes apoptose [152], implying that small 
cholangiocytes may act to replace the lost large cholangiocytes. The exact function of 
the small cholangiocytes is unclear as they do not express the secretin receptor (SR) or 
somatostatin receptor (SSTR2) which allows the large cholangiocytes to participate in 
hormone regulated bile secretion (Fig 3.1) [151]. Furthermore the water content of the 
bile is modified by selective secretion and re-absorption via aquaporins (AQPs). Large 
cholangiocytes are known to express at least 6 different AQPs (AQP0, AQP1, AQP4, 
AQP5, AQP8 and AQP9), while small cholangiocytes express, at least AQP8 at 

























Figure.3.1. Mechanism of bile modification by large cholangiocytes 
 Binding of secretin to the secretin receptor (SR) causes an increase in intracellular cAMP, 
activation of the cystic fibrosis transmembrane regulator (CTFR), Cl- efflux and subsequent Cl-
/HCO3
- exchanger activity which ultimately leads to bicarbonate secretion. In contrast binding of 
somatostatin to the somatostain receptor (SSTR2) causes a reduction in intracellular cAMP which 




3.1.B. Transdifferentiation of Cholangiocytes to Hepatocytes 
Hepatocytes can be generated from developmentally-related cell types such as 
pancreatic cells. Conversion of pancreatic cells to hepatocyte-like cells can occur both 
in vivo and in vitro. For example, feeding rats a copper-deficient diet for 8-10 weeks (in 
combination with a copper chelator) induces the appearance of hepatocytes in the 
pancreas [21]. The hepatocytes-like cells did not express any of the normal pancreatic 
markers (such as insulin or amylase) but expressed liver markers including albumin, 
carbamoylphosphate synthetase-I and glutamine synthetase [153].  Further in vivo 
studies have demonstrated that ectopic expression of KGF (Keratinocyte Growth 
Factor) under the control of the insulin promoter induces formation of hepatocyte-like 
cells in the islets of Langerhans [22].  
In vitro transdifferentiation of pancreatic cells to hepatocytes has also been achieved 
via treatment of the rat pancreatic cell line AR42J-B13 (B13) cells with the synthetic 
glucocorticoid dexamethasone (Dex) [23]. Addition of Oncostatin M to the Dex 
enhances the hepatic phenotype [14, 154-155]. The mechanism controlling the 
transdifferentiation of B13 cells to hepatocytes, is thought to involve activation of the 
transcription factor CCAAT/Enhancer binding protein beta (C/EBPβ) [23].  
While the transdifferentiation of pancreatic cells to hepatocytes is well documented, 
the conversion of hepatocytes to cholangiocytes (and vice versa) is also possible. In 
vitro examples of bile duct to hepatocyte and hepatocyte to bile duct 
transdifferentiaton already exists in the literature. Rats subjected to bile duct ligation 
show periportal hepatocytes that undergo gradual transdifferentiation to biliary 
epithelial cells [156]. These form a ring of intermediate cells that express both biliary 
and hepatic markers similar to  that observed in the ductal plate during embryonic 
development [156]. Similar results have been obtained using organoid cultures of 
hepatocytes maintained in the presence of HGF and EGF [157]. Bile duct to hepatocyte 
transdifferentiation has been observed in mice treated with carbon tetrachloride. 
Livers damaged by CCl4 show duct cell and hepatocyte proliferation to regenerate the 
liver. However if the capacity of hepatocytes to proliferate is impaired, biliary cells are 
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thought to proliferate and differentiate to replace the lost hepatocytes [158], 
potentially through an  intermediate cell type referred to as an oval cell.   
 
3.1.C. Transdifferentiation of Cholangiocytes to Pancreatic Lineages 
As liver cells, cholangiocytes share a common developmental origin with pancreatic β-
cells as they develop from adjacent regions of the foregut endoderm, thus satisfying 
the hypothesis that developmentally-related tissues may be capable of 
transdifferentiation. The observation that pancreatic digestive enzymes α-amylase, 
trypsinogen and lipase are expressed in foetal hepatocytes and cholangiocytes is 
further evidence of the developmental relationship between liver and pancreas [149]. 
Hepatocytes loose expression of these pancreatic digestive enzymes in adult life 
however in some large cholangiocytes, pancreatic enzyme expression not only 
becomes stronger but also changes from diffusely cytosolic to granular, but expression 
of pancreatic genes is not observed in the small cholangiocytes [149]. Some β-cells are 
found to occur naturally in the extrahepatic bile ducts of mice, these cells are not 
thought to be the result of metaplastic events, but rather develop embryologically and 
persist, with slow multiplication into adult life [37]. There is also evidence of 
heterotopic pancreas (pancreatic cells that occur outside of the pancreas) in both 
normal and diseased human cholangiocytes at a frequency of 4.1%, the heterotopic 
pancreas consists of acinar cells, centriacinar cells and pancreatic duct-like cells, 
however no β-cells or islet-like structures were observed [159].  
Transdifferentiation of mature cholangiocytes to β-cells has been observed in the 
extrahepatic biliary epithelium of Hes1 knockout mice, which has been found to 
contain pancreatic endocrine and exocrine cells. Hes 1 (Hairy Enhancer of Split 1) 
usually represses the proendocrine gene Ngn3 and, in the absence of Hes 1, pancreatic 
genes are expressed and islet-like structures are observed in the biliary epithelium 
[152]. Transdifferentiation of hepatocytes to β-cells has been demonstrated by several 
labs [40-41, 43-44, 49], and as both cholangiocytes and hepatocytes develop from the 
same bipotential precursor population it is proposed that cholangiocytes may be 
converted to β-cells using similar mechanisms. Hepatocyte transdifferentiation to β-
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cells has been achieved by expression of the pancreatic transcription factor Pdx1 both 
in vitro, using the HepG2 cell line[160] and in vivo, using Pdx1 expression and/or 
expression of other pancreatic transcription factors including NeuroD, Ngn3, MafA and 
BetaA2 [40-41, 43-44, 49].   
3.1.D. The BEC Line as a Model of Normal Cholangiocytes 
Primary isolated cholangiocytes can be isolated from either rats or mice following 
collagenase perfusion of the liver. However cholangiocytes represent only 5% of liver 
cells and thus isolation by this method leads to very low cell yields. Primary 
cholangiocytes also suffer from diminishing viability after isolation as well as de-
differentiation in culture [161]. For these reasons a model of normal mouse 
cholangiocytes was obtained from Dr Ueno, Tohoku University School of Medicine, 
Japan. The cell line is referred to as Biliary Epithelial cells BECs. The cell line was 
produced by isolating mouse cholangiocytes followed by transformation with the SV40 
large T antigen, and subsequent cloning to establish cell lines [147]. Stable BEC lines 
were found to express markers of normal cholangiocytes including Cytokeratin 19 
(CK19) expression [147]. BECs also demonstrated, at least some functional 
characteristics of primary cholangiocytes in terms of secretin-induced cAMP elevation 
[147].     
3.1.E. Chapter Aims 
This chapter aims to: 
1. Characterise the expression of hepatic and pancreatic genes in the BEC line, by 
immunostaining and RT-PCR, to confirm that the line is a robust model for normal 
cholangiocytes and identify potential for transdifferentiation. 
2. Establish an optimised protocol for efficient transgene expression in BECs, using 
adenoviral infection.  
3. Overexpress hepatocyte-specific, candidate master-switch genes, including C/ebpα, 
C/ebpβ and Hnfα in BECs to induce transdifferentiation to hepatocyte-like cells. 
64 
 
4. Treat BECs with extracellular factors that have been shown to induce hepatic gene 
expression to induce transdifferentiation. 
5. Overexpress pancreatic, candidate master-switch genes, including Pdx1, Ngn3, 
NeuroD and Pax4 to induce up-regulation of pancreatic genes including Amylase, 






















3.2.A. Characterisation of the BEC Line 
3.2.A.1. The BEC Line Expresses Markers Typical of Normal Cholangiocytes 
Cholangiocytes express cytokeratins 7 and 19 as well as Epithelial-specific cadherin (E-
cad)[162]. In order to investigate the phenotype of the BEC line we initially determined 
the expression pattern of cytokeratin 7, 19 and E-cad. The BEC cell line was positive for 
all three cholangiocyte markers.  Many of the BECs expressed the epithelial marker E-
Cad (Fig 3.2 C). In contrast, the staining for the cytokeratins was more heterogenous 
(Fig 3.2 A-B).  The BECs strongly expressed CK7 and 19 and although these cytokeratins 
are not exclusively cholangiocyte markers (they are also thought to be expressed in 
oval cells of preneoplastic or injured livers [163]), but they are not expressed in 
hepatocytes. Surface markers known to be expressed by cholangiocytes include 
connexion 43 (Cx43) and the lectins Dolichos Biflorus Agglutinin (DBA) and Peanut 
Agglutinin (PNA)[162]. Connexin 43, PNA and DBA are all expressed in the BEC 
population (Fig.3.2 D-F). 
We used semi-quantitative RT-PCR to determine the expression of cholangiocyte 
markers in BECs, primary mouse hepatocytes and in a mouse insulinoma cell line, 
MIN6. At the gene level, CK7, CK 19 and E-cad were expressed in the BEC line (Fig.3.3). 
In addition, RT-PCR was used to determine the expression of other cholangiocyte 
markers including Gamma-Glutamyl Transpeptidase (GGT), the transcription factors 
Hepatocyte Nuclear Factor 1β (Hnf1β) and SYR (sex determining region Y)-box 9 (Sox 
9). GGT is an enzyme expressed throughout the liver, bile ducts and kidney and is 
responsible for metabolism of glutathione; the BECs showed expression of GGT 
although the hepatocyte control did not. Hnf1β is known to be expressed in both 
hepatocytes and cholangiocytes and is present in the BECs (Fig.3.3). Sox9 is a 
transcription factor characteristic of ducts in both the liver and pancreas and, as 
expected, is present in the BECs. Surprisingly, we also observed expression of Sox9 in 
primary mouse hepatocytes (Fig 3.3). This was unexpected and presumably reflects the 
dedifferentiation of mouse hepatocytes to a progenitor-like state (similar observations 
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have been made in primary rat hepatocyte populations K. O’Neill and D. Tosh personal 
communication).  
3.2.A.2. The BEC Line Expresses Some Markers Typical of Mature Hepatocytes 
In order to convert BECs to hepatocyte or pancreatic-like beta-cells we wished to 
determine the expression of transcription factors in the cell line and then ectopically 
express the missing transcription factor(s) based on our understanding of normal 
developmental biology. The liver enriched transcription factors CCAAT/Enhancer 
Binding Protein α and β (C/ebpα and C/ebpβ) and Hepatocyte Nuclear Factor 4 α 
(Hnf4α) are transcription factors involved both in liver development and in the normal 
functions of mature hepatocytes.   Primary cholangiocytes are known to only express 
C/ebpα, C/ebpβ and Hnf4α at very low levels [85]. The BECs showed weak staining for 
C/ebpα similarly in most cells (Fig.3.4 C and D), however they strongly express C/ebpβ 
and Hnf4α (Fig.3.4 E-H).  Despite the presence of hepatocyte transcription factors the 
BECs did not express the functional hepatocyte proteins albumin or transferrin (Fig. 3.4 
B and J), suggesting that either the level of expression may be important or that 
additional liver-enriched transcription factors are required to promote hepatic 
transdifferentiation. 
The immunostaining data for the transcription factors was confirmed by semi-
quantitative RT- PCR. C/ebpα, β and Hnf4α were expressed in the BECs (Fig.3.5). These 
transcription factors are normally restricted to hepatocytes in the adult liver. Other 
liver enriched transcription factors were also studied by RT-PCR including Hnf1α, Hnf1β 
and Hnf6 (Fig.3.5). The BEC line expressed Hnf1α which is uncharacteristic of normal 
cholangiocytes; however the expression was weak in comparison to that observed in 





































3.2.A.3. Some BECs Express the Pancreatic Transcription Factor Pdx1 but Not Other 
Typical Pancreatic Markers 
We determined the expression of the key pancreatic transcription factor Pdx1 in BECs 
and in control Min6 cells. In the Min6 cell line the Pdx1 was exclusively localised to the 
nuclei of cells. Surprisingly BECs also expressed Pdx1. The level of expression was 
weaker compared to that in Min6 cells when images were collected under the same 
condition (Fig.3.6). Two distinct patterns of Pdx1 expression were observed in the 
BECs. Pdx1 was either weakly expressed in the nucleus (Fig 3.6 C and D) or in the peri-
nuclear region (Fig 3.6 E and F) of BECs. The nuclear localisation of Pdx1 is important to 
regulate target gene transcription effectively. Due to the atypical subcellular staining 
pattern of Pdx1 in BECs (Fig. 3.6) the expression of Pdx1 protein was confirmed by 
western blotting (Fig 3.7 A and B). We extracted protein from BECs and Min6 cells and 
probed for Pdx1. Two bands were present on the western blot for Pdx1 at around 160 
and 46 kDa, the 46kDa band represents that active form of Pdx1. The expression of 
Pdx1 was lower in BECs compared to Min6 cells.  However the blot confirmed the Pdx1 
protein was present in the BECs. 
RT-PCR results showed that the pro-endocrine transcription factor Ngn3 or indeed the 
transcription factors downstream of Ngn3, NeuroD or Pax4 were not expressed in BECs 
(but NeuroD and Pax4 were both expressed in Min6 cells)(Fig.3.7 C). The Ngn3 
antagonist Hairy Enhancer of Split 1 (Hes1) was expressed in BECs (as well as 
hepatocytes) (Fig.3.7 C), but not in Min6 cells. Insulin I and II were not expressed in 
BECs but both were present in Min6 cells (Fig. 3.7 C). Surprisingly, we also observed 

















3.2.B. Optimisation of BEC Culture Conditions for Infection with Adenoviral Vectors 
We normally seeded BECs at a density of 4x105 cells/ml. At this density the BECs grow 
very rapidly, and even when seeded at lower density (we experimented with seeding 
densities as low as 4x103 cells/ml) the cultures become overconfluent and die within 3-
4 days. Furthermore if cells were seeded at low density, then infected with adenovirus 
and allowed to grow, only a small proportion of the resulting population will have been 
exposed to the virus and express the transgene. It is therefore desirable to maintain 
the cells for at least five days to achieve robust transgene expression following 
adenoviral infection. The growth conditions of the BECs were therefore changed to 
achieve viable five day cultures prior to optimisation of adenoviral infection protocol.   
3.2.B.1. Culture of BECs under Different Media Conditions Alters Cell Viability but not 
the Growth or Phenotype 
In order to optimise the growth conditions for adenoviral infection we tested a 
number of different media. We selected the media based on our previous experience 
of cell culture in the lab. The BECs were cultured in either control DMEM, RPMI 1640, 
DS (DMEM supplemented with 50µg/ml bovine pituitary extract and 5ng/ml EGF), KS 
(Keratinocyte serum free media supplemented with 50µg/ml bovine pituitary extract 
and 5ng/ml EGF) , or KDS (KS media supplemented with 10nM Dexamethasone). The 
BECs were cultured for three days and assessed in terms of culture confluence, growth 
pattern (cells observed in clumps or single cells), the presence of dead cells in the 
media and cell morphology. On day three the BECs were fixed and immunostained for 
the cholangiocyte marker CK7 to determine whether the marker expression was 
maintained under the different culture conditions examined. 
 BECs cultured in control DMEM rapidly became almost confluent by day three, they 
formed clusters of cells and as these clusters became overconfluent and cells began to 
appear in the media. DMEM cultured BECs had flattened epithelial-like morphology by 
day three (Fig.3.8 A). As previously, CK7 was expressed widely, although not all cells 
expressed CK7 to the same level, suggesting some heterogeneity within the cell 
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population (Fig.3.8 B), CK7 expression was most robust in cells in the middle of clusters 
where cell-cell contact was maintained.  
BECs were cultured in RPMI media supplemented with 10% FBS and 2mM L-glut, RPMI 
is a basal media known to support a wide range of cell types, including human 
lymphoid cells [164] and myeloma cell lines [165]. BECs cultured in RPMI were also 
almost confluent by day three as in DMEM controls (Fig.3.8 C). RPMI cultured BECs 
also grew in clusters of cells although counterstaining of nuclei with DAPI 
demonstrated that the cells appeared less dense within the clusters (Fig.3.8 D). The 
morphology of cells grown in RPMI media was similar to controls (Fig.3.8 C). CK7 
expression appeared to be weaker (Fig.3.8 D). 
BECs were cultured in DS media composed of DMEM supplemented with 10% FBS, 
2mM L-glut, 50µg/ml bovine pituitary extract and 5ng/ml EGF. DS media is known to 
promote dedifferentiation of cultured hepatocytes and cause up-regulation of ductal 
genes (K. O’Neill and D. Tosh personal communication). BECs cultured in DS media did 
not form clusters as in controls, but rather grew as individual cells that eventually grew 
to form epithelial sheets (Fig.3.8 E). DS cultured BECs were not confluent by day three 
(Fig.3.8 E). The morphology of DS cultured BECs was comparable to controls, but CK7 
expression may be weaker within sheets of cells (Fig.3.8 F). 
BECs were cultured in KS media, composed of KSFM supplemented with L-glut, bovine 
pituitary extract and EGF. KS media has previously been used by our lab to maintain 
the hepatic phenotype of cultured hepatocytes for long culture periods and prevent 
dedifferentiation [166]. The morphology (Fig.3.8 G) and CK7 expression (Fig.3.8 H) in 
BECs were unaffected by culture in KS media compared to DMEM culture.  
BECs were also cultured in KDS media which is composed of KS media supplemented 
with 10nM dexamethasone, this is thought to maintain and improve hepatic gene 
expression of hepatocytes cultured for up to 2-3 weeks. BECs cultured in KDS showed 







3.2.B.2. Altering Supplement Concentrations in Growth Media Allows Control of 
Growth  
As an alternative approach to using different media to reduce the growth of the BECs 
we also tried reducing the concentrations of culture supplements. 
BECs were cultured in varying concentrations of L-glut: 2mM (control), 1.2mM and 
0.4mM. Lowering the L-glut concentration to 1.2mM allowed four days growth (Fig.3.9 
D-G). Further reducing the L-glut concentration to 0.4mM allowed for five days of 
culture (Fig.3.9 H-L). 
BECs were also cultured in 10% FBS (control), 1% FBS and 0.1% FBS. Lowering FBS 
concentration to 1% allowed the cells to grow for 5 days (Fig.3.10 D-H). Further 
reduction of the FBS concentration to 0.1% allowed for extended culture (Fig.3.10 I-M).  
Lowering the FBS concentration to 1% seemed to be the most efficacious method of 
reducing BEC growth. We therefore decided to use an FBS concentration of 10% for 
adenoviral infection and after 12 hours of infection the media was changed to DMEM 
containing 1% FBS and 2mM L-glut for the remaining five days of culture. 
3.2.B.3 .BECs can be Infected with Adenoviral Vectors  
BECs were infected at a multiplicity of infection (MOI) of 100 and 500 infectious units 
per ml (ifu/ml). Although GFP expression was observed, the number of cells expressing 
the transgene was low (around 2-5% of cells) (data not shown). As expression was low 
the infection protocol was altered to include 10µg/ml DEAE-dextran.  Dextran has been 
shown to improve viral infection rates [167]. BECs were unaffected by dextran 
treatment and showed no negative effects of infection with high titre virus up to an 
MOI of 100 ifu/ml (Fig. 3.11 B). Infection with GFP at an MOI of 100 gave 
approximately 10% infection within three days (the point at which GFP expression 
peaks, although all cells were cultured for five days). Infection at MOI 500 gave 30-50% 
infection (Fig.3.11 C) within three days and as there were no obvious side-effects of 
using such high titres we used an MOI of 500 ifu/ml plus 10µg/ml dextran for the 
remainder of the adenoviral infections. No GFP or autofluorescence was observed 
78 
 
when BECs were infected with the Ad-Null virus (Fig.3.11 A), an empty vector 


































3.2.C. Transdifferentiation to a Hepatic Phenotype 
3.2.C.1. Overexpression of C/ebpα and β Causes Increased Expression of Hepatic 
Markers Albumin and GS  
The hepatic transcription factors C/ebpα and β have previously been shown to become 
expressed in the pancreatic AR42J-B13 cell line when treated with Dex. Expression of 
C/ebpβ in the transdifferentiated cells correlated with induction of the hepatocyte 
phenotype suggesting that the C/ebp may represent a potential “master-switch” 
gene for hepatocyte development. We therefore wished to test whether ectopic 
expression of C/ebpα and β were able to induce a hepatocyte phenotype in the BECs. 
BECs were infected with C/ebpα and β, both alone and in combination, for five days. 
RNA was extracted from treated cells and RT-PCR analysis performed as a high 
throughput analysis of relative gene expression. Neither C/ebpα nor β alone or in 
combination was able to elicit an increase in the early hepatocyte markers alpha-
fetoprotein (AFP) or the transcription factor Hnf4 (Fig. 3.12). Infection also failed to 
induce expression of important hepatic enzymes expressed including (i) 
carbamoylphosphate synthetase (CPS), a urea cycle enzyme important in ammonia 
detoxification, (ii) glucokinase, the first enzyme in the glycolytic pathway and (iii) 
PEPCK, an enzyme involved in gluconeogenesis.  
Infection with C/ebpα and β in combination increased expression of the hepatocyte 
marker albumin (Fig. 3.12).  Although Albumin was not detected in the control BEC cell 
line at low cycle numbers by PCR (Fig 3.12 and 13) or by immunoflourescence (Fig 3.4), 
increasing the cycles used in the PCR allowed for detection of a low level of Albumin 
transcript in control BECs (Fig 3.14). The presence of low levels of Albumin transcript in 
control BECs indicates albumin up-regulation rather than de-novo expression. Dual 
infection also increased the expression of the ammonia detoxification enzyme 
glutamine synthetase (GS), an enzyme restricted to the perivenous zone of the mature 
liver sinusoid. GS transcript was also detected at low levels in control BECs, when the 
cycle number used for PCR was increased (Fig 3.13).  
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These data suggest that infection with C/ebpα and β in combination can increase 
expression of some hepatic genes that are expressed at low levels in the BECs.      
3.2.C.2. Overexpression of Hnf4 Causes an Up-Regulation of the Hepatic Markers AFP, 
C/ebpα and Albumin Expression 
Hnf4 is a transcription factor involved in liver development and (along with the 
C/ebps) in the normal functioning of mature hepatocytes. Both primary cholangiocytes 
and BECs express low levels of Hnf4. For this reason Hnf4 expression was increased 
in BECs by adenoviral infection for five days prior to collection of RNA for analysis. 
Ectopic Hnf4 expression alone caused an increase in C/ebpα but not C/ebpβ 
expression (Fig. 3.13). Albumin was once again increased, however this time 
independently of C/ebpβ expression as in previous experiments expression of both 
C/ebps were required (Fig. 3.13). Glucokinase and PEPCK expression was not observed 
in BECs following infection with Hnf4 (Fig.3.13). AFP expression was observed, after 
infection with Hnf4 (Fig.3.13). AFP is typically found in foetal hepatocytes, however 
expression is also observed along with albumin in atypical mature hepatocytes, this 
perhaps indicates an immature hepatocyte-like induction caused by Hnf4 
overexpression.  
3.2.C.3. Combining C/ebpα, β and Hnf4 Overexpression in BECs does not Further 
Enhance the Hepatic Phenotype 
Having established that infection with either C/ebps or with Hnf4 can increase some 
hepatic gene expression, we attempted to improve the hepatic phenotype of the 
resulting cells by combining ectopic C/ebp and  and Hnf4 expression. No adverse 
effects on the cells were observed due to triple infection for five days, and in this time 
no phenotypic change in the BECs was observed. Expression of AFP, albumin and GS 
was again observed (Fig.3.14), however levels were comparable to previous 
experiments (Figs 3.12 and 3.13). No change in other hepatic genes was observed 
indicating the cells are probably immature.  
3.2.C.4. Treatment with Extracellular Factors Cannot Induce Transdifferentiation to a 
Hepatic Phenotype in BECs  
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Studies have previously shown that application of extracellular factors can either 
induce hepatic transdifferentiation or improve the phenotype of transdifferentiated 
cells ([23, 168-170]. For this reason a number of commonly used liver-specific factors 
were used to treat the BECs for six days.  These factors include: Dexamethasone 
(1µM), Insulin/Transferrin/Selenium (ITS; 1X), Oncostatin M (10ng/ml), Nicotinomide 
(Nic; 20mM) and Sodium butyrate (0.5mM). In the case of Dex, ITS, OSM and Nic, 
expression of C/ebpα, C/ebpβ, and Hnf4 was unchanged and there was no further 
induction of typical hepatocyte markers was observed (Fig. 3.15). In the case of NaB, 
the expression of C/ebpα, C/ebpβ and Hnf4 was reduced and a small increase in GS 



































3.2.D. Transdifferentiation to a Pancreatic Phenotype 
3.2.D.1 Overexpression of Pancreatic Transcription Factors Weakly Induces Insulin II 
Expression in BECs 
The developmental relationship between cholangiocytes and pancreatic cells is not as 
close as that between cholangiocytes and hepatocytes. However the development of 
pancreatic cells and liver cells from adjacent regions of the foregut endoderm may 
indicate that only a few transcription factors may control their differences. For this 
reason the BECs were infected with a combination of transcription factors which have 
been shown to induce insulin expression in hepatocytes [171]. Viruses containing the 
transcription factors Pdx1, Ngn3, NeuroD and Pax4 were used to infect the BECs, both 
alone and in combination using the standard infection protocol for BECs. Although 
Pdx1 is already expressed in the BEC line (Figs. 3.6 and 3.3.7) it was found at very low 
levels and not in the correct subcellular location, therefore overexpression using viral 
vectors may be beneficial in terms of inducing a pancreatic phenotype.  
Expression of any of the four pancreatic transcription factors alone was not sufficient 
to increase the expression of any pancreatic marker genes. Combined infection with all 
four transcription factors (Pdx1, Ngn3, NeuroD and Pax4) resulted in low level up-
regulation of insulin II (Fig 3.16) but not insulin I, which is a potential indicator of an 












3. 3 Discussion 
The goal of this chapter was to induce transdifferentiation of BECs to hepatocyte-like 
or pancreatic lineages by overexpression of proposed ‘master switch’genes.  
We first demonstrated that BECs expressed a range of markers typical of normal 
cholangiocytes including CK7, Ck19, E-cad, GGT, Hnf1β, Sox9 and the lectins DBA and 
PNA. Surprisingly we also observed expression of some transcription factors typically 
found in mature hepatocytes including C/ebpα, β and Hnf4α but not expression of 
other hepatic proteins such as albumin and transferrin. We also observed atypical 
staining of the pancreatic transcription factor Pdx1.  We did not observe expression of 
any other pancreatic transcription factors such as Hes1, NeuroD, or Pax4 nor did we 
observe insulin expression.  
We demonstrated that culturing BECs in reduced FBS (1%) allowed for infection with 
adenoviral vectors and the cells could be maintained for five days allowing optimal 
adenoviral infection. Overexpression of the transcription factors C/ebpα and β in 
combination caused increased expression of the hepatic markers albumin and GS. Up-
regulation of albumin and GS was also observed in BECs on overexpression of Hnf4α 
and Hnf4α overexpression also increased C/ebpα expression. Co-expression of C/ebpα, 
β and Hnf4α did not improve the hepatic phenotype of BECs. 
Overexpression of a combination of four pancreatic transcription factors, Pdx1, Ngn3, 
NeuroD and Pax4 in BECs caused initiation of insulin II expression but no other 
pancreatic genes were affected.  
3.3.A. Characterisation of the BEC Line 
In order to test the utility of the BEC line for use in studies on the transdifferentiation 
of cholangiocyte-like cells to hepatocytes or pancreatic beta-cells, we determined the 
expression of cholangiocyte markers by a combination of PCR and 
immunohistochemistry. We confirmed the expression of the markers CK7, CK19, E-cad, 
and Cx43 by both PCR and immunostaining.  Although these individual markers are not 
specific for cholangiocytes their combined presence in the BECs indicates that the cell 
line retains the ductal epithelial phenotype of normal cholangiocytes (Fig. 3.2).  While 
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we observed expression of these markers there was some heterogeneity of expression 
in the immunostaining results. Cholangiocytes show innate heterogeneity within the 
biliary system, both in terms of phenotype and function [151] and this is probably the 
reason for the heterogeneity observed here. 
As well as CK7, CK19, E-cad, and Cx43, we also determined the expression of GGT in 
BECs.  GGT is an enzyme expressed in ductal cells as well as hepatoblasts and foetal 
hepatocytes but not in mature hepatocyte [161]. We found GGT was expressed in the 
BECs (Fig 3.3). 
In addition to CK7, CK19, E-cad, and Cx43, cholangiocytes also express a number of key 
transcription factors.  These transcription factors include Sox9, Hnf6 and Hnf1β (Fig 
3.3).  The expression of Hnf6 and Hnf1β in the BECs is further evidence of their typical 
cholangiocyte phenotype as Hnf6 is responsible for regulation of biliary tree 
development via Hnf1β. Hnf6-/- mice lack expression of HNF1β in hepatoblasts or 
cholangiocytes indicating that HNF6 regulates HNF1β expression. Furthermore HNF6-/- 
mice show no development of the ductal plate, their cholangiocytes differentiate from 
hepatoblasts much earlier than in normal mice and many more hepatoblasts 
differentiate to cholangiocytes than wild-type mice. This indicates that HNF6 not only 
restricts cholangiocyte development but also regulates the positioning of the 
developing duct [172]. 
Sox9 was shown to be a marker for adult liver progenitors during regeneration 
following different liver injury regimens including carbon tetrachloride administration 
[173]. Sox9 has many important functions in embryonic development including the 
differentiation of Sertoli cells during testis development and chondrogenesis [173-
174]. Grompe and colleagues have also demonstrated using lineage tracing techniques 
that the cells proliferating during progenitor-driven regeneration are the offspring of 
Sox9-expressing precursors [175].  These results together provide evidence of a critical 
role for Sox9 in progenitor cell activation in adult livers and given the presence of Sox9 
in the PECs suggests that at least some, of the BECs may represent early progenitor-
like cells.  
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Although hepatocytes and cholangiocytes arise from the same precursor population 
the mature cells differ significantly in terms of phenotype. Markers not usually 
expressed in cholangiocytes were observed during the course of the characterisation 
of the BECs; specifically Hnf4α, C/ebpα and C/ebpβ which are usually expressed 
strongly in hepatocytes but are barely detectable in cholangiocytes [172].  Expression 
of the transcription factors Hnf4α and Hnf1α is also indicative of a hepatocyte 
phenotype.  Despite the unusual expression of hepatic markers in the BEC line they do 
not express typical markers of mature hepatocytes including albumin and transferrin.  
Although the cholangiocyte markers used (Fig 3.2 and 3.3) are typical of large 
cholangiocytes the appearance of some hepatic markers may indicate that the BEC 
population is more immature and therefore more like a small cholangiocyte population 
[152].   
Expression of the key pancreatic transcription factor Pdx1 has not previously been 
observed in intrahepatic cholangiocytes but is observed in the extrahepatic biliary 
system during embryonic development [37]. Pdx1 expression is essential for pancreatic 
development [38, 176].  The expression of Pdx1 quickly becomes restricted to β-cells 
[177]. The immunostaining pattern of Pdx1 in the BECs appears to be perinuclear and 
weakly nuclear rather than being strictly restricted to the nucleus as might be 
expected (Fig.3.6). Perinuclear localisation may explain the absence of insulin 
expression in the BECs even in the presence of Pdx1 as it is only able to activate target 
genes when expressed in the nucleus. There is expanding evidence that Pdx1 may 
translocate from the perinuclear region to the nucleus in high glucose conditions and 
in the presence of GLP1 i.e. conditions under-which insulin production is required 
[178-179]. Furthermore Pdx1 translocation out of the nucleus has been observed in 
the case of oxidative stress [177] and in the presence of the transcription factor FoxO1 
[180].  However Pdx1 autoregulates its own expression, therefore lack of Pdx1 in the 
nucleus would be expected to lead to a decrease in Pdx1 transcription. The RT-PCR 
data suggests that the level of Pdx1 transcript remains high it is possible that the 
presence of Pdx1 transcript could be controlled by the low level of nuclear Pdx1 
observed in the immunostaining and by western blotting.  
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The expression pattern of the BECs is similar to that found in normal cholangiocytes 
despite the appearance of some unexpected hepatic and pancreatic genes. The 
presence of these genes may indicate that the BECs represent a precursor population 
or be more representative of small cholangiocytes which are known to be less well 
differentiated than large cholangiocytes. The BECs are however a plentiful, easy to 
culture model of normal cholangiocytes in which to test many different combinations 
of genes and extracellular factors that may induce transdifferentiation towards 
hepatocytes or pancreatic β-cells. Primary cholangiocytes are notoriously difficult to 
isolate and culture successfully [161], and the BECs have been used by other groups as 
a model, of normal cholangiocytes [147, 181]  to study gene expression and bile 
modification. The BECs can be used as a model on which to test factors to induce 
transdifferentiation prior to testing the optimal combination of factors in primary cells.   
 
3.3.B. Optimisation of BEC Culture and Infection with Adenoviral Vectors 
In order to achieve expression of transgenes without the need for further sub-
culturing, the rate of cell growth had to be reduced.  In order to achieve this we 
cultured the BECs in different types of media including RPMI, DS, KS and KDS and 
looked at the cell density at day five.  Unfortunately none of the media tested were 
sufficient to maintain the cells to make them suitable for infection (Fig.8). It has 
previously been shown that culture of primary hepatocytes in KDS media prevented 
de-differentiation in culture and maintained expression of liver-enriched transcription 
factors [182], whereas cells cultured in KS media rapidly lost their hepatic phenotype.  
Culture of BECs in KS or KDS media showed more dead cells in the media, however 
culture under these conditions resulted in no change in expression of cholangiocyte 
genes. In addition, there was a change towards typical hepatocyte morphology 
suggesting that additional factors may be required to direct the differentiation of 
cholangiocytes to hepatocyte-like cells (Fig. 3.8).    
Culture of BECs in normal DMEM but with a lower concentration of L-glut (1.2mM or 
0.4mM) allowed cells to be maintained for up to five days.  However, many cells failed 
to survive under these conditions (Fig.3.9). It is possible that the lower L-glut 
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concentration induces a stress response resulting in the loss in viability and phenotypic 
changes. It is known that stress-induced signalling pathways result in changes in 
cellular morphology and apoptosis, supplementation of media with 4mM L-glut was 
shown to decrease expression of stress related and apoptotic genes and improve cell 
survival [183]. Reduction of FBS concentration in the cell culture media allowed the 
required culture for five days. The optimal concentration of FBS in the media was 
found to be 1% and this was used subsequently for culture of BECs post-infection with 
adenoviral vectors. 
 The optimal conditions for infecting the BECs were estimated by infecting them at 
different MOIs in the presence of 10ng/ml DEAE-Dextran (Fig. 3.11). Optimal 
conditions for infection of the BECs were found to be at an MOI of 500 for 12 hours of 
infection in 10% FBS media containing 10ng/ml DEAE-dextran, prior to changing media 
to 1% FBS for 5 days, these conditions led to an estimated efficiency of 30-50 %.  
 
3.3.C. Transdifferentiation to a Hepatocyte-like Phenotype 
3.3.C.1. Overexpression of C/ebp α and β 
The CCAAT-enhancer binding proteins (C/EBP) are basic region/leucine zipper (bZIP) 
transcription factors expressed during differentiation of adipose tissue and liver. 
C/ebpα suppression is thought to be a prerequisite of biliary cell differentiation in the 
hepatoblast population during development [184].  Another member of the C/ebp 
family, C/ebpβ, is required for the Dex-induced transdifferentiation of pancreatic B13 
cells to a hepatocyte-like phenotype [23]. Based on this study, Westmacott et al 
demonstrated that both C/ebpα and C/ebpβ are present in the developing liver but 
not the pancreas [185].  Together, these observations suggest a role for the C/ebp 
family of transcription factors in hepatocyte development. C/EBPβ can be transcribed 
into one mRNA, which can then be translated into three isoforms designated C/EBPβ, 
liver inhibitory protein (LIP) and liver activator protein (LAP) [186]. The 21-kDa LIP lacks 
the transactivation domain and acts as a dominant-negative form of C/EBPβ by 
heterodimerizing with full-length C/EBPβ [187]. Based on this information C/ebpα and 
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C/ebpβ (LAP the actvivated form of C/ebpβ) were over-expressed in the BEC line, both 
alone and in combination (Fig. 3.12). Although neither C/ebpα or β alone were 
sufficient to up-regulate any of the hepatic genes studied, co-expression of C/ebpα and 
C/ebpβ resulted in the up-regulation of albumin and glutamine synthetase (GS).  The 
increase in albumin expression following ectopic on expression of C/ebps may be the 
result of direct activation of the albumin gene by C/ebpα, as it is known to bind to and 
activate the promoter of the albumin gene [188-189]. Surprisingly, albumin gene 
activation was not achieved in the BEC line by over-expression of C/ebpα alone, which 
may indicate that albumin gene expression may be regulated by a combination of 
transcription factors, as is the case with hepatoblast to hepatocyte differentiation 
during embryonic development [190]. Ectopic expression of C/ebpβ alone was also not 
sufficient to up-regulate any of the hepatocyte genes studied.  These observations may 
be consistent with data that demonstrates that different liver enriched transcription 
factors control the differentiation of hepatocytes during postnatal development [191] 
indicating that multiple transcription factors are required to form fully differentiated 
hepatocytes.  
It is well established that hepatic functions are heterogeneously distributed across the 
liver lobule or acinus [4]. The organisation of the functional unit of the liver (referred 
to as the hepatic acinus or lobule) is accompanied by functional heterogeneity at the 
cellular level. The unit is broadly divided into three zones: the periportal zone, which 
surrounds the afferent vessel and portal triad and receives blood rich in oxygen and 
nutrients, the intermediate zone, which surrounds the periportal zone and finally the 
outer, perivenous zone cells. Periportal and perivenous hepatocytes can be 
distinguished according to differences in function which run as gradients from one 
zone to the other. The functional gradients arise because the activities of key rate-
limiting enzymes for some pathways e.g. hepatic fatty acid -oxidation are higher in 
the periportal zone whereas the activities of other enzymes e.g. the cytochrome P450 
detoxification pathway enzymes are higher in the perivenous zone [192].  As a result 
most of the major hepatic functions exhibit differences in activity within the periportal 
and perivenous zones.  Perhaps the most striking example of zonation is observed in 
the enzymes and pathways of ammonia detoxification.  The liver contains two systems 
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for the removal of ammonia: the urea cycle and the enzyme glutamine synthetase 
(GS). The urea cycle enzymes (including carbamoylphosphate synthetase) are 
expressed in the periportal, intermediate and first few layers of the perivenous zone 
[193].  In contrast, GS is expressed in a complementary pattern in the last few layers of 
perivenous hepatocytes [194].   
The up-regulation of the perivenous marker GS by C/ebpα and β over-expression was 
unexpected as there was no observed change in the expression of the periportal 
markers CPS or PEPCK (Fig. 3.12). There was also no alteration in HNF4 expression  
after infection with C/ebpα and β.  There is evidence that C/ebp mRNA is 
predominantly expressed in the perivenous region of the adult liver [195]. However, in 
situ hybridisation experiments have found the zonation of C/ebps to be so weak that it 
is unlikely that they are directly responsible for governing zonation [195]. 
Dexamethasone-treated rats showed an increase in glucokinase mRNA in perivenous 
regions [196]. The expression of glucokinase was similar to the up-regulation of C/ebp 
mRNA expression [196], indicating that C/ebps may be responsible for regulating 
glucokinase expression. Although GS expression was up-regulated by Dex treatment 
the pattern of C/ebp mRNA and GS mRNA expression was not overlapping enough to 
infer a direct relationship [196]. 
 
3.3.C.2. Overexpression of HNF4 
Hnf4 expression is known to be essential for both morphological and functional 
differentiation of hepatocytes, establishment of hepatic epithelium and maintaining 
normal liver architecture in postnatal life [76]. Over-expression of Hnf4 in BECs leads to 
an increase in C/ebpα, albumin and AFP expression (Fig. 3.13). Up-regulation of 
C/ebpα RNA by HNF4 was surprising as there is no evidence that HNF4 directly 
activates expression of C/ebps. Rats that have undergone partial hepatectomy 
followed by suppression of regenerative capacity of hepatocytes by AAF 
administration, are able to activate oval cell compartments to regenerate hepatocytes 
[190]. In this case Hnf4 expression is up-regulated early in oval cell activation and 
differentiation and is followed by activation of C/ebps [190].  However there is no 
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evidence that oval cell activation is as a direct result of Hnf4 and not other 
transcription factors [190].  
The observation that albumin is up-regulated on Hnf4 over-expression may be the 
result of direct binding C/ebp to the upseream enhancer of GS, which is known to 
cause suppression of GS expression in periportal regions as [188-189]. However it may 
also be evidence of HNF4 enhancement of the early periportal phenotype [197], 
although again no enhancement of PEPCK or CPS expression is observed following 
Hnf4 over-expression (Fig. 3.13). Furthermore Hnf4 has been shown to suppress 
expression of perivenous proteins [197] but this is not the case in BECs infected with 
HNF4 as there was no reduction in GS.  
Increases in AFP expression on Hnf4 over-expression may also be the result of indirect 
C/ebpα activation as the AFP gene has C/ebpα binding motifs in the upstream 
regulatory elements [184] and C/ebp binding has been shown to activate the AFP 
proximal enhancer [198].  However no increase in AFP was observed on expression of 
C/ebpα alone or in combination with C/ebpβ (Fig. 3.12). This may be explained by a 
synergistic relationship between Hnf4 and C/ebps which has been previously described 
resulting in the induction of hepatic genes. HepG2 cells do not express CYPs 
(Cytochromes P450), which are involved in drug metabolism in human hepatocytes, 
can be induced to express CYP2B6 and other phase I and II detoxification genes when 
infected with C/ebpα and Hnf4 in combination [199].  
Combining C/ebpα, β and Hnf4 over-expression in the BECs did increase AFP, albumin 
and GS expression, however the level of expression was not significantly higher than 
that observed on expression of C/ebpα and β or Hnf4 infection alone, thus does not 
provide evidence for a synergistic relationship between C/EBPs and HNF4 in terms of 
inducing ductal to hepatocyte transdifferentiation.  
Although up-regulation of some hepatocyte genes (AFP, Albumin and GS) was 
observed following infection of BECs with the hepatic transcription factors C/ebpα, β 
and Hnf4 induction of a more mature hepatic phenotype was not possible. It is likely 
that this is due to the complex cross-regulatory cascades of transcription factors that 
are necessary to induce and maintain the normal hepatic phenotype [86]. It is also 
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possible that if we had maintained cells for longer periods of time in culture following 
adenoviral infection more pronounced differences may have been observed.  Despite 
the close developmental relationship between biliary duct cells and hepatocytes this 
work demonstrates that a relatively complex network of interacting transcription 
factors may be required to control the conversion of one cell type to another. Only 
three hepatic transcription factors were used to induce direct transdifferentiation 
between duct cells and hepatocytes, however the literature describes many other 
transcription factors that may play important roles in hepatic differentiation such as, 
HNF1β, FoxA2 and DBP [190]. These three factors are all up-regulated in bile ducts on 
severe liver injury and oval cell activation [190], and are therefore additional factors 
that could be investigated as master regulators of bile duct to hepatocyte 
transdifferentiation.  
3.3.D. Transdifferentiation to a Pancreatic Phenotype 
As previously discussed the transcription factors Pdx1, Ngn3, NeuroD and Pax4 have 
been used to induce transdifferentiation of HepG2 cells to pancreatic lineages in vitro 
[158] and hepatocyte to pancreas transdifferentiation in vivo [40-41, 43-44, 49]. For 
these reasons the four transcription factors were over-expressed, alone and in 
combination, in the BEC line. Over-expression of all four transcription factors increased 
the level of Insulin II mRNA but did not alter the expression of other pancreatic genes 
including Insulin I, amylase or glucagon. Previous work demonstrated that mouse 
embryonic stem cells can be induced to differentiate into insulin producing cells [200].  
Interestingly, induction of insulin II is achieved more readily than induction of Insulin I 
[200]. 
 
This work demonstrates that over-expression of pancreatic transcription factors is not 
sufficient to induce a ductal to β-cell transdifferentiation.  Ectopic expression of 
transcription factors may not be the only method of inducing transdifferentiation in 
this case. Activation or inhibition of molecular signalling pathways may produce more 
efficacious results than over-expression of transcription factors alone. Notch signalling 
pathways are known to be important in β-cell development [201] as are the 
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phosphatidylinositol controlled signalling pathways [202].  These pathways may 
therefore be potential targets for induction of transdifferentiation between bile duct 
and β-cells.  
3.3.E. Future Work 
In terms of the work remaining for this project, it is clear that the optimal combination 
of transcription factors to direct cholangiocyte transdifferentiation to hepatocyte or 
pancreatic lineages remains to be found. Although the combinations of transcription 
factors used here were previously successful in inducing transdifferentiation of other 
cell types to hepatocyte or pancreatic lineages, they may not be the correct 
combination to direct cholangiocyte differentiation to a mature phenotype. In 
addition, the length of exposure to the transcription factors may also be a limiting 
factor so extended studies could be performed to test this possibility.  In terms of 
transdifferentiation to hepatocyte-like cells, other transcription factors that should be 
tested include, FoxA2 and Hnf1α. In terms of cholangiocyte to pancreatic cell 
transdifferentiation transcription factors including MafA, Nkx2.2 and Nkx6.1 should be 
further investigated. These transcription factors are all important for embryonic 
development of either hepatic or pancreatic cells so may be able to direct 
transdifferentiation of cholangiocytes to these lineages. The possibility that a 
transcription factor exists in BECs that represses the hepatocyte or pancreatic 
phenotypes should also be considered. It may therefore be necessary to repress the 
expression of this factor as well as introducing additional cell type-specific 
transcription factors. Approaches to repressing the expression of a transcription factor 
include introducing a dominant-negative form (e.g. with the engrailed repressor) or by 
siRNA.  
Once the optimum combination of transcription factors have been found it would be 
desirable to induce transdifferentiation in primary cells and also in vivo, to establish 




Chapter .4. Signalling Pathways in 
Liver and Pancreas Development 
4.1. Introduction 
4.1.A. Signalling Pathways Involved in Endodermal Organ Development  
4.1.A.1. Notch Signalling 
The Notch signalling pathway is a critical factor during the differentiation and 
development of many cell types including those of the central nervous system and 
cardiovascular system, influencing factors such as differentiation, proliferation and 
apoptotic programmes. Notch signalling provides a cell interaction mechanism that 
allows for cell-cell communication between adjacent cells thereby allowing them to 
respond to developmental cues, via activation of gene expression and thus 
differentiation towards particular cell types (for more detailed reviews see; [203-204].  
Canonical Notch signalling involves DSL (Delta-Serrate, Lag-2) ligands binding to the 
extracellular domains of Notch receptors on the cell surface of adjacent cells. Ligand/ 
receptor binding induces cleavage of the Notch intracellular domain (NICD) by gamma 
secretases, and translocation of NICD into the nucleus (Fig 4.1).  Once inside the 
nucleus, NICD binds to CSL (CBF1, Suppressor of Hairless, Lag-1)-type transcriptional 
co-factors, allowing activation of transcription of target genes (reviewed  in [205]). 
Notch target genes including HES (Hairy enhancer of Split) and HERP (HES-related 
repressor protein)-family members, act as transcriptional repressors controlling cell 







Notch signalling is known to be important for development of endodermal organs due 
to the clinical manifestations of the disease Alagille syndrome (AGS) , which is the 
result of mutations in the Notch ligand JAG1 [207-208] or NOTCH2 receptor [209]. 
Alagille syndrome is characterised by both intrahepatic bile duct paucity [210] and 
pancreatic insufficiency [208] as well as heart and skeletal abnormalities including 
pulmonary valve stenosis and characteristic butterfly-shaped vertebrae [210].  
In the liver Notch signalling is known to be important in controlling hepatoblast to 
cholangiocyte differentiation by altering expression of liver-enriched transcription 
factors , specifically down-regulation of the typical hepatocyte transcription factors 
HNF1α, HNF4 and C/EBPα, and up-regulation of the cholangiocyte transcription 
factor HNF1β[85]. A role for Notch signalling in liver regeneration has also been 
implicated as rats that have undergone partial hepatectomy show activation of Notch 
signalling in regenerating liver. These data indicate that notch is important for 
proliferation of hepatocytes, although the mechanism by which notch acts is unclear 
[211].  
In the pancreas Notch gene expression is observed throughout development, firstly in 
the pancreatic epithelium, then in embryonic ducts and finally in pancreatic 
Figure 4.1 Canonical Notch Signalling 
Notch signalling is activated by Delta-Serrate-type ligands which bind to the notch receptors on 
the surface of adjacent cells. Upon activation the intracellular domain of the notch receptor 
(NICD) is cleaved by the action of gamma secretases. NICD translocates to the nucleus where it 
activates transcription of target genes.   
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mesenchyme and endothelial cells [212]. During development ectopic activation of 
Notch signalling has been found to increase ductal development in zebrafish [213], and 
more recently mice over-expressing Notch signalling components showed increased 
ductal structures at the cost of both α- and β-endocrine cell types [214].  
In order to specifically investigate the role of Notch signalling in liver and pancreas 
development, we inhibited Notch signalling using the gamma secretase inhibitor DAPT 
(N-[N-(3,5-Difluorophenacetyl)-L-atnyl]-S-phenylglycine t-butyl ester) and activated the 
pathway using the Notch ligand Jagged1 protein.  It is worth mentioning that DAPT 
may have off-target effects so in this context we will refer to DAPT treatment as an 
inhibitor of gamma secretase rather than an inhibitor of Notch signalling per se. 
4.1.A.2. TGFβ and HGF Signalling 
TGFβ signalling is responsible for control of processes such as cell proliferation, 
differentiation and apoptosis and is therefore responsible for controlling cell fate and 
tissue morphology. Canonical TGFβ signalling requires binding of a TGFβ superfamily 
ligand to a TGFβ type II receptor on the cell membrane. TGFβ superfamily ligands 
include BMPs, Activins, Nodal and TGFβs. Binding of ligands to type II receptors forms 
a hetero-tetrameric complex of type I and type II receptors and ligand. Activated 
receptor complexes phosphorylate R-SMADs which then form complexes with co-
SMADs, translocate to the nucleus and activate target genes or relieve the action of 
transcriptional repressors ([215-216]). 
The effects of TGFβ signalling have been observed in liver regeneration, where levels 
of TGFβ protein in hepatocytes have been shown to increase after 70% hepatectomy 
[217]. It has recently been proposed that a gradient of activin/TGFβ signalling may be 
responsible for hepatocyte vs ductal differentiation during liver development, in which 
high TGFβ signalling gives rise to cells of biliary fate and low TGFβ activity induces 
hepatocyte differentiation [84]. HGF signalling is proposed as a mechanism for 
producing and maintaining the TGFβ gradient that controls hepatocyte vs biliary 
development [83].  
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In the pancreas, HGF is thought to function independently of TGFβ signalling to induce 
differentiation of pancreatic ductal cells to insulin-producing -cells, when treated with 
a combination of HGF and betacellulin, although the exact mechanism of HGF action is 
unclear [218]. 
To investigate the effects of TGFβ and HGF signalling pathways on liver and pancreas 
development TGFβ and HGF proteins were incubated with embryonic liver and 
pancreatic bud cultures.  
4.1.A.3. Wnt/β-Catenin Signalling 
Canonical Wnt/β-Cat signalling involves binding of Wnt ligands to Frizzled and LRP 
receptors which form a complex that recruits and phosphorylates Dishevelled. 
Activated Dishevelled leads to inhibition of formation of a second complex of proteins 
which includes Axin, GSK-3β and APC, this complex typically functions to 
phosphorylate and ubiquitinate β-catenin (β-cat), targeting it for destruction. 
Activated Dishevelled inhibition of the complex that leads to proteolysis of β-cat allows 
a stable pool of β-cat to accumulate within the cytoplasm, this then translocates to the 
nucleus, where it mediates transcription of Wnt target genes via interaction with 
LEF/Tcf1 ([219]).  
Wnt/β-cat signalling is known to be important in hepatic development and has been 
implicated in liver regeneration, differentiation and carcinogenesis, Wnt independent 
stabilisation of β-cat has also been implicated in hepatic specification and 
morphogenesis [220]. Wnt/β-cat signalling is thought to be the molecular mechanism 
governing establishment and maintenance of metabolic zonation in the mature 
hepatic lobule [154], where activated Wnt genes are thought to interact with the liver 
enriched transcription factor HNF4 to repress expression of periportal genes [221].  
To investigate the effects of Wnt/β-cat signalling on liver development and 
differentiation cultured liver buds were incubated with a Glycogen synthase kinase 3 
inhibitor (GSKi).  Addition of the GSKi inhibits GSK-3β, prevents the formation of the 
complex that targets β-cat for proteolysis, simulating Wnt activation independently of 




4.1.A.4. Phosphatidylinositol Signalling 
Phosphatidylinositol signalling is controlled by the action of Phosphatidylinositol 
kinases (PIKs). PIKs are intracellular signal transducer enzymes that phosphorylate  
Phosphatidylinositols producing 1, 2 or 3 phosphorylated inositol lipids or 
phosphoinositides (PtdIns). These PtdIns are responsible for lipid signalling, cell 
signalling and membrane trafficking [222] and are therefore important in processes 
including cell growth, proliferation, differentiation, cellular function and survival [223].  
In the pancreas activation of PI3 Kinase has been found to regulate Pdx1 expression in 
ductal cells inducing a switch from ductal cells to insulin-producing cells, this switch in 
phenotype is thought to involve activation of HGF signalling [224]. In adult β-cells PI3 
Kinase signalling pathways have been found to protect β-cells from the effects of 
oxidative stress by regulating apoptotic programmes [225]. More recently PtdIns, 
PtdIns(3,4,5)P3, PtdIns(3,4)P2 and PtdIns(3,5)P2 have been implicated in adult β-cell 
function and survival and are thought to be regulated via an autocrine insulin feedback 
loop, i.e. insulin exocitosis increases PtdIns, which in turn increase insulin expression 
and exocitosis [202]. At least PtdIns(3,5)P2 is thought to be phosphorylated by the 
action of PIKfyve, a PIK with a specificity for the 5 position and a five finger domain 
[226], indicating that this PIK may be important in β-cell function and survival.  
To investigate the effects of Phosphatidylinositol signalling in pancreas development 
and β-cell function, dorsal pancreatic buds maintained in culture were treated with 
HGF and PIKfyve inhibitors.  
4.1.B. Embryonic Ex vivo Liver and Pancreas Cultures as Models of Development 
4.1.B.1. Ex vivo Liver Buds 
The ex vivo liver cultures were obtained from E11.5d mouse embryos and cultured as 
described in Chapter 2. Cultures represent a mixed population of epithelial cells 
surrounded by an outgrowth of mesenchymal cells. Culture of the epithelium with 
associated mesenchyme aids the growth, differentiation and survival of epithelial cells. 
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The cell population within the epithelium is thought to include hepatoblast-like cells 
and hepatocytes of varying maturity in terms of marker expression and functionality, 
as would be observed in a normal embryonic liver. The epithelial component also 
includes duct cells or cholangiocytes, also at varying levels of maturity and mixed 
functionality as observed in normal embryonic liver and mature liver ducts. The ex vivo 
buds can be maintained in Basal media for up to two weeks and although buds from 
different isolations do show some heterogeneity in terms of phenotype, experiments 
are repeated sufficiently to account for slight variations between cultures. This model 
has previously been used to study the growth and differentiation of hepatic cell types 
[227].  
4.1.B.2. Ex vivo Pancreatic Buds 
Ex vivo pancreatic buds were dissected from the dorsal bud of the developing pancreas 
of E11.5d mouse embryos. The bud is composed of a ball of epithelium surrounded by 
a layer of mesenchyme, co-culture of the mesenchyme with the epithelium is essential 
for normal epithelial growth, survival and differentiation. Within 7 days of culture, 
pancreatic buds demonstrate branching morphogenesis of duct-like cells and 
formation of acini-like structures. Endocrine gene expression is also observed by 7 days 
culture indicating the presence of α-, β-, δ- and PP-cells which are often clustered in 
islet-like structures, at least in part recapitulating normal pancreatic architecture. 
Pancreatic buds can be maintained in basal media for up to two weeks and some 
heterogeneity is observed between isolations which can be overcome by stringent 
repetition and pooling of experimental data. This model system has been used 
previously in our lab to demonstrate the effects of betacellulin on β-cell development 
in embryonic pancreas [48] and on the transdifferentiation of pancreatic cells to 
hepatocyte-like cells [23].  
The advantage of our ex vivo system over typical cell line culture is the ability to 
recapitulate normal development in terms of cell diversity and, at least in part, 
morphology and tissue architecture. This model allows for high throughput testing of 
multiple signalling pathways via application of exogenous factors and inhibitors 
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directly to the medium without the need to generate and maintain costly and time 
consuming animal models, required for in vivo experiments.      
 
4.1.C. Chapter Aims 
This chapter aims to investigate the effects of different signalling pathways on the 
differentiation of hepatic and pancreatic cell types. In particular we aim to investigate 
the effects of Notch signalling, Activin/TGFβ signalling and Wnt signalling in hepatic 
development.  We also aim to investigate the effects of Notch, HGF and 
phosphatidylinositol signalling on pancreatic development. The effects of these 
signalling pathways on hepatic and pancreatic development will be investigated using 












4. 2. Results 
4.2.A. Treatment of ex vivo liver buds with the Gamma-Secretase Inhibitor DAPT  
4.2.A.1. DAPT Treatment Reduces Differentiation of Hepatoblasts to Ductal Cells 
Control liver buds are composed of hepatoblasts; a bipotential precursor population 
that gives rise to both hepatocytes and cholangiocytes or ductal cells. By day 6 of 
culture, cells expressing the ductal markers CK7 and Pan CK were observed throughout 
the original explant and surrounding the migrating epithelium (Fig. 4.2C). Culture with 
50µM of the gamma-secretase inhibitor DAPT altered expression of the ductal markers 
(Fig. 4.2 F). Further analysis by RT-PCR confirmed that CK7 expression was reduced by 
DAPT treatment (Fig. 4.3) and no increase in the expression of the ductal transcription 
factor Sox9 was observed (Fig. 4.3) indicating no increased differentiation of 
hepatoblasts to a ductal phenotype. 
An enhancement in GGT expression (Fig. 4.3) is not sufficient to indicate ductal 
differentiation. Although GGT is known to be expressed in mature ducts, it is also 
expressed in hepatoblasts [150]. The change in GGT compared to untreated controls 
could therefore indicate an alteration in the hepatoblast population of the buds in 
response to the lack of normal ductal differentiation.  
 
4.2.A.2. DAPT Treatment May Allow Differentiation of Hepatoblasts to an Early 
Hepatocyte-like Phenotype 
As previously observed the hepatoblast population of DAPT-treated ex vivo liver buds 
may be increased (Fig.4.2). A change in the hepatoblast cell population in the DAPT-
treated buds, is further supported by the cells expressing AFP (Fig. 4.3 and 4.4 A-D). 
AFP is however also a marker for differentiating hepatocytes, and may represent a 
population of immature hepatocytes. Furthermore DAPT treatment induced a change 
in the liver enriched transcription factor HNF4 (Fig. 4.3 and 4.4 E-H) which is essential 
for hepatoblast to hepatocyte differentiation.  
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The absence of mature, functional hepatocyte markers is not sufficient to exclude the 
hepatoblast to hepatocyte hypothesis but may indicate an intermediate hepatoblast 













































4.2.B. Ex vivo Liver Buds Treated with Jagged to Activate Notch Signalling 
4.2.B.1. Jagged Treatment is not Sufficient to Induce Hepatoblast to Hepatocyte 
Differentiation 
DAPT treatment to inhibit gamma secretase has been shown to reduce hepatoblast to 
ductal differentiation (Figs 4.2-4.4). Treatment of liver buds with the Notch activator 
Jagged, however resulted in no change in either CK7 or Pan CK expression within the 
ex vivo bud (Fig. 4.5 A,B and 4.6). Furthermore no change in the mature ductal marker 
GGT was observed (Fig.4.6) nor was there any alteration in the ductal transcription 
factor Sox9 (Fig. 4.6). The similar expression levels of GGT also indicate that no 
significant change in the hepatoblast portion of the bud is observed as a result of 
Jagged treatment. AFP expression did not appear to change in the cultures (Fig.4.5 C-D 
and Fig 4.6). 
4.2.B.2. Jagged Treatment Prevents Differentiation of Hepatoblasts to a Mature 
Hepatocyte-like Phenotype 
Treatment with Jagged did not alter AFP expression in the bud (Fig. 4.5 C-D and Fig. 
4.6). Re-examining the AFP staining shows that the AFP-expressing cells present after 
Jagged treatment appear to be clustered within the original explants rather than 
distributed throughout the growing epithelium, as in controls (Fig. 4.5 C-D). This may 
indicate that the remaining AFP-positive cells are hepatoblasts rather than the early 
hepatocyte-like cells previously described (4.2B). The absence of these intermediate 
hepatocyte-like cells is confirmed by the similar levels of HNF4 at the gene expression 
level (Fig. 4.6), but may also indicate a lack of mature hepatocytes in the Jagged 
treated buds. To confirm the change in mature hepatocytes in the Jagged treated buds 
the expression of the functional hepatocyte marker Transferrin was determined by 
immunostaining. The Transferrin expression was less intense in the Jagged treatment 






















4.2.C. Ex vivo Liver Buds Treated with HGF to Interfere with Activin/TGFβ Signalling 
4.2.C.1. HGF Treatment is not Sufficient to Induce Differentiation of Hepatoblasts to 
Hepatocyte or Ductal Phenotypes 
Hepatocyte growth factor (HGF) has been reported to interact with Activin/TGFβ 
signalling to induce differentiation of hepatoblasts to hepatocyte or ductal phenotypes 
[83]. However treatment of ex vivo buds with HGF was not sufficient to alter 
expression of AFP, Cytokerains 7 or 19, GGT, Sox9 or HNF4 (Fig. 4.7).  
 
4.2.D. Ex vivo Liver Buds Treated with GSKi to Activate Wnt Signalling 
4.2.D.1. GSKi Treatment has no Effect on the Ductal Component of Liver Buds 
Liver buds treated with (Fig. 4.8 C and H) or without (Fig. 4.8 E and J) a GSK inhibitor 
exhibited a similar morphology.   
Although previously described as composed of hepatoblasts, ductal and hepatocyte-
like cells the composition of the hepatocyte compartment of the adult liver is more 
complex. Adult hepatocytes show remarkable heterogeneity, in terms of function, 
called liver zonation, which is thought to be controlled by Wnt/β-catenin signalling 
[58]. Treatment of the liver buds with GSKi to activate Wnt signalling had no effect on 
the ductal component of the buds as shown by CK7, CK19 and Sox9 RT-PCR (Fig. 4.9). 
 
4.2.D.2. GSKi Treatment Induces a Perivenous Phenotype in Maturing Hepatocytes of 
the Liver Bud 
Glutamine synthetase expression was upregulated in GSKi treated liver buds compared 
to controls (GS; Fig. 4.9). GS is typically associated with perivenous hepatocytes, this 
observation is concurrent with the down-regulation of albumin (Fig. 4.9) which is more 
commonly associated with periportal hepatocytes [58]. AFP expression also appears 
weaker following GSKi treatment and may represent a change in the hepatoblast 
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component of the liver buds. The expression of the liver enriched transcription factor 
HNF4 was also lower following GSKi treatment suggesting further possible changes in 











































4.2.E. Ex vivo Pancreatic Buds Treated with DAPT to Inhibit Gamma Secretase 
4.2.E.1. Treatment with DAPT is Sufficient to Induce Alterations in Branching 
Morphogenesis and Islet Structure. 
Inhibition of Gamma secretase signalling by treatment of pancreatic buds with DAPT 
severely affected branching morphogenesis. Branching structures are discontinuous 
and significantly reduced, which can be observed even with only DAPI nuclear staining 
(Fig 4.10). Due to the many changes observed on Gamma secretase inhibition this work 
is expanded in chapter 5.   
4.2.F. Ex vivo Pancreatic Buds Treated with Jagged to Activate Notch Signalling  
4.2.F.1. Treatment with Jagged is not Sufficient to Induce Endocrine Over Exocrine 
Differentiation of Ex vivo Pancreatic Buds 
Inhibition of Gamma secretase by culturing pancreatic buds with DAPT is sufficient to 
promote exocrine differentiation of pancreatic cells at the cost of endocrine cells in the 
developing bud (due to the extent of changes observed this is expanded in chapter 5). 
Treatment of pancreatic buds with the Notch activator Jagged is not sufficient to 
change the expression of the endocrine markers insulin I, II or glucagon or the exocrine 
marker amylase (Fig. 4.11). Immunofluorescent staining demonstrates that normal 
branching morphogenesis occurs in the presence of Jagged (Fig. 4.11). Further 
evidence for normal branching morphogenesis and ductal cell number is provided by 
the ductal cell markers CK7 and CK19, which do not change on treatment of the buds 































4.2.G. Ex vivo Pancreatic Buds treated with HGF  
4.2.G.1. HGF Treatment is Not Sufficient to Induce Ductal to β-cell Differentiation in Ex 
vivo Pancreatic Buds 
It has been proposed that treatment with HGF can induce ductal cells of the pancreas 
to transdifferentiate towards a β-cell phenotype. Pancreatic buds treated for 6 days 
with HGF show no changes in branching morphogenesis of the ducts (Fig. 4.13 A, B) 
and no change in expression of the ductal cell markers CK7 and CK19 (Fig. 4.13 C). 
Expression of the β-cell markers insulin I and II were unaltered by HGF treatment (Fig. 

























4.2.H. Ex vivo Pancreatic Buds Treated with PIKfyve Inhibitor 
4.2.H.1. Treatment of Pancreatic Buds with a PIKfyve Inhibitor Suppresses Branching 
Morphogenesis 
PIKfyve is a phosphoinositide kinase that activates 3-phosphorylated inisitol lipids. 
Treatment of the pancreatic buds with the PIKfyve inhibitor YM201636 at 400nM 
reduced branching morphogenesis of the bud. Immunostaining for E-Cad does not 
seem to demonstrate a change in epithelial cells (Fig. 4.15 B ,D), but does demonstrate 
the disruption in branching morphogenesis. Acini-like structures appear to form in 
clusters close to the central ducts in PIKfyve inhibitor treated buds (Fig. 4.15D) rather 
than at the terminus of extended branches, as observed in controls (Fig. 4.15B).  
 
4.2.H.2. Treatment of Pancreatic Buds with a PIKfyve Inhibitor Suppresses β-cell 
Differentiation and Formation of Islet-like Structures 
Immunostaining for pancreatic markers demonstrates that not only is ductal branching 
altered by PIKfive inhibition but also endocrine and exocrine differentiation. The 
expression pattern of amylase immunostaining was altered and was found distributed 
throughout the bud, rather than in acini-like structures as in controls (Fig. 4.16 A, B). 
The pattern of insulin-positive staining in β-like cells may be lower compared to 
controls (Fig. 4.16 C, D). Although insulin-positive cells remain clustered together in 
PIKfyve inhibited buds these clusters were not associated with glucagon-positive cells, 






















4. 3. Discussion  
The aim of this chapter was to investigate signalling pathways important in hepatic and 
pancreatic development, using our ex vivo model of embryonic liver and pancreas 
development.  
We first demonstrated the effects of inhibiting gamma-secretase using DAPT. We 
observed a change in differentiation of hepatoblast cells to ductal lineages and an 
apparent enhancement in differentiation of hepatoblasts to early hepatocyte-like 
phenotypes. We were not able to observe an opposing phenotype on Jagged 
treatment of liver buds. Treatment of ex vivo liver buds with a GSK inhibitor had no 
effect on ductal differentiation but did appear to push differentiation of maturing 
hepatocytes to a perivenous-like phenotype based on the expression of Glutamine 
synthetase. 
We next investigated the effects of different signalling pathways on pancreatic 
development. We observed that inhibition of gamma secretase using DAPT, induced 
many changes in the pancreatic bud, including changes in branching morphogenesis 
and endocrine vs. exocrine differentiation. As there were so many changes induced by 
DAPT treatment this was examined in more detail in chapter 5. No clear phenotype 
could be induced by Jagged treatment of pancreatic buds. Finally we investigated the 
treatment of pancreatic buds with the PIKfyve inhibitor YM201636 and observed a 
suppression in branching morphogenesis and differentiation of β-cells and a failure to 
form normal islet-like structures in treated buds.   
4.3.A. Notch and TGFβ Signalling in Embryonic Liver Buds 
We first examined the potential role of Notch signalling on embryonic liver 
development using the gamma-secretase inhibitor DAPT in an established ex vivo 
model of liver development [148]. Multiple Notch ligands, receptors and Hes-family 
effectors are expressed in embryonic liver [228-229] and some functional redundancy 
is thought to occur between Notch receptors. Inhibition of Notch signalling using a 
gamma-secretase inhibitor, may not lead to complete pathway inactivation, if not all 
gamma-secretase enzymes are inhibited.  In addition, some caution must be taken in 
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interpreting the results as the DAPT may also have off-target effects.  Further work is 
necessary to confirm that the DAPT is acting specifically through gamma-secretase 
(e.g. using a reporter-based assay for gamma secretase or inhibition of NICD 
translocation). 
We have demonstrated that treatment of embryonic liver cultures with DAPT alters 
differentiation of hepatoblasts to ductal cells as we observed a relative decrease in the 
staining intensity of the ductal markers CK7 and PanCK (Fig 4.2). The human pathology 
Alagille’s syndrome is the result of mutations in the notch ligand JAG1 [207-208] or 
NOTCH2 receptor [209] and is characterised by bile duct paucity [210]. This implies an 
essential role for Notch signalling in bile duct differentiation in the liver. Lozier et al 
demonstrated the importance of Notch signalling in bile duct morphogenesis, by use of 
a Jag1/Notch2 double heterozygous mouse model that displays bile duct paucity. They 
propose that deficits in bile duct cells that occur on notch pathway inactivation are the 
result of failures in bile duct morphogenesis and not cell fate specification [230]. It is 
unlikely that the effects of gamma secretase inhibition observed in our system are the 
result of errors in ductal tubulogenesis as it does not occur in our system. Despite the 
absence of ductal tubulogenesis in our ex vivo model, under control conditions, duct 
cell differentiation still takes place and markers such as CK7, GGT and Sox9 are 
observed. Therefore our data imply that Notch signalling may be required for duct cell 
differentiation. Zhong et al have demonstrated that Notch activation in postnatal 
hepatocytes can induce a biliary fate, which supports our observation that Notch 
pathway activation is required for biliary cells differentiation as well as tubulogenesis 
[79]. 
Surprisingly, we did not observe any change in the duct cell differentiation induced by 
exogenous Jagged1 treatment (Fig.4.5 and 4.6). It has been observed that Notch2 (but 
not Notch1) is responsible for mediating bile duct cell differentiation [231]. However, 
mutations in Jag1 or Notch2 are responsible for Alagille syndrome and errors in bile 
duct morphogenesis [207-208]. These data may indicate that Notch pathway activation 
is responsible for both bile duct cell differentiation and tubulogenesis but different 
receptors may be responsible for the mechanism of Notch activation. 
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We also observed that treatment with the gamma-secretase inhibitor DAPT resulted in 
the appearance of an enhanced expression of early hepatocyte-like cells by expression 
of AFP and Hnf4 but no increase in mature hepatocyte markers. This early 
differentiation to hepatocyte lineages is consistent with a model that proposes a 
reduction in cholangiocyte differentiation causes an increase in hepatocyte 
differentiation. Tanimizu et al demonstrated that Notch signalling controls hepatoblast 
differentiation by altering expression of liver enriched transcription factors. They 
observed that activation of Notch signalling, by overexpression of the Notch 
intracellular domain (NICD) resulted in down-regulation of Hnf4 and inhibition of 
Notch resulted in hepatic differentiation in vitro [85]. These data are consistent with 
our observed enhancement in Hnf4 expression on DAPT treatment, but we did not 
observe an overall increase in hepatocyte differentiation.  
Our data indicates the presence of a population of hepatoblasts that have begun part 
of a stepwise commitment to hepatocyte lineage, as they express Hnf4 but do not 
express late markers of hepatocyte differentiation.  It is possible that although active 
Notch signalling inhibits hepatic differentiation, Notch inhibition alone may not be 
sufficient to drive differentiation to mature hepatic phenotypes. Clotman et al have 
demonstrated the requirement for a gradient of activin/TGFβ signalling for hepatocyte 
vs. cholangiocyte differentiation. In this model low activin/TGFβ signalling is required 
for hepatocyte development and Notch is thought to act downstream to promote 
biliary differentiation [83](see Fig 1.7). This implies that inhibition of both Notch and 
activin/TGFβ signalling might be required to observe an increase in hepatic 
differentiation.   
To determine the effects of perturbed activin/TGFβ signalling on liver development, 
buds were initially incubated with an anti-TGFβ antibody. Even at very low 
concentrations the liver buds failed to grow in the presence of the antibody. HGF was 
used to modify activin/TGFβ signalling in the liver buds but showed no effect on 
cellular differentiation or gene expression. This may indicate that HGF alone is 
insufficient to modify activin/TGFβ signalling in our system.  
4.3.B. Wnt Signalling in Embryonic Liver Buds 
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Another signalling pathway that has recently been implicated in liver development is 
the Wnt/-catenin pathway. We sought to investigate the effects of Wnt signalling on 
liver development by treatment of liver buds with a GSK3i. GSK3β normally 
phosphorylates β-catenin causing it to be broken down in the cell.  Therefore, 
inhibiting GSK3β allows -catenin to accumulate before translocating to the nucleus 
where it activates target genes.    
Initially we observed that the buds treated with the novel GSKi lagged behind the 
controls between day one and three in culture. This observation may be a side effect 
of treatment with the inhibitor but it is also in line with evidence that suggests that 
stabilised β-catenin leads to hypoplastic livers with failed hepatocyte differentiation 
[232]. Despite these early observations hepatocyte differentiation was largely restored 
to normal by day 6 of treatment. We also observed that buds treated with GSKi had 
cells that were morphologically epithelial-like compared to cells cultured under control 
conditions, this has also been shown to be the case in mouse knockouts for β-catenin 
[233]. Cells that maintained β-catenin expression were found to have 25% higher cell 
volume than those that did not express β-catenin [233].  
We observed no effect on the biliary cell differentiation within the GSKi treated buds, 
this is contrary to evidence that suggests that Wnt signalling disrupts ductal cell 
differentiation.  Other groups have demonstrated that deletion of β-catenin causes a 
reduction in biliary differentiation [234] and conversely stabilisation of β-catenin 
results in enhanced biliary cell differentiation [232]. One possible explanation for the 
discrepancies between these data and our own is the temporal effects of Wnt 
signalling.  Tan et al observed the effects of β-catenin deletion by E12, our ex vivo 
cultures are taken form E11.5 mice embryos and the GSKi is not added for another 24 
hours to allow the buds to attach. The window for the early effects of Wnt signalling 
on bile duct cell differentiation may have closed by this point and therefore normal 
bile duct development can occur. One way to test this hypothesis would be to isolate 
embryonic liver from earlier stages of gestation (E9.5 or 10.5) and test the inhibitor. 
The GSK inhibitor was found to play a role in directing differentiation of hepatoblasts 
to periportal or perivenous phenotypes. Addition of GSKi enhanced expression of the 
perivenous enzyme glutamine synthetase (GS) (Fig. 4.9). The role of Wnt signalling in 
135 
 
the establishment of hepatocyte zonation is well documented [154], our system shows 
an inhibition of AFP, a hepatoblast marker suggesting differentiation to a more mature 
hepatic phenotype. We also observed an inhibition of HNF4expression. HNF4 has 
been shown to suppress the expression of GS in periportal hepatocytes as HNF4 
deficiency results in GS expression in periportal regions [197]. The effect of Wnt 
signalling on HNF4 expression has been demonstrated by Colletti et al who have 
shown that LEF1, a factor down-stream of Wnt, interacts directly with HNF4. Indeed 
activation of perivenous genes by addition of a GSK3β inhibitor correlates with LEF1 
binding to the HNF4 consensus sequence [221]. 
4.3.C. Notch Signalling in Embryonic Pancreas Buds 
We also investigated the signalling pathways involved in branching morphogenesis and 
cellular differentiation of embryonic pancreas, in order to establish potential methods 
for induction of transdifferentiation of cholangiocytes to pancreatic lineages.  
We demonstrated that treatment of embryonic pancreas with the gamma-secretase 
inhibitor DAPT was sufficient to cause changes in branching morphogenesis and also 
appeared to alter the differentiation of endocrine and exocrine cell types. Due to the 
extreme changes observed on Notch inhibition of embryonic buds, further analysis was 
required and this can be seen in Chapter 5. 
As well as testing the utility of inhibiting Notch signalling in the embryonic pancreas we 
also wished to test the effect of activating Notch signalling to see if a reciprocal 
phenotype was observed. Pancreatic buds were treated with exogenous Jagged1, a 
ligand for Notch signalling. Contrary to our expectations we did not observe any 
significant changes in branching morphogenesis or differentiation of endocrine vs. 
exocrine cell types. Previous studies have found that activated Notch prevents 
differentiation of early pancreatic progenitors to both endocrine and exocrine cell 
fates [201] and Notch signalling is known to regulate stem cell compartments in other 
tissues [235]. Again the fact that we do not observe a similar effect is probably due to 
the temporal effects of Notch signalling, in our model progenitors have already 
committed to an endocrine or exocrine lineage. We did however expect to observe a 
reciprocal phenotype to our Notch inhibited buds i.e. an increase in exocrine cells and 
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a decrease in endocrine differentiation, which was not observed. This may be due to 
our ineffective activation of Notch signalling by addition of Jagged1. Su et al 
demonstrated that activation of Notch2, 3 and 4 required expression of the ligands 
Jagged 1 and 2 as well as delta1 and that all three receptors needed to be expressed  
for pancreatic regeneration after chronic pancreatitis [236]. Notch activation may not 
be the only pathway that requires activation to observe our expected phenotype. 
Differentiation to endocrine lineages may also require activation of other pathways 
including Hedgehog, TGFβ and/or FGF pathways [201, 237].  
4.3.D. HGF Treatment of Pancreatic Buds 
We wanted to determine if HGF treatment could be used to enhance differentiation of 
insulin-producing cells in our ex vivo pancreas cultures. Previous experiments have 
revealed that the rat pancreatic ductal cell line ARIP can be converted to insulin-
producing cells using exogenous HGF treatment [238]. We did not observe any change 
in insulin expression upon treatment with HGF or any changes in ductal branching or 
gene expression. It is possible that the concentration of HGF was not sufficient to 
cause changes in our cultures, which are far more complex than monolayer cell 
cultures. We did however use 100ng/ml, twice the concentration used to induce 
insulin-producing cells in ARPI cells. HGF has been shown to stimulate insulin 
production in duct cells by activation of PI3K signalling [239], therefore we desired to 
directly modify PI3K pathways in the absence of HGF. 
4.3.E. PIKfyve Treatment of Pancreatic Buds 
To investigate the effects of PI3K signalling on insulin production in our ex vivo 
pancreatic buds we treated them with a PIKfyve inhibitor called YM201636 [240]. 
PIKfyve is a phosphoinositide kinase with a specificity for the five position and a five 
finger domain. Inhibition of PIKfyve signalling resulted in a suppression of branching 
morphogenesis and expression of E-cadherin. We also observed a loss in expression of 
amylase and insulin. 
We believe the inhibition in branching morphogenesis may be the direct result of PI3K 
signalling inhibition.  Indeed Uzan et al have demonstrated that KGF-mediated 
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activation of PI3K signalling is required for pancreatic duct cell differentiation and 
proliferation [241]. It is also possible that the suppression in branching morphogenesis 
may be the result of failure to form an epithelial sheet as a result of PIKfyve inhibition.  
Dukes et al, have demonstrated that inhibition of PIKfyve in MDCK cells results in 
blockage of claudin 1 and 2 (two tight junction proteins) recycling and a delay in the 
formation of a epithelial seal [242]. More work is required to establish the mechanism 
of inhibition of branching morphogenesis caused by inhibition of PIKfyve, including 
establishing the role of tight junction formation.  
The observed decrease in amylase and insulin expression may indicate endocrine 
differentiation is favoured over exocrine differentiation as observed in HGF treated rat 
ductal cells [243]. One caveat to this hypothesis is the function of PIKfyve in adult β-
cell function. PIKfyve is important for both adult β-cell survival and insulin secretion 
[224]. Our observations are based on insulin expression and not secretion, however it 
is possible that inhibition of PIKfyve has a direct effect on β-cell survival, further 
experiments would be required to determine the exact mechanism of PIKfyve 
inhibition on insulin expression.  
4.3.F. Future Work 
While the results of the present Chapter are interesting further research is necessary 
to generate more robust evidence for involvement of the different pathways in 
embryonic development and to provide more quantitative data.  One obvious point to 
start is investigating whether there are any off-target effects of the inhibitors used.  In 
order to test the utility of DAPT as a specific inhibitor of Notch signalling we would 
need to demonstrate that addition of the compound prevented the induction of the 
Notch downstream target genes Hey1 and Hey2.   We could also increase the 
robustness of the results by testing other gamma-secretase inhibitors such as BMS-
906024.  Quantitative changes between different treatments could be measured either 
by area measurements of the immunofluorescence staining or alternatively in changes 
in gene expression could be measured by quantitative PCR. 
The advantage of our system over transgenic knockout models is that we can activate 
or inhibit signalling pathways at different stages of development, knockout animals 
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often die at early developmental stages due to the essential nature of signalling 
pathways in development. For this reason it would be interesting to investigate other 
signalling pathways in our model. Signalling pathways important for liver regeneration 
and liver disease and cancer could also be investigated such as the VEGF and MAPK 
pathways. 
The effects of inhibition of gamma-secretase in pancreatic development is explored in 
more detail in this thesis in Chapter 5, but other work that could be continued from 
this chapter is the effect of PIKfyve inhibition on pancreas development. The effect of 
PIKfyve inhibition on junction proteins could be investigated in more detail to establish 
a link with branching morphogenesis in development. It would also be interesting to 
use our model to investigate the mechanism of PIKfyve action in insulin expression and 




Chapter 5. Notch Signalling in 
Pancreatic Development 
5.1. Introduction 
In chapter 4 we noticed significant changes in pancreatic buds treated with the 
gamma-secretase inhibitor DAPT. We observed changes in branching morphogenesis 
and the differentiation of endocrine and exocrine cell types. In the present chapter the 
phenotype of DAPT-treated buds is examined in more detail in terms of branching 
morphogenesis, endocrine and exocrine differentiation and the functionality of β-cells 
within the bud.  
5.1.A. Notch Signalling in the Pancreas 
Notch signalling is activated by ligand binding to transmembrane Notch receptors 
located on the surface of cells. The action of gamma secretases is then recruited to the 
membrane to cleave the intracellular domain of the Notch receptor (NICD). After 
cleavage, the NICD translocates to the nucleus where it effects transcription of Notch 
target genes that can both activate and inhibit transcription of other genes (for detail 
see chapter 4.1.A).  
All four Notch receptors are expressed in the pancreas during development. Notch 1 is 
expressed the earliest in the pancreatic epithelium (E9.5) and is followed later by 
Notch 2 expression, which is restricted to embryonic duct cells during branching 
morphogenesis [212]. Notch 3 and 4 are expressed in the pancreatic mesenchyme 
through development [212].  
In the present study we used the gamma-secretase inhibitor DAPT, which may 
therefore effectively prevent signalling from all four Notch receptors.  
5.1.B. Ductal Cells of the Pancreas 
Ductal cells of the pancreas are responsible for the delivery of enzymes produced by 
acinar cell to the duodenum, and also secrete bicarbonate and mucins [244]. Ductal 
cells are arranged into highly branched structures that terminate in acini, their 
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differentiation is strongly linked to both correct branching morphogenesis and 
differentiation of endocrine and acinar cell types [38, 245]. Although little is 
understood about the factors that control differentiation at later developmental 
stages, ductal cells are derived from Pdx1-positive pancreatic progenitors that also 
produce endocrine and acinar cells [110]. Ductal cells express Pdx1 between E9.5 and 
E11.5 in mouse embryos, and cells that continue to express Pdx1 past E11.5 become 
endocrine cells [246]. Notch is thought to function in duct cell development by 
repression of endocrine and acinar cell fates [201].  
Embryonic ducts form through a process called branching morphogenesis at around 
E12.5. During branching morphogenesis pancreatic progenitors divide asymmetrically 
and produce branches that push away from the central epithelium of the developing 
bud [117] (for a more detailed description see Chapter 1.3.C).  
Ductal cells have frequently been described as pancreatic progenitors due to their 
ability to differentiate into endocrine cells in vivo following pancreatic injury [247-249]. 
Differentiation of pancreatic duct cell lines to β-cells in vitro has also been extensively 
characterised [20, 250-252].  
5.1.C. Acinar Cells of the Pancreas 
Acinar cells are arranged into clusters called acini that are found at the terminus of 
branching ducts. Acinar cells produce digestive enzymes, such as amylase, that are 
secreted into the duodenum through the pancreatic ducts (for review see [24]).  
Acinar cell differentiation occurs from Pdx1-positive pancreatic progenitors at around 
E14.5 and requires expression of the transcription factors Ptf1α and Mist1 [141-142] 
(see Chapter 1.3.C for detail). Notch is thought to inhibit acinar cell differentiation by 
inhibition of Ptf1α function [143]. Acinar cells have also been shown to display some 






5.1.D. The Islet of Langerhans 
The rodent islet of Langerhans is composed of approximately 2000-4000 cells of all five 
islet cell lineages α-, β-, δ-, PP-, and ε-cells (Fig 5.1A and Table 5.1). The islet is 
surrounded by acini and embedded in a dense capillary network that allows detection 
of blood glucose levels and secretion of hormones directly into the blood stream. The 
endothelial cells of the islet capillary network are also responsible for enhancing 












Figure 5.1. Schematic of the composition of the adult islet (A) and position of the islet in relation to 
surrounding acini and capillary network. 
A. Islets are composed of α-, β-, δ-, PP-, and ε-cells with β-cells making up the majority of the islet 
and being located within the islet core. α- and ε-cells are found around the periphery of the islet 
and scant δ- and PP-cells are distributed through the core. B. Islets are found surrounded by acini 
structures composed of acinar cells and are embedded within a capilliary network that allows for 
blood glucose sensing and secretion of hormones. 





Table 5.1. Summary of the five different cell types that comprise the islet of Langerhans, their 
hormone secretions, function and location within the islet. 
Islet Cell Type Hormone Produced Function Cellular Location  
α-cell Glucagon 
Increases blood glucose 
levels by induction of 
gluconeogenesis and 
glycogenolysis 
Around the periphery 
of the islet 
β-cell Insulin 
Decreases blood glucose 
levels by activating 
glycogenesis and inhibits 
glucagon release 
Forms the central 
core of the islet 
δ-cell Somatostatin 
Inhibits release of  insulin 
and glucagon and 
suppresses production of 
exocrine secretions 
Distributed sparsely 
through the islet 
PP-cell Pancreatic 
Polypeptide 
Regulates endocrine and 
exocrine secretions 
Distributed sparsely 
through the islet 
ε-cell Ghrelin 
Regulates insulin and 
increases β-cell 
proliferation and inhibits 
apoptosis 
Very scent 
distribution less than 
1% of islet cells 
around the periphery 
 
By far the most numerous cell type in the islet is the β-cell which comprises 70-80% of 
islet cell mass [24]. β-cells produce the hormone insulin (Table 5.1) and secrete it into 
the bloodstream primarily in response to increases in blood glucose, but also in 
response to other nutrients and hormones. It is therefore important that β-cells 
produced for therapeutic treatments must be able to produce insulin and respond to 
changes in blood chemistry. 
5.1.E. Insulin Production in Pancreatic β-cells 
In adult cells insulin expression is strictly limited to β-cells of the pancreatic islet. 
Unlike humans mice have two insulin genes Ins1 and Ins2, Ins2 is structurally and 
functionally most similar to the human insulin gene [254]. Insulin gene expression in 
adult β-cells is regulated by glucose levels in the blood. Glucose causes binding of Pdx1 
to the insulin promoter, the mechanism by which this takes place is unclear however 
one possibility that has been proposed is that glucose modifies an inactive form of 
Pdx1 causing its translocation from the cytoplasm to the nucleus [178]. Other 
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transcription factors that are important for insulin gene expression include MafA and 
NeuroD whose expression and binding to the insulin promoter are also regulated by 






Insulin gene expression is controlled by glucose-induced transcription factor binding to 
the insulin promoter as well as epigenetic control. Insulin gene transcription has been 
shown to require demethylation of CpG sites in the insulin promoter, to allow 
Figure 5.2 Structure and processing of the protein preproinsulin to mature insulin for 
secretion. 
Preproinsulin is targeted to the endoplasmic reticulum by an N-terminal sequence that is 
quickly cleaved after entry into the ER, to form Proinsulin. Proinsulin forms three sulphide 
bonds that give the correct structure for mature insulin and moves into the Golgi region. 
Proinsulin is converted to insulin by cleavage of C-peptide. Source: The Beta Cell Consortium, 
2004.   
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transcription factor binding [256] and also hyperacetylation of histone H4 at the 
promoter site, this is also mediated by glucose [257-258].  
Once transcription is initiated, insulin mRNA is translated into an inactive protein 
called perproinsulin. Preproinsulin is composed of insulin A and B chains linked by C-
peptide and an N-terminal signal sequence that allows the movement of preproinsulin 
through the membrane of the endoplasmic reticulum (ER) (Fig 5.2). Interestingly 
glucose is also thought to regulate insulin expression by stabilisation of preproinsulin 
mRNA at this stage [259].  Production of insulin initially, as inactive preproinsulin is an 
efficient method of ensuring correct folding and structure. After movement of 
preproinsulin into the ER the signal sequence is cleaved and three disulphide bonds 
from between insulin A and B chains (Fig 5.3), this forms an intermediate called 
proinsulin.  Proinsulin moves to the Golgi region where C-peptide is cleaved by the 
combined action of prohormone convertases PC2 and PC1/3 and carboxypeptidase-E 
(CPE) resulting in the formation of functional insulin (for review see [260]. Insulin is 
stored in granules for release, but because cleavage of C-peptide occurs after 
proinsulin has entered the Golgi network, vesicles contain both insulin and C-peptide 
results in approximately equimolar release into the blood.  
5.1.F. Glucose Stimulated Insulin Secretion 
Insulin secretagogues include metabolised nutrients and drugs but the main initiator of 
insulin secretion from β-cells is glucose. These secretagogues initiate insulin secretion 
through opening of calcium channels that cause insulin granules to fuse with the cell 
membrane, releasing insulin into the blood. A number of insulin potentiators also 
regulate insulin release, such as glucagon-like peptide 1 (GLP1) [261-262], 
acetylcholine [263-264] and amino acids [265-266]. Insulin potentiators are thought to 
be unable to initiate insulin release independently of secretagogue action [267]. 
In an unstimulated β-cell a resting potential of -70mV is maintained by the presence of 
voltage-gated calcium ion channels, which are closed in unstimulated cells, and ATP-
sensitive potassium channels, which remain open [267]. When glucose levels increase, 
glucose is taken into the β-cell by the glucose transporter GLUT2 and is converted to 
glucose-6-phosphate by the action of the enzyme glucokinase [268]. The increase in 
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metabolism results in production of ATP which causes closure of ATP-sensitive 
potassium channels. Closure of potassium channels results in depolarisation of the 
membrane and opening of voltage-gated calcium channels. Influx of calcium ions 
causes insulin granule fusion with the cell membrane and release of insulin into the 
blood (Fig 5.3).  
Insulin granule docking with the cell membrane is dependent on SNARE proteins that 
tether the granule to the membrane and the calcium channel itself. After granule 
docking the two membranes fuse via the action of a calcium-sensor which is thought to 
be of the synaptotagmin family [269]. 
 
   
 
Figure 5.3 Schematic of glucose-stimulated insulin secretion in pancreatic β-cells.  
Glucose transport and metabolism results in and increase in intracellular calcium concentration. 
Increased Calcium concentration leads to insulin granule fusion with the β-cell membrane and 
insulin release. Blue arrows represent intergration of insulin signalling with glucose stimulated 
insulin secretion. SERCA-Sarcoplasmic endoplasmic reticulum calcium, IRS- Insulin receptor 
substrates, PI3Kinase- Phosphatidyl inositol 3-kinase. Source: Kulkarni, 2004 [270].  
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Glucose-stimulated insulin secretion is also modified by interactions with insulin/IGF2 
signalling pathways (Fig 5.3)[270]. β-cells lacking  IGF2 receptors demonstrate 
impaired glucose tolerance and a decrease in glucose-dependent insulin release [271].  
The secretion of insulin in response to glucose is often referred to as biphasic, as initial 
exposure to sustained high glucose results in a marked increase in insulin release 
(phase one) followed by a decrease in secretion, the second phase is characterised by 
lower intensity, sustained insulin release (for review see [272]). The mechanism of 
biphasic insulin secretion is unclear; however two models exist to explain the 
phenomena, the storage-limited model and the signal-limited model. The storage-
limited model indicates that the first phase of insulin secretion is the result of 
exocytosis of a readily releasable pool of insulin granules and the second phase 
requires the release of a pool of granules that must dock with the membrane prior to 
exocytosis, resulting in a time lag [273]. The signal-limited model proposes the 
presence of either a single stimulatory signal that is also biphasic or the interaction of 
two different signals that stimulate the two phases independently [274].    
The mechanism of insulin secretion is important in both autoimmune and non-
autoimmune diabetes as GLUT2 receptors are down-regulated leading to a reduction 
in responsiveness to insulin. In autoimmune diabetes some immunoglobulins directly 
inhibit functional GLUT2 transporters [275]. The mechanism of insulin secretion is also 
a therapeutic target for treatment of diabetes, sulphonylureas are a group of drugs 
that close potassium ion channels and induce insulin release by mimicking the effects 
of glucose stimulation and are often used to treat type II diabetes [269].  
In our ex vivo model developing β-cells do not normally demonstrated glucose-
stimulated insulin secretion, neither do they increase insulin production in response to 
insulin potentiators such as amino acids. It is thought that the β-cells within the buds 






5.1.G. Chapter Aims 
This Chapter aims to (1) examine in detail the effects of gamma-secretase inhibition on 
ex vivo pancreatic buds. The differentiation of exocrine and endocrine cells and effects 
on branching morphogenesis will be examined. (2) Investigate the maturity of the 
DAPT-treated ex vivo pancreatic buds in terms of their ability to respond to glucose 


















5.2. Results  
5.2.A. Ex vivo Pancreatic Buds Display Branching Morphogenesis and Both Endocrine 
and Exocrine Cell Differentiation 
5.2.A.1. Normal Branching Morphogenesis  
On isolation of the dorsal pancreatic bud the central ball of epithelial cells and 
surrounding mesenchyme is placed, cut side down, onto fibronectin coated coverslips. 
By day two after isolation the epithelium and mesenchyme of the pancreatic bud 
attach to the fibronectin and the epithelium is observed as a central ball of cells 
surrounded by a more flattened mesenchyme (Fig 5.4A). At day three both the 
epithelial and mesenchymal cells have flattened to the fibronectin and the onset of 
branching morphogenesis is observed as a series of finger-like protrusions (Fig 5.4B). 
Branching morphogenesis continues between day four and six in culture, the original 
finger-like protrusions undergo further branching to form a highly branched structure 
approximately 3-4 times as large as the original bud (Fig 5.4C-E). Branches clearly 
terminate in acini-like clusters by day five in culture (Fig 5.4D) and ductal structures are 
clear by day six, although some small sections of ductal lumen may be observed prior 
to day six (Fig 5.4E).   
Ductal branching was confirmed by the distribution of Pan cytokeratin positive cells 
within the bud by day six (Fig 5.5E). These branched ducts clearly form luminal 
structures and were distinct from surrounding mesenchymal cells (Fig 5.5E). The 
branched structures of the ducts formed acini-like structures along their length and 
particularly at the termini of extended branches.  
5.2.A.1. Normal Endocrine and Exocrine Cell Differentiation 
The presence of acini-like structures along the length and at the terminus of ducts was 
confirmed by the presence of amylase-positive clusters within these structures (Fig 
5.5B). At day six in culture endocrine cells were observed in clusters associated with 
the ducts. These clusters appeared to be islet-like, in terms of cellular composition; 
containing both glucagon-positive and insulin-positive cells (Fig 5.5A and C). δ-like cells 
expressing somatostatin were also present in ex vivo buds by day six, however they 
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appeared to be more associated with the ducts rather than residing in the islet-like 
structures (Fig 5.5D). Although pancreatic polypeptide is clearly expressed within the 
bud by days six, by RT-PCR (Fig 5.5F) the level of expression and number of PP-positive 





























5.2.B. DAPT Treatment Disrupts Normal Branching Morphogenesis 
Treatment of the ex vivo pancreatic buds with DMSO (control) does not affect normal 
branching morphogenesis and by day six the DMSO-treated buds were consistent with 
untreated controls in terms of and branching structures (Fig 5.6 A,C,E). Treatment of 
the ex vivo buds with the gamma-secretase inhibitor DAPT did not appear to prevent 
normal attachment of epithelium or outgrowth of mesenchyme by day two (Fig 5.6B), 
however by day four of treatment DAPT-treated buds failed to show normal branching, 
although small acini-like structures were observed within the epithelium (Fig 5.6D). 
The proliferating epithelial cells did not branch into the surrounding epithelium and 
failed to form branched structures (Fig 5.6F). 
Immunofluorescent staining for the ductal markers CK7, PanCK and E-cad showed that 
duct-like epithelial cells developed within the DAPT-treated buds (Fig 5.7 B,D,F,H). 
Clusters of ductal cells still appeared after DAPT-treatment but are not phenotypically 
characteristic of acini, as observed in controls, furthermore these clusters were not 




















5.2.C. DAPT Treatment Disrupts Endocrine and Exocrine Cell Differentiation 
We have previously demonstrated that both endocrine and exocrine differentiation 
and islet formation is continuous with ductal branching in the ex vivo pancreas model 
(Fig 5.5), and that ductal branching fails to occur in buds treated with DAPT (Fig 5.6 and 
Fig5.7). Further staining for the exocrine marker amylase (Fig 5.8 A, B) demonstrated 
an inhibition of amylase expression, indicating that the discontinuous duct structures 
formed after DAPT treatment did not develop into true acini-like clusters. Endocrine 
markers glucagon (Fig 5.8C,D) and insulin (Fig 5.8 E,F) appeared enhanced upon DAPT 
treatment, based on the morphology of cell clusters.  Clusters composed of both 
glucagon and insulin-expressing cells were observed in larger islet-like structures in 
comparison with control buds. Glucagon and insulin were never co-expressed within 
individual cells, indicating differentiation to distinct α- and β-cell types (Fig 5.8 B, D,F). 
Whole bud RT-PCR results confirmed that overall expression of the exocrine marker 
amylase may be reduced and this was concurrent with an enhancement in the 
endocrine markers glucagon and Insulin I and II (Fig 5.9). There was no change in the 
expression of the endocrine markers Pancreatic polypeptide (PP), expressed in PP cells, 
or somatostatin (SS), expressed in δ cells (Fig 5.9). Treatment with DAPT inhibits 
gamma-secretases required for normal Notch signalling, this reduction in Notch 
signalling on DAPT treatment is confirmed by down-regulation of the known Notch 
target Hes1 (Fig 5.9). The reduction in Hes1 expression was followed by de-repression 
of the pro-endocrine gene Ngn3, which may be up-regulated in DAPT-treated buds (Fig 































5.2.D. DAPT Treatment Promotes Islet-like Structures in Ex vivo Pancreatic Buds 
To confirm the gain of the endocrine phenotype at the cost of exocrine differentiation, 
DAPT treatment was continued to 14 days. Amylase-positive cells were once again 
reduced both in terms of the intensity of amylase expression (Fig 5.11 A, B). The level 
of expression of glucagon and insulin was enhanced by 14 days of DAPT treatment (Fig 
5.11 C,D and E,F). The size of glucagon and insulin-expressing islet-like structures 
produced after 14 days of DAPT treatment were approximately 2-5 times as large as 
observed in control buds. The morphology of the islet-like clusters also allowed 
observation of their cellular structure; DAPT treated islets were composed of a core of 
insulin-expressing cells, surrounded by a ‘mantle’ of glucagon-expressing cells (Fig 5.11 
H).  
DAPT treatment for 14 days showed amylase-positive cells forming clusters that 
appeared around the periphery of the islet. In control buds amylase-positive cells were 
grouped into acini-like structures with islet-like clusters distributed among the 
developing ducts (Fig 5.11B) this distribution was not observed in the DAPT treated 















5.2.E. DAPT Treatment Does Not Enhance Proliferation of Pancreatic Progenitors or 
Increase Proliferation of Insulin-expressing Cells 
The enhancement in cells expressing insulin within enlarged islet-like clusters observed 
after DAPT treatment was also characterised by the cells expressing the pancreatic 
transcription factor Pdx1 (Fig 5.12 B ,D). Pdx1 was expressed in both pancreatic 
progenitors and mature β-cells, raising the question; does DAPT treatment enhance 
the differentiation of pancreatic progenitors to β-cells? Co-staining for insulin and Pdx1 
expression demonstrated that Pdx1 expressing cells almost always co-expressed 
insulin (Fig 5.13D), which may indicate differentiation towards a mature β-cell 
differentiation.  
The promotion of glucagon and insulin-positive cells in DAPT treated buds could also 
be the result of increased cell division of cells that have already committed to an 
endocrine cell fate. This was shown not to be the case due to co-staining of DAPT 
treated buds with the endocrine markers glucagon and insulin and the cell division 
marker phosphohistone H3 (PH3). Interestingly, PH3 expression was more pronounced 
in control buds compared to DAPT treated buds (Fig 5.14 E,F). Co-staining for PH3 and 
endocrine markers showed little or no co-localisation of PH3 with either glucagon or 































5.2.F. DAPT Treatment Increases β-cell Responsiveness to Amino Acid and Glucose 
Challenge 
Co-staining for Pdx1 and insulin in DAPT treated buds suggested mature β-cell 
differentiation. To establish the maturity of developing β-cells within DAPT treated 
buds, buds were challenged with either glucose or amino acids and insulin release into 
the media was measured by ELISA. Twenty buds were pooled for each experiment, 
cultured for 14 days in either DAPT (hereafter called treated buds -T) or DMSO 
(hereafter called control buds-C). After 14 days, the glucose challenged buds were 
treated for one hour with either 5.5mM glucose (hereafter called low glucose L Glu) or 
25mM glucose (hereafter called high glucose- HGlu). Amino acid challenged buds were 
treated for one hour with either 0.1mM amino acids (Hereafter called low amino acids- 
L AA) or 10 mM amino acids (hereafter called high amino acids –H AA). Media was 
collected and concentrated as described in the Materials and Methods and the ELISA 
was performed according to the manufacturer’s instructions.  Protein was quantified 
and the results corrected to total protein resulting in calculation of pmols insulin/g 
total protein and results were analysed using a student’s t-test. Protein was also 
extracted from the pancreatic buds as described in the methods and an ELISA 
performed this data was used to calculate the percentage of intracellular insulin 
released into the media on stimulation with either glucose or amino acids (% insulin 
release/h).  
5.2.F.1. Glucose Stimulated Insulin Released into Media 
Control pancreatic buds secreted insulin into the media at relatively low levels 
(21.42pmol insulin/g total protein) however stimulation of control buds with high 
glucose for one hour did significantly increase insulin secretion into the media (Fig 
5.15). Treated pancreatic buds with low glucose treatment show increased insulin 
secretion into the media, almost 2.4 times that of unstimulated control buds, 
(p=0.024). This is consistent with our previous observations that β-cell mass and insulin 
production was significantly increased by treatment with the gamma-secretase 
inhibitor (Fig 5.11). 
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Treated pancreatic buds stimulated with high glucose also significantly increase insulin 
secretion into the media compared to control high glucose buds p=0.0058, however 
not significantly more than treated buds with low glucose p>0.05 (Fig 5.15).  
5.2.F.2. Amino Acid Stimulated Insulin Released into Media 
Control pancreatic buds secreted insulin into the media at relatively low levels, 
consistent with control buds in glucose challenge experiments (Fig 5.15 and 5.16). 
Stimulation of control buds with amino acids did not significantly increase insulin in the 
media (Fig 5.16). Treated buds with low amino acids showed a large increase in insulin 
in the media, this increase was higher than treated buds in our glucose experiments 
and was most likely due to variation between buds used in individual experiments. The 
increase in insulin in the media in treated buds that have low amino acid treatment 
was significantly greater than control buds with low amino acid treatment p=0.003.  
Treated buds stimulated with high amino acids showed a large increase in insulin in the 
media, more than 22 times that of control buds treated with high amino acids (Fig 
5.16). Insulin released by treated buds stimulated with insulin was significantly greater 
than both high amino acid controls (p=0.0005) and treated buds with low amino acids 
(p=0.0012).  
5.2.F.3. Percentage of Intracellular Insulin Released into the Media on Stimulation with 
Glucose or Amino acids. 
The caveat to the above data is that it does not take into account the amount of insulin 
produced within the cells of the bud. To account for potential differences, the insulin 
within the cells of the bud was collected and quantified by ELISA, the proportion of 
intracellular insulin secreted into the media was calculated as a percentage (Fig 5.17).  
Glucose stimulated buds secreted a greater proportion of their intracellular insulin into 
the media and the percentage secreted was significantly more than untreated buds 
stimulated with high glucose (p=0.0048) and treated buds with low glucose treatment 
(p=0.0018) (Fig 5.17). 
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Amino acid stimulated buds also showed an increase in the percentage of intracellular 
insulin released into the media however the increase from treated buds with low 
amino acids was not significant (p>0.05) (Fig 5.17).  
Overall the DAPT treated buds stimulated with high amino acids produce more than 10 
times more intracellular insulin than glucose stimulated buds, this huge increase in 
intracellular insulin accounted for the increase in insulin in the media. DAPT treated 
buds treated with high glucose also increased intracellular insulin production but a 



































The aim of the research described in the present chapter was to further investigate the 
phenotype of ex vivo pancreatic buds treated with the gamma-secretase inhibitor 
DAPT.  Treatment of our pancreatic buds with DAPT resulted in disruption of normal 
branching morphogenesis and a reduction in cells expressing the markers CK7, CK19 
and E-Cadherin (Fig5.7). We also observed that inhibition of gamma secretase resulted 
in inhibition of exocrine differentiation, in terms of duct and acinar cells, and an 
enhancement in endocrine differentiation, in terms of α- and β-cells. We propose that 
enhanced endocrine differentiation is the result of the reduction in expression of the 
Notch target Hes1 which usually represses the pro-endocrine gene Ngn3. Presumably, 
in the absence of Notch signalling Hes1 expression is reduced and Ngn3 is de-
repressed and directs differentiation of progenitors to endocrine fates. Finally we 
observed that gamma secretase inhibition of pancreatic buds resulted in more mature 
β-cells within the bud, in terms of β-cell responsiveness to glucose and amino acids.  
5.3.A. Disruption of Normal Branching Morphogenesis in DAPT Treated Pancreatic 
Buds 
We first observed that treatment of the pancreatic buds with a gamma-secretase 
inhibitor resulted in failure of the buds to undergo normal branching morphogenesis. It 
has previously been demonstrated that activation of Notch signalling in adult pancreas 
results in accumulation of pancreatic precursors and metaplastic ductal epithelium 
[276]. Notch has also been implicated in acinar to duct cell metaplasia, which is 
thought to be dependent on activation of the Notch target Hes1 [277]. These data 
support our observation that active gamma secretase is required for duct cell 
differentiation and is also consistent with the observation that Notch1 and 2 are 
expressed in early duct progenitors and by E15.5 Notch2 expression is absolutely 
restricted to ductal cells [212].  
Reduced ductal cell differentiation may explain the deficits we observe in branching 
morphogenesis, as insufficient duct cell differentiation may result in failure to branch 
normally. It is also possible that inhibition of gamma secretase may directly alter 
branching morphogenesis. Although little is understood about the mechanisms that 
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control branching morphogenesis, recent work has implied a direct role for Notch 
signalling. Notch signalling has been proposed as a mechanism of lateral inhibition of 
ductal branching that regulates organ size in the developing pancreas [278]. VEGF 
induced pancreatic hyper-vascularisation in transgenic mice resulted in an overall 
decrease in pancreas size and inhibition of branching morphogenesis. The authors 
proposed that the mechanism of lateral inhibition of branching morphogenesis was 
increased Notch signalling from endothelial cells present in hyper-vascularised 
pancreata. Inhibition of branching morphogenesis in hyper-vascularised pancreata was 
partly rescued in vitro by addition of a gamma-secretase inhibitor [279]. These data are 
contrary to our observation that inhibition of Notch signalling inhibits branching 
morphogenesis, and may therefore support the hypothesis that our observations are 
the result of decreased ductal cell differentiation.  
5.3.B. Disruption of Endocrine and Exocrine Cell Fates in DAPT Treated Pancreatic 
Buds 
We next observed that treatment of the pancreatic buds with a gamma-secretase 
inhibitor promoted α- and β-cell differentiation at the cost of ductal and acinar cell 
differentiation i.e. Notch inhibition favours endocrine differentiation over exocrine cell 
fates. The role of Notch signalling in differentiation of pancreatic endocrine and 
exocrine cells was first demonstrated by Apelqvist et al, who showed that deletion of 
Delta-like gene 1 (Dll1) or RBP-Jκ (Dll1 is a Notch ligand of the delta/serrate/jagged 
family and RBP-Jκ is a transcriptional activator of Notch targets classically used to 
identify active Notch signalling) resulted in accelerated differentiation of endocrine 
cells [120]. The limitation of these experiments is that RBP-Jκ deficient mice die at 
around E8.5-9.5 and Dll1 deficient mice show developmental arrest at around E10-12 
[120], meaning that only very early stages of pancreatic cell differentiation could be 
examined. Later work has demonstrated that activation of Notch signalling prevents 
both endocrine and exocrine differentiation and traps pancreatic progenitors in an 
undifferentiated state [201]. The authors also proposed that differentiation to 
endocrine lineages was associated with escape from active Notch signalling [201], 
although this has not yet been demonstrated by loss-of-function experiments. Our 
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observations confirm that inhibition of gamma secretase is sufficient to allow 
differentiation of endocrine cells from pancreatic precursors. 
The mechanism of Notch-mediated repression of endocrine differentiation is thought 
to act via the Notch target Hes1 [280], which represses the pro-endocrine gene Ngn3. 
As previously discussed all endocrine cells are derived from Ngn3-positive precursors 
and Ngn3 deficient mice fail to produce endocrine cells [122]. We observed both a 
down-regulation of Hes1 in gamma-secretase treated pancreata and up-regulation of 
Ngn3 which is consistent with this mechanism. Notch inhibition may also be required 
down-stream of Hes1 de-repression of Ngn3, as in Xenopus neuronal differentiation 
Notch1 has been shown to inhibit NeuroD [281], which is also required for early 
differentiation of endocrine cells (See Fig 1.12). 
Pancreatic β-cells are known to proliferate, both due to changes in physiological 
demand for insulin and after β-cell ablation (For review see: [282]). β-cells are also 
thought to recover from pancreatic injury by activation of facultative progenitors in the 
ductal epithelium [283]. We have demonstrated that the enhanced β-cell mass 
observed on gamma-secretase treatment is not due to increased proliferation of 
existing β-cells or proliferation of Pdx1-positive progenitors, indicating that our 
observations are the result of increased differentiation of progenitors to β-cells  
5.3.C. Functionality and Maturity of β-cells within DAPT Treated Pancreatic Buds 
We wished to examine the maturity of β-cells within our enlarged islets. Under control 
conditions ex vivo pancreatic buds do not respond significantly to either amino acids or 
glucose, this is supported by work on foetal β-cells which only respond minimally to 
glucose stimulation [284]. Glucose or amino acid stimulated insulin secretion is not 
observed in human pancreatic cultures prior to 24 weeks of gestation [285].  
Insulin secretion into culture media was detected by ELISA after stimulation of either 
DAPT treated or control pancreatic buds after treatment with high glucose or amino 
acid stimulation. Intracellular insulin production was also quantified by ELISA. Insulin in 
the media is the result of both constitutive insulin release and stimulated insulin 
secretion in response to secretagogues. β-cells constitutively express and secrete 
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insulin in a glucose-independent manner, that is thought to  be necessary for glucose-
stimulated insulin secretion to be effective [286]. Previous studies have demonstrated 
that around 1% of total intracellular insulin is released from β-cells by constitutive 
pathways [287].      
We initially observed that DAPT treatment resulted in a significant increase in insulin 
present in the media, independently of stimulation with either glucose or amino acids 
(Fig 5.15 and 16). This was concomitant with our immunostaining results (Fig 5.8 and 
5.11) that demonstrated increased insulin-producing cells within DAPT treated islets 
and is likely to be the result of increased constitutive insulin release form these cells.  
We next observed that glucose stimulation of DAPT treated buds resulted in a 
significant increase in insulin in the media compared to glucose stimulated controls but 
not to unstimulated DAPT treated buds (Fig 5.15). Amino acid stimulation of DAPT 
treated buds induced a significant increase in insulin in the media in comparison to 
controls and unstimulated DAPT treated buds. This initially confounded our 
expectation that glucose stimulation would increase insulin secretion, however when 
we quantified the amount of insulin produced within the buds and expressed insulin in 
the media as a percentage of insulin within the bud we observed that insulin secretion 
from DAPT treated buds on stimulation with glucose was significantly higher than both 
controls and unstimulated DAPT treated buds. The reason for this discrepancy is 
probably that although the total amount of intracellular insulin produced by 
stimulation with glucose was not great, the percentage secreted into the media was 
high. This indicated that β-cells within DAPT treated buds are able to respond to 
glucose by secretion of insulin indicating that they are functionally more mature than 
untreated buds.  
Although we initially observed that amino acid stimulation of DAPT treated buds 
induced a significant increase in insulin in the media, when total intracellular insulin 
was taken into account we observed that amino acid stimulation resulted in a huge 
increase in intracellular insulin but the proportion of this secreted into the media was 
relatively low and not significantly greater than controls (Fig 5.17). This indicated that 
amino acid stimulation of pancreatic buds greatly increases intracellular insulin 
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expression and therefore constitutive insulin release but does not significantly increase 
active insulin secretion into the media. There is significant evidence that amino acids 
are able to augment glucose-stimulated insulin secretion but not activate insulin 
secretion independently of glucose. In humans with type II diabetes consumption of 
amino acids in combination with a carbohydrate meal, increases insulin secretion into 
the blood by 114-189% in comparison to consumption of a carbohydrate meal alone 
[288]. In vitro culture of rat islets stimulated with both glucose and amino acids 
induced a 20-30 fold increase in insulin secretion into media [266]. The mechanism for 
amino acid augmentation of insulin secretion is thought to act via three different 
pathways (i) metabolism of amino acids generating ATP and closure of ATP-gated 
potassium channels (ii) co-transport of amino acids with sodium ions resulting in 
membrane depolarisation (iii) uptake of cationic amino acids such as L-arginine and L-
lysine resulting in membrane depolarisation [289]. Amino acid stimulation of insulin 
independently of stimulatory levels of glucose has been demonstrated in the 
pancreatic β-cell line BRIN-BD11 but only at low levels and the effects were greatly 
increased by addition of glucose [290], the authors did not include data on the 
intracellular effects of insulin production. In fact there is very little data on the effects 
of amino acids on insulin biosynthesis to support our observations. Amino acid 
signalling is known to be active in β-cells and is thought to promote insulin production 
by enhancing β-cell proliferation and growth [291]. This is unlikely to be the 
mechanism of our observations as the buds were only exposed to high amino acids for 
one hour. Amino acids are also known to stimulate global protein synthesis and inhibit 
proteolysis in skeletal muscle cells [292]. Amino acids have been found to regulate 
signal transduction pathways involving mammalian target of rapamycin (mTOR), which 
is involved in translation of mRNA on a global scale and causes preferential changes in 
mRNA translation of specific proteins [293]. Although there is no evidence that insulin 
release is directly regulated by mTOR, it is known that amino acid signalling is active in 
β-cells and therefore may be one explanation for our observations.  
One clear caveat to our observations is the variation observed between buds, which is 
a feature of all our investigations using the ex vivo model. Although there is variation in 
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the amount of insulin produced and secreted by individual buds the magnitude to the 
effects observed are similar.  
5.3.D. Future Work  
We have demonstrated that gamma secretase inhibition of pancreatic buds produces 
functionally more mature, β-cells, at least in terms of responsiveness to glucose and 
amino acid challenge. This work could be continued to test these islets in non-obese 
diabetic, severe combined immunodeficient (NOD-SCID) mice. Transplantation of these 
islets would test their ability to improve glucose tolerance in vivo.   
 
 














Chapter 6. Final Discussion and 
Future Prospects 
The overall aim of this thesis was to (1) demonstrate transdifferentiation in 
cholangiocytes to hepatic and pancreatic lineages and (2) identify the signalling 
pathways important for pancreatic development that could be used to promote 
transdifferentiation to other endodermally derived cell types. 
Two of the cell types most in demand for therapeutic purposes are (i) the hepatocyte 
and (ii) the pancreatic beta-cell.  In terms of the hepatocyte this is because liver 
diseases are associated with a marked reduction in the viable mass of hepatocytes. 
The most severe cases of liver disease (liver failure) are treated by orthotopic liver 
transplantation or alternatively by hepatocyte transplantation, but the major problem 
to overcome is the shortage of organ donors. The other cell type in demand for 
therapeutic purposes is the pancreatic beta-cell. This is because type 1 diabetes is a 
one of the major healthcare problems in the world.  Diabetes can be treated by islet 
transplantation but the major limitation is the shortage of organ donors. To overcome 
the shortfall in donors, alternative sources of pancreatic beta-cells must be found.  
BECs offer one such source of cells for hepatocytes and pancreatic beta-cells.  This is 
because BECs are developmentally related to hepatocytes and pancreatic beta-cells 
(both liver and pancreas arise from the same region of the developing endoderm). 
Beta-cells have also been found to occur in the extrahepatic bile ducts [37] However, 
using BECs as a starting material for generating hepatocyte-like or beta-cells cannot be 
exploited fully until the transcription required for transdifferentiation are elucidated. 
In chapter three we initially confirmed that BECs are a potential model of normal 
cholangiocytes. BECs express typical cholangiocyte proteins including CK7, CK19, Cx43, 
GGT, as well as the transcription factors Hnf1β and Sox9 and the lectins DBA and PNA. 
We also demonstrated that BECs can be effectively maintained and infected with 
adenoviral vectors to give rise to expression of transgenes.  BECs were infected with 
key transcription factors that have been demonstrated to induce either hepatocyte or 
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β-cell transdifferentiation for a period of five days and screened for typical hepatocyte 
or β-cell markers using RT-PCR as a high throughput screen.  
 In terms of BEC transdifferentiation to the hepatocyte lineage we were able to 
demonstrate the co-infection of C/ebpα, C/ebpβ and Hnf4 was sufficient to induce 
up-regulation of the hepatocyte genes albumin and Gs and to initiate expression of 
Afp. Despite the appearance of albumin, Gs and Afp, no further hepatocyte genes were 
induced and the phenotype of infected cells did not become more hepatocyte-like. 
In terms of BEC transdifferentiation to the β-cell lineage we were surprised to observe 
that BECs already expressed low levels of Pdx1 (we demonstrated this by RT-PCR and 
western blot), however when we examined Pdx1 expression by immunostaining we 
observed that the staining pattern was perinuclear and moreover insulin was not 
expressed. It is possible that the perinuclear Pdx1 is not able to translocate to the 
nucleus and therefore is not able to induce insulin expression. Overexpression of Pdx1 
alone was not able to induce expression of any pancreatic genes. However, in 
combination with Ngn3, Pax4 and NeuroD induction of insulin II but insulin protein 
could not be detected.   
It is possible that the lack of a clear transdifferentiation event in these experiments is 
due to the combination of transcription factors used. Although C/EBPα C/EBPβ have 
been demonstrated to induce transdifferentiation of pancreatic AR42J-B13 cells to 
hepatocyte-like cells [23] they do not appear to have the same effect in BECs. Other 
potential transcription factors that may induce cholangiocyte to hepatocyte 
transdifferentiation may include FaxA1 and FoxA2, further work is required to be 
conducted into the optimal transcription factors and the optimal combination required 
to give rise to a true transdifferentiation between cholangiocytes and hepatocytes.  
One possibility is that rather than adding the transcription factors together the 
phenotype may be improved by sequential addition.  Alternatively the 
transdifferentiation may be enhanced by the addition of extracellular factors including 
the synthetic glucocorticoid dexamethasone.  
The combination of Pdx1, Ngn3, Pax4 and NeuroD has been shown to induce 
transdifferentiation of hepatic cells to pancreatic lineages both in vitro and in vivo [40-
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44, 49]. However, under the present conditions a mature pancreatic beta-cell 
phenotype was not achieved suggesting that the optimal combination of transcription 
factors for cholangiocyte to β-cell transdifferentiation was not achieved. Other 
transcription factors that may produce more effective transdifferentiation may include 
MafA, Nkx2.2 or Nkx6.1, again further experimental evidence is needed to determine 
the optimal combination of factors. Although Pdx1 has been described as a ‘master 
switch’ gene for pancreatic development we cannot exclude the possibility that Pdx1 
(or indeed some of the other transcription factors (such as C/ebpα, C/ebpβ, Hnf4α) 
used in these experiments) actually has off-target effects that are not observed by the 
screens conduced. For example Pdx1 has recently been shown to direct cholangiocyte 
transdifferentiation to neuroendocrine lineages [294], as neuroendocrine markers 
were not investigated in this work, this represents another area for further work.  
Directly altering transcription factor expression is one method for inducing 
transdifferentiation, but transdifferentiation may also be induced by activating or 
indeed suppressing signalling pathways that are important for development of a 
particular cell type, thus indirectly affecting gene transcription. This approach was the 
focus of the work performed in chapter four which aimed to investigate the signalling 
pathways important in embryonic liver and pancreas development.      
Our ex vivo model of embryonic hepatic and pancreatic development involved 
dissection of 11.5d mouse embryos to remove either the embryonic liver or dorsal 
pancreatic bud, and subsequent culture on fibronectin coated coverslips.  We have 
utilised the dorsal pancreatic bud cultures to investigate the conversion of pancreatic 
cells to hepatocyte-like cells [23] and to investigate the role of extracellular factors 
(betacellulin and retinoic acid) in the development of the mouse embryonic pancreas 
[48, 295]. 
Signalling pathways investigated in hepatic development included Notch signalling, 
Activin/TGFβ signalling and Wnt signalling. We were able to demonstrate that 
treatment with DAPT inhibited differentiation of hepatoblasts to ductal cells, 
supporting previous data that indicated active Notch signalling is essential for hepatic 
biliary differentiation. Upon gamma secretase inhibition we observed a larger 
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population of early hepatoblast-like cells that had not undergone differentiation to 
hepatocytes indicating that gamma secretase inhibition was required to give rise to 
early hepatocyte precursors but was insufficient to drive hepatocyte differentiation 
(Chapter 4.2.A). Although we propose that a gradient of Activin/TGFβ signalling is 
required to drive hepatocyte differentiation in Notch inhibited precursors, we were 
unable to prove this hypothesis in this investigation and this hypothesis remains to be 
tested. 
We investigated the role of a number of signalling pathways in pancreatic 
development.  These included Notch signalling, HGF and PI3 Kinase signalling. We 
observed that inhibition of the PI3 kinase, PIKfyve resulted in inhibition of branching 
morphogenesis and ductal cell differentiation, as well as suppression of amylase and 
insulin expression. We propose that PIKfyve is important for pancreatic duct cell 
development and may also play a role in promoting endocrine differentiation. 
However it is important to note that this data is preliminary and further work is 
required to confirm this hypothesis and to more robustly quantify the observations. 
Furthermore we acknowledge the unknown function of PIKfyve in embryonic 
development, in adult pancreatic β-cells PIKfyve is important for regulation of insulin 
secretion and β-cell survival, but we believe further work is necessary to establish a 
direct role for PIKfyve in pancreas development.  
The most interesting observation from our work in chapter four was the phenotype of 
pancreatic buds treated with the gamma-secretase inhibitor DAPT. We believed that 
the inhibition in branching morphogenesis observed on DAPT treatment of our ex vivo 
pancreatic buds was the result of suppression of duct cell differentiation. This 
hypothesis supports previous studies demonstrating that pancreatic ductal cell 
differentiation requires active Notch signalling [120]. We also demonstrated that 
gamma secretase inhibition favours endocrine differentiation over exocrine cell fates, 
as we observed α- and β-cell differentiation at the cost of acinar cell differentiation in 
Notch inhibited buds. We propose that this is due to de-repression of the 
proendocrine transcription factor Ngn3 by Hes1 (a target of Notch signalling). Although 
previous work has demonstrated that escape from Notch signalling is important for 
endocrine differentiation, limitations in loss-of-function studies have failed to show 
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increased endocrine differentiation in the absence of Notch [201]. Future work could 
prove that these observations are the result of de-repression of Ngn3 by Hes1 by 
direct inhibition of Hes1. Inhibition of Hes1 had been achieved in gall bladder epithelial 
cells, where it was shown to promote insulin expression [296].  
We demonstrated that gamma secretase inhibition results in β-cells that are 
functionally more mature in terms of responsiveness to amino acids and glucose 
stimulation. Untreated buds did not secrete insulin in response to stimulation with 
either amino acids or glucose. Treatment of buds for 14 days with DAPT and 
subsequent stimulation for one hour with amino acids resulted in an increase in the 
amount of intracellular insulin produced by β-cells, although the proportion of insulin 
secreted into the media did not significantly increase. DAPT treatment followed by 
glucose stimulation did not induce a large increase in intracellular insulin production 
but did increase the proportion of intracellular insulin secreted into the media, 
indicating increased insulin secretion and β-cell maturity. The next step for this 
research would be to test the β-cells produced by gamma secretase inhibition in NOD-
SCID mice to test their ability to regulate blood glucose in vivo.  
Future prospects for the work in this thesis may be to combine the effects of transgene 
expression and signalling pathway activation or repression to attempt to bring about a 
true transdifferentiation event. An optimal combination of transcription factors or 
‘master switch genes’ needs to be identified to induce transdifferentiation between 
cholangiocytes and hepatic or pancreatic cells. The results of this thesis may also 
indicates that activation or inhibition of Notch signalling may be required as part of the 
transdifferentiation process or could be used to improve the  maturity or functionality 
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